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PREFACE
Preface
As a public health officer, I started working in Burkina Faso in 1984, 
and soon after, the first reports on AIDS cases in East Africa (Tanzania, 
Uganda, and Rwanda) came out. From a distance, living in West Africa, 
I observed and read about the panic in western countries concerning 
the AIDS epidemic in Africa. I was startled when some Dutch people 
refused to travel to West Africa fearing the virus, while it seemed 
totally absent in the hospital, health centres and communities where I 
was working at that time. Only when I moved to Zimbabwe in 1989 did 
I come to understand the scope of the AIDS epidemic, and began to 
grasp the extent and nature of its sizeable impact. In 1997, eight years 
after I had come to Zimbabwe, the official HIV prevalence rate among 
adult Zimbabweans reached its peak at 27% of the adult population 
(Halperin et al. 2011: 414). 
 In my workplace at the UNICEF office in Harare, colleagues and 
friends fell ill and died; while others lost their loved ones. It was a 
chaotic period, during which I felt and observed fear, grief, shame, 
secrecy and confusion. People from all walks of life were constrained to 
talk about AIDS. There was a huge societal taboo to address sexual 
transmission. In this period information spread about a new HIV 
prevention technology, the female condom1. Mary Bassett, a lecturer 
and researcher based at the Medical Faculty of the University of 
Zimbabwe in Harare, told me enthusiastically about the studies she was 
conducting on the use of female condoms by married and unmarried 
women, and its potential impact. The majority of women who had tried 
the female condom indicated that they felt empowered by the thought 
that they could now finally protect their bodies from HIV infection. 
Certainly there was enthusiasm and interest in this commodity for 
women. 
 In 1997, the Zimbabwean Women and AIDS Support Network 
(WASN) organised a march through the streets of Harare, requesting 
the Government to create access to female condoms (Osewe 1999). This 
1 In this thesis I use the terms ‘female condom’ and ‘male condom’ to distinguish 
between condoms that are used by women and by men, respectively. These terms are 
practised worldwide, although it would be more appropriate to speak of a ‘woman’s 
condom’ and a ‘man’s condom’.
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made me realise that there was a potential for the female condom to 
grow into a success story, not only because of its capacity to prevent HIV 
infections and unintended pregnancies, but also because it implicitly 
recognised sexuality as a natural part of women’s life. It could change 
women’s power position into equality in sexual relationships. 
 It was my hope that the AIDS pandemic would lead to greater 
consciousness about the overall importance of tackling gender 
discrimination, while appreciating the preciousness of sexuality to 
human life and human relationships, acknowledging the rights of 
women to have control over their own bodies, and accepting the 
importance of consensus in sexual relationships. Women’s perspectives 
on sexual and reproductive issues gained attention for the first time 
during the 1994 International Conference on Population and Development 
in Cairo. Feminist advocates from all over the world, such as Rosalind 
Petechsky, Gita Sen, Sonia Corrêa, and Adrienne Germain urged the 
United Nations and its member states to consider the perspective of 
women in population policies, pleading that women should have as 
much personal autonomy in the matter as the other sex, people born as 
men. The concept of sexual and reproductive health and rights was 
born, including the right for a woman to have sex in the way she likes 
it, and using preferred contraceptive devices, of which the female 
condom might be one. 
 Between 2005 and 2009 when I worked as AIDS policy officer at 
Oxfam Novib, I learned a hard lesson whilst advocating for AIDS 
prevention from a gender and sexuality perspective. Invited as one of 
the speakers at a conference organised by the Netherlands Ministry of 
Foreign Affairs, I presented the potential of the female condom and the 
need for women to get access to this commodity, especially for those 
living in the context of a severe AIDS epidemic. Although my statement 
that African women urgently needed access to female condoms drew 
applause, some top decision makers from the Ministry of Foreign 
Affairs and an advisor to this Ministry, a former Minister of Health in 
the Netherlands, ridiculed the female condom. They blamed me for 
being ‘so out of touch with reality’ in promoting the female condom in 
the context of developing countries, where, in their view, it would be 
more appropriate for African men to contain their sexual drives. They 
portrayed African women as helpless victims, not in a position to 
negotiate safe sex with their male partners. They further argued that 
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the female condom was far too expensive for women in developing 
countries, a statement I could only agree with. 
 This confrontation triggered the desire to start studying views on 
the female condom of different stakeholders in more depth. At the 
2008 International AIDS Conference in Mexico, Oxfam presented the 
report ‘Failing women, withholding protection: 15 years lost in making 
the female condom accessible’ (Oxfam 2008), and I relived some of my 
earlier experiences, realising that at the global level, a similar type of 
denial, negation and stigma of the ‘sexual’ part of the AIDS problem 
seemed to be at work as during the initial days of the epidemic in my 
time in Zimbabwe. However, I could not quite put my finger on it: it 
needed to be teased out, explored, and studied. This marked the 
beginning of my efforts to understand the operation of political powers 
surrounding the female condom at global level. In March 2009 I started 
my PhD research, which marked the end of my professional career as 
an advocate for the female condom, and started working at Rutgers on 
sexual and reproductive health and rights in general. Academic 
integrity was kept by putting the research findings up to the scrutiny 
of my promotor professor W. Jansen and co-promotor F. van Driel, and 
partly to some other experts such as Lisa van Son, anthropologist and 
Maja Micevska Scharf, health economist. By publication in academic 
journals, the research results were independently peer reviewed. 
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THE ISSUE OF THE FEMALE CONDOM
1.1 Background
Since the beginning of the AIDS epidemic, condoms have been the 
single most efficient available prevention technology to reduce the 
transmission of HIV/AIDS and other sexually transmitted infections. 
In 1984, Lasse Hessels invented the female condom, a transparent 
vaginal sheath of the same length as the male condom, with a flexible 
ring at each end. It was introduced into the global market in 1993. 
At present, more than twenty years after its introduction most women 
in sub-Saharan Africa still lack easy and inexpensive access to this 
protective commodity. 
 The female condom is proven to be as effective as the male condom 
in giving dual protection against unintended pregnancy and sexually 
transmitted infections, including HIV/AIDS. The merit of dual 
protection is acknowledged by global AIDS and family planning policy 
makers, such as UNAIDS and UNFPA; however, its implementation at 
field level is neglected. This disconnection has been little analysed, and 
especially not from a women’s rights perspective, or from the 
perspective of sexual and reproductive health and rights, both rights 
which are prioritised and recognised at the global policy level by the 
different United Nations agencies and its donor agencies (Roseman et 
al. 2010). The female condom is still expensive compared to the male 
condom and is hardly available in AIDS afflicted regions, such as 
sub-Saharan Africa, though it is the object of many political debates. 
Moral and religious judgements tend to restrict condom promotion in 
general (UNAIDS 2014). Such restrictions are closely related to existing 
socio-cultural norms regarding sexuality known to inhibit condom 
use, for example in Kenya (Kyeremeh 2009). 
 Access to female condoms became an increasingly urgent issue in 
sub-Saharan Africa as not only the absolute number of women infected 
with HIV, but also the relative proportion of women among those living 
with HIV/AIDS, rose rapidly. Since 1985, this percentage rose from 55% 
in 2000 (UNAIDS 2001:3), to 57% in 2004 (UNAIDS 2005a:4) and 61% in 
2007 (UNAIDS 2008a:33). Currently, in the age group between 15 and 49 
years, girls and women still account for approximately 57% of all people 
living with HIV in sub-Saharan Africa (UNAIDS 2013:78). For young 
women between 15 and 24 years of age the impact is even higher: 76% 
of the young people between 15 and 24 years of age infected are female 
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(UNAIDS 2010:1). Women are more likely to acquire HIV at an early age, 
resulting in a global HIV prevalence among girls and young women 
that is greater than among males of the same age. In sub-Saharan 
Africa, national surveys also find that young women (age 15–24 years) 
have lower levels of accurate and comprehensive knowledge about HIV 
than young men of the same age. Young women in sub-Saharan Africa 
are also less likely to report having used a condom the last time they 
had sex (UNAIDS 2013:78). Many girls and women who could have 
benefited from the female condom, though, have never heard of it; and 
if they have heard of it, they cannot obtain it (Hoffman et al. 2008). 
Female condoms remain highly underfunded and inaccessible for 
women who need them (Izazola-Licea et al.2009). 
 Why is it that the female condom has not become an option or 
choice for women, especially in sub-Saharan Africa, who seek to protect 
themselves from unintended pregnancies and sexually transmitted 
infections? How do global AIDS policy actors perceive female condom 
promotion and its potential role in the global answer to AIDS? At what 
critical junctures and in what ways did these public stakeholders 
choose to act or not, and for what reasons? Are these reasons transparent 
or is there fumbling with the female condom, so to speak? Who is 
prioritising what and why at global level? This thesis will look at the 
role of global AIDS policy actors in determining the fate of the female 
condom using the theoretical framework about political prioritization 
in global health (Shiffman et al. 2007). What is happening in the global 
health sector and the global response to AIDS such that a new public 
health technology which is invented does not get the attention it might 
be expected to get? 
 Global political priority is defined as the degree to which international 
and national political leaders actively give attention to an issue, and 
back up that attention with the provision of financial, technical, and 
human resources that are commensurate with the severity of the issue. 
Walt (1994) studied the way health policies were developed and 
concluded that the largest health problem and the most effective way 
to improve such a health problem were often not politically prioritized 
(Walt 1994). The choice to (not) support a global health initiative is 
recognised to be highly subject to politics, highly complex, and so far 
lacking theoretical understanding (Labonté et al. 2010; Rushton 2010; 
Shiffman et al. 2007). Some academics have been studying the reasons 
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why some global health issues get more attention and political priority 
than others, and have come up with different theoretical frameworks 
which I will discuss in more depth in section 1.5. 
 I study the political prioritisation in global health, and more 
specifically the political neglect, of the female condom in the global 
response to AIDS. Why has the global health sector not facilitated the 
conditions for success for the female condom in the global response to 
AIDS? What has been the power of the actors involved with this issue 
and in what way did they define and describe the issue at hand? 
What political circumstances and which characteristics of the female 
condom mattered in this prioritization? This research mainly concerns 
itself with the region of sub-Saharan Africa, which endures the greatest 
impact of the AIDS epidemic and which would greatly have profited 
from better access to the female condom. To contextualise this research 
I will first describe in short the AIDS epidemic.
1.2 Short history of the AIDS epidemic
In 1983, the human immunodeficiency virus (HIV) was identified as the 
etiological agent of the acquired immune deficiency syndrome (AIDS). 
By the mid-1980s, it turned out that the virus had spread among various 
population groups throughout most of the world. The size and spread 
of the epidemic was difficult to estimate as infected people carry the 
virus for a relatively long time (6 to 10 years) before falling ill or even 
presenting any symptoms (Morgan et al. 2002). The virus turned out to 
spread quickly through sexual contact: in the USA predominantly 
among homosexual men; in sub-Saharan Africa mainly among 
heterosexual partners (Padian 1987). Although AIDS is predominantly 
a sexually transmitted disease (STD), it also spreads through infected 
blood like other retroviruses (Guttmacher Institute 2009). In Eastern 
Europe and certain parts of Asia, the initial spread of HIV was among 
intravenous drug users, who shared needles for drug injections (Hamers 
et al. 2003).
 Through the 1990s AIDS became a pandemic, peaking globally 
in 1997 with varying types of viruses in different parts of the world, 
and wide variations in HIV prevalence estimates among and between 
continents and individual countries (UNAIDS 2003). Sub-Saharan 
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Africa still carries the highest burden of adults and children living 
with HIV infections: 70% (25 million) of the total of 35,5 million HIV 
infected people worldwide; it is also the region where most new 
infections happened in 2012: 70% (1,6 million) of the total of 2.3 million 
new HIV infections worldwide (UNAIDS 2013: 4). About one in every 20 
adults (15-49 years) in sub-Saharan Africa (4.7%) is living with HIV 
(UNAIDS 2013: 4), resulting in high mortality rates among adults in the 
most productive years of their lives. Consequently, the epidemic 
impacts not only individuals, but families, local communities, entire 
countries and their institutions. 
 In 1996, almost 15 years into the AIDS pandemic, a most significant 
new scientific discovery was celebrated, anti-retroviral therapy (ART) 
(Kallings 2008; McGough et al. 2005). ART changed the deadly disease 
AIDS into a chronic condition, although initially only for those patients 
who lived in high-income countries with well-funded health infra-
structures which could ensure life-long treatment for people living 
with HIV. At first, the high cost of treatment was prohibitive for low- 
income countries. But with growing demand, and the global societal 
pressure on pharmaceutical companies that produce and market 
antiretroviral therapies, the price of ART came down (Hanefeld 2002; 
Nauta 2011; Reuters 2001). This resulted in increased access to treatment 
for people in low-income countries, supported by new global initiatives, 
notably the Global Fund to fight AIDS, tuberculosis and malaria, 
founded in 2001 (www.theglobalfund.org) and the US president’s 
emergency plan for AIDS relief (PEPFAR), launched in 2003 (www.
pepfar.gov). These funding mechanisms successfully contributed to 
access to ART in sub-Saharan Africa, slowly covering an increased 
percentage of people living with HIV: this upward trend can be seen in 
the following table – across sub-Saharan Africa the majority of those 
who live with HIV and were eligible for ART, received ART in 2012. 
 The table clearly shows that the peak in the AIDS epidemic has been 
reached, and that access to anti-retroviral therapies has been prioritised. 
However the number of newly infected people in sub-Saharan Africa is 
still 1.6 million per year (WHO 2013:16). 
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Women and AIDS
The AIDS epidemic hits women disproportionately hard (Van Eerdewijk 
2007; Shiripinda 2012). Biologically, women are more susceptible to HIV 
infection than men. The female genital tract has a greater vulnerable 
surface area than the male’s and therefore gets easily exposed during 
sexual contacts. This makes women more prone to the risk of infection 
than men (Glynn et al. 2001). Moreover, young women are more 
vulnerable than older women as their body tissues are less mature and 
thus more easily damaged during sexual intercourse (Türmen 2003). 
Compared to men, women are twice as likely to acquire HIV from an 
infected partner during unprotected sexual intercourse. 
 Women and girls in sub-Saharan Africa also suffer from other 
sexual and reproductive health related problems such as sexual 
violence, unintended pregnancies and unsafe abortion (Eastburn 2012; 
Gerein et al. 2006). The presence of sexually transmitted infections 
significantly increases susceptibility to HIV. The annual abortion rate 
in this part of the world stands at 29 induced abortions per 1,000 
women aged 15-44 years, which is the average rate for all developing 
countries (Guttmacher Institute 2012:3). This amounts to a total of 5.5 
million induced abortions per year, mainly caused by an unmet need 
for contraception products, including the female condom. At least one 
quarter of married women in sub-Saharan Africa do not have access 
to contraception even though they are interested in using modern 
contraceptives (United Nations 2011:1). The unmet need for contraception 
for unmarried or young women between 15-24 years is assessed to be 
higher, between 25-45% (MacQuirry 2013: 7). 
 Women’s greater physiological vulnerability to HIV infection and 
unmet need for contraception is problematic. The predominantly 
patriarchal norms and values in societies, particularly strong with 
regard to sexual relations and behaviour, restrict women’s opportunities 
to prevent HIV and compound women’s greater vulnerability to HIV 
and unintended pregnancies (Albertyn 2003; Campbell 2003). As the 
pandemic has unfolded, the proportion of women among people 
infected with HIV has increased in all continents (Auvert et al. 2001; 
Chin 1990; Quinn et al. 2005), but women are hit hardest in sub-Saharan 
Africa where they represent the majority (57%) of those living with HIV 
(UNAIDS 2013:78). Worldwide the percentage of women is less, but they 
still make up the majority of those living with HIV (52%). 
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 Logically, therefore, one would expect extra attention to the situation 
of women and to prevention in global policies to fight AIDS. But on the 
contrary, there is evidence that attention to women’s situation in the 
AIDS epidemic has seriously lagged behind (Henry J. Kaiser Foundation 
2013:2), though the reasons are not understood. This phenomenon is 
problematised and analysed in this thesis in terms of the case of one 
particular technology: the female condom, the only existing effective 
HIV prevention tool for women’s bodies. The AIDS epidemic can never 
be halted without preventing acquisition of the virus in the first place. 
Prevention is especially important for young people as currently about 
half of the new infections (1,6 million people in sub-Saharan Africa) 
concern those between 15 and 24 years (Henry J. Kaiser Family 
Foundation 2013:1). The female condom could be one of the choices for 
young people to protect themselves from infection and unintended 
pregnancy. 
The female condom
The female condom is a barrier method that effectively offers protection 
against both unintended pregnancies and sexually transmitted infections 
(STIs), including HIV and AIDS. It does not require fitting by a health 
care professional and prevents people from becoming chronically 
ill and needing lifelong anti-retroviral therapies (Vijayakumar et al. 
2006). Female condoms offer women greater control to protect their 
bodies (Cecil et al. 1998; Hoffman et al. 2004; Ray et al. 1995; Weeks 
et al. 2010). 
 The idea that women deserve a protection device for their bodies 
first received attention from a Danish physician, Lasse Hessels. In 1984, 
he designed the female condom with two flexible polyurethane rings 
and a thin, soft, loose-fitting, 6 inch-long polyurethane sheath to line 
the vagina. One ring lies inside the closed end of the sheath and is used 
for inserting the condom and anchoring it internally in the vagina. The 
outer ring is designed to cover the labia and protect the base of the 
man’s penis during intercourse. Hessels obtained a U.S. patent for his 
invention, which became identified as female condom ‘FC1’. He 
subsequently sold this to Chartex Resources Ltd, a British private 
company, which licensed the product to Wisconsin Pharmacal. 
Wisconsin Pharmacal changed its name to the Female Health Company 
in 1996 (http://www.femalehealth.com), and also acquired Chartex. 
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 More than a decade later, in 2009, a successor to FC1 was developed, 
with a nitrile sheath instead of a polyurethane sheath, and was labelled 
FC2.
The change in material from polyurethane to nitrile had two main 
advantages: firstly, nitrile is cheaper than polyurethane. Secondly, 
nitrile, an artificial rubber, does not ‘crackle’ like polyurethane, 
which has some characteristics of plastic, and which, in FC1, caused for 
some people certain typical noises when it was used during sexual 
intercourse. 
 A new variety of the female condom, the Cupid1 produced by the 
Indian company Cupid Ltd, was only recently (2012) approved by WHO 
and has a slightly different design from the female condom of the 
Female Health Company since it has an octagonal outer frame instead 
of a round one and is inserted using a sponge which holds the condom 
in place during use. The Cupid1 condom is available in a limited way in 
a few countries (UAFC 2013). Other female condoms are currently being 
developed and tested (see chapter 3). For the purposes of this study, the 
primary focus is on FC2, the female condom with the inner ring, as this 
is the type most commonly produced, marketed and spread (chapter 3).
 The female condom FC1, although invented in 1984, did not come 
onto the global market until after its official approval as a safe device 
in 1993. Currently only FC2 is produced and available on the market 
Picture 1.1
 Female condom (FC2)
(source: Rutgers)
Picture 1.2
 Female condom (Cupid 1)
(source: Rutgers)
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in 130 countries, for around US$ 1 per piece in commercial outlets, 
although consumer prices vary greatly from one country to another. 
 For the majority of women in sub-Saharan Africa, the price of 1 US$ 
per piece is far beyond their purchasing power (UNFPA 2012:14). The 
price of the female condom considerably hinders its access (Brown et al. 
2007; Friel 2005). The issue of pricing with respect to the female condom 
is not understood. Is it a matter of lack of investments by the private 
sector? Is there a lack of a market, potential clients? What role is there 
for the public sector? Do they subsidise the technology? These questions 
are explored in greater depth in chapter 3.
  In addition, the high price of the female condom is also related to 
the recommendation that it is for one-time use only. The disposability 
of the female condom has been criticised from the beginning by women 
in sub-Saharan Africa (Ray et al. 1995), who advocated for a reusable 
commodity, which is more convenient for women with limited 
resources (Osewe 1999). In 2002, the World Health Organisation held a 
conference specifically on the issue of reusability, and as a result, on 
affordability. However, this conference issue was not followed up, 
although a WHO commissioned study had found that FC1 could be 
washed, disinfected, re-lubricated and reused up to seven times without 
ill effects (Beksinska et al. 2001). Nevertheless the conference and the 
positive study about reuse of female condoms (FC1) did not lead to 
further concrete actions from the side of the World Health Organization, 
which is an important actor in the global health sector (WHO 2002).  
  In my thesis, I will elaborate on the lack of interest in AIDS 
prevention at global level. It is problematic that treatment activities 
are successfully scaled up, and prevention efforts not (Piot et al. 2008; 
Stover et al. 2006). Why is prevention not scaled up? This is not due to a 
lack of results, as prevention has been very successfully approached in 
a number of countries, such as in Uganda (De Cock 2000), in Senegal 
(Lom 2001) and in Zimbabwe (Halperin et al. 2011). Some scholars have 
already studied reasons why policy priorities for HIV prevention at 
global level have dwindled (Gupta et al. 2008; Kippax et al. 2003; Merson 
et al. 2008), though this is not yet satisfactorily understood, either in 
practice or in theory. By studying issues related to the female condom 
more extensively, I hope to gain better insight into some major factors 
determining political interest at the global level. For this reason, I first 
describe some general trends in health at the global level. 
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Globalisation, public health and sexual and reproductive 
health and rights (SRHR)
Health globalisation is the process of consolidating the health field 
worldwide, when health-related actions are carried out with global 
expectations (Inoue et al. 2006). Since the International Conference on 
Primary Health Care of 1978 in Alma Ata, health is considered a 
fundamental human right. The World Health Organisation developed 
its ‘Health for All’ strategy, based on the notion of health care as a 
public good, to which access should not be restricted by particular 
economic circumstances (Thomas et al. 2004). Soon after Alma Ata, 
neoliberal principles increasingly invaded the global health agenda. 
Market mechanisms in global health gained importance, while the role 
of national governments and the United Nations decreased (Willets 
2000). Global economic institutions, such as the International Monetary 
Fund (IMF), the World Bank (WB), and the World Trade Organisation 
(WTO) became increasingly involved in global health governance, 
gradually shifting public health from the public sphere towards the 
arena of the transnational private commercial sector (Buse et al.; 2009; 
Ollila 2005;Thomas 2004). With the adoption of the Millennium 
Development Goals (MDGs) by the United Nations General Assembly in 
2001, global health became a pressing foreign policy issue (Labonté et 
al. 2010), with HIV/AIDS selected as one of the top priorities (MacKellar 
2005; Ravishankar et al. 2009; Woods et al. 2013). 
 Some global health scholars argued that this prioritisation was not 
only justified by scientific arguments, but by power at play through 
implicit norms and values (Thomas 2004; Woods et al. 2013). This 
research looks into these norms and values underlying political 
decisions in global health, especially concerning the AIDS epidemic. 
And what about the norms and values surrounding sexual and 
reproductive health and rights? Does gender play a role, and how do I 
research this type of power? For example, when researching the global 
lack of interest in the male contraceptive pill, it became clear that 
neither the private commercial sector nor the public sector has had any 
motivation or incentive to develop this male pill. Though technical 
reasons were often ‘framed’ as the main stumbling block, in fact such 
reasons were found to be rather scarce (Oudshoorn 2003). The more 
deeply rooted causes for not technically innovating the male pill were 
found through some honest reflections afterwards; when a director of 
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a successful Dutch contraceptive company was asked why his company 
never invested in developing and researching a male contraceptive 
pill, in hindsight he reasoned that ‘middle age male chauvinism’ played 
a role in not developing a male contraceptive pill: ‘Indeed for years 
the men from my age at the top management level said to each other: 
“Men will never use this”. During management meetings the male pill 
was always ridiculed: “Would you use it? You would surely not use it?” 
There was a basic resistance against the whole principle: “We don’t 
want it, so all men don’t want it” ’ (Rensman 2006: 163, translated by 
AP). The mind-set of the actors in the management room of this private 
commercial company mattered more than technical arguments. 
Oudshoorn concluded that arguments against the male contraceptive 
pill were stuck in the highly gendered arena of sexual and reproductive 
health and rights (Kammen et al. 2002; Oudshoorn 2003). Therefore, in 
my thesis, I will focus on studying the often implicit norms and values 
as they seem significant in blocking global health goals as also found 
and studied by Alkire et al. (2004), who argued that there is a lack of 
clarity regarding the morality underlying global health initiatives, 
both for why and how programmes should be undertaken. 
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1.3 Central question
Based on the above, my central research question is: 
Why has the female condom remained a low priority product on the global 
health agenda in the response to AIDS?
Before dividing the central research question into sub-questions, I will 
first explain the aim of this thesis. 
1.4 Aim
This thesis ‘Fumbling with the female condom’ aims to contribute to 
an understanding of the reasons and subtle mechanisms which have 
led to not prioritising the female condom as an effective HIV prevention 
tool for women in the response to AIDS, a global problem whose 
solutions are otherwise well funded. Moreover, by creating insights 
into global mechanisms which are in place when prioritising products 
that protect against AIDS, it aims to add theoretical insights into the 
gender dimension of the global response to AIDS and into political 
prioritisation in global health in general. 
 Based on this thesis, I hope global health policy actors recognize 
and accept that reasons for prioritizing global health issues might be 
hidden or implicit and thus often need discussion and reflection. This 
might improve sexual and reproductive health and rights for women. 
Further I hope it will inspire scientists and technologists to develop a 
well-designed, convenient, affordable, re-usable vaginal protection sheath, 
as many women seem to wish. When proven marketing strategies are 
in place which not only respond to an initial demand, but also increase 
demand, such a vaginal protection sheath will greatly enhance women’s 
health, agency, and room to manoeuvre; it will lower the incidence of 
cervical cancer, HIV/AIDS and other sexually transmitted infections, as 
well as unintended pregnancies and unsafe abortions, and empower 
women when negotiating for safer sex. 
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1.5   Concepts and theories on political 
prioritization
I will introduce the concepts and scientific positioning on how I 
deconstructed the dynamics regarding the central research question 
about the low political priority given to the female condom at global 
level. I define political priority for global health initiatives as the degree 
to which leaders of international organisations actively pay attention to 
a global health issue, and take decisions and instruct their organisations 
to provide financial, technical, and human resources to address it 
(Shiffman et al. 2007). This definition emphasises that political priority 
is not only the political willingness or commitment to act, but includes 
agency: the active decision making, and provision of concrete resources 
towards this priority. As mentioned above, this prioritisation is not a 
neutral process; it works in the context of power relations. In the 
following I explain the concept of power as used in my research.
Power 
Power normally operates in all human beings and their relationships, 
in private and public life (Mann 1986; Therborn 1990). Theorizing the 
concept of power in terms of individuals ‘having power’, means that 
individuals have the capacity to make or receive or resist any change 
(Klein 1998; Veneklasen et al. 2002). It is also about the space individuals 
have or can make to express themselves. 
 Power does not only refer to individuals, it also refers to institutions. 
Referring to political priority as mentioned earlier, ‘having power’ means 
that decision-makers have the power to concretely provide resources 
toward the implementation of a set of policies, which is different from 
only showing political will or commitment. 
 Most definitions of politics or political prioritisation involve power. 
Power has been prominent in discussions of international interactions. 
Gilpin describes the concept of power as ‘one of the most troublesome 
in the field of international relations’ (1975: 13) There is, however, 
widespread consensus about both the necessity of addressing the role 
of power in international interactions and the unsatisfactory state of 
knowledge about this topic (Guzzini 2000; Barnett et al. 2005; Berenskoetter 
et al. 2007) as quoted in Baldwin (2008: 278).
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 In my research I do not make a strict distinction as both types of 
power, the power held by individuals and the power embedded in 
institutions, both matter and are related. According to Foucault (1997) 
power is embodied in a web of relationships or in an institution, affects 
everyone, and no single actor holds this power as it is based on dominant 
social norms and discourses. This discursive power, the power to frame 
ideas in a certain way, is for example expressed in narratives that represent 
frames that reveal how reality is constructed within institutions (Fisher 
1989). For example the 1994 International Conference on Population 
and Development (ICPD) has shaped the way European donors and 
advocates have framed their support for sexual and reproductive health 
and rights (SRHR) (Lancker 2010).
Sexual and reproductive health and rights (SRHR), 
sexualities and sexual meanings
In the context of sexual and reproductive rights, ‘having power’ means 
that each individual (man or woman) has the power to make decisions 
regarding with whom, when and how to have sex. This ability to identify 
their own interests and to stand up for them and express them is often 
called ‘the power within’. When people are ignorant of their rights, 
they do not realise they have the power to speak up. The concept of 
being empowered is essential to sexual and reproductive health, 
especially for people who have not learned to speak up or who have a 
low social status or low self-esteem (Marmot 2005). 
 The female condom has been identified as an empowering tool for 
women (Gollub 2000) and might contribute to fulfilling women’s individual 
choices, their sexual rights. However breaking through cultural barriers 
which block women’s rights, including sexual rights, is identified as 
essential, though extremely hard (Brems 2013; Malhotra et al. 2005). 
Both Brems and Malhotra argue that lack of women’s rights are deeply 
rooted in cultural norms and values which people and institutions 
hold on to. 
  Sex refers to the biological characteristics that define humans as 
women or men. However, it is known that the sets of biological charac-
teristics of a woman and those of a man are not mutually exclusive, as 
there are individuals who possess both. ‘If the immutable character of 
sex is contested, perhaps this construct called ‘sex’ is as culturally 
constructed as gender; indeed, perhaps it was always already gender, 
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with the consequence that the distinction between sex and gender 
turns out to be no distinction at all’ (Butler 1990: 346).
 Also ‘sexuality’ triggers people to think in a very narrow, limited 
way, referring to sexual acts or sexual intercourse, which in turn is 
often narrowly perceived as penetration by the man (Simon et al. 1986). 
The concept of sexuality is complex and includes different dimensions, 
though not all of them are always experienced or expressed. WHO 
(2010:5) proposed the following definition: ‘Sexuality is a central aspect 
of being human throughout life, encompassing sex, gender identities 
and roles, sexual orientation, eroticism, pleasure, intimacy and 
reproduction. Sexuality is experienced and expressed in thoughts, 
fantasies, desires, beliefs, attitudes, values, behaviours, practices, roles 
and relationships. It is influenced by the interaction of biological, 
psychological, social, economic, political, cultural, legal, historical, 
religious and spiritual factors’. Thus sexuality has a broad meaning 
and is a complex and dynamic phenomenon and therefore it is better to 
speak of sexualities.
 Foucault (1979) argued that the concept of what type of activities 
and sensations are defined as ‘sexual’ is historically influenced, thus 
not fixed, but part of a changing ‘discourse’. He viewed the constructions of 
sexual meanings as instruments by which social institutions (religion, 
marketing, the educational system, psychiatry, etc.) control and shape 
human relationships (Foucault 1979). Foucault further argued that 
social institutions influence these beliefs on what is considered sexual 
and what is not. 
 Ortner and Whitehead (1981) argue that what male and female, sex 
and reproduction mean in given social and cultural contexts is essential 
and they treat gender, sexuality and reproduction as symbols, invested 
with meaning by the society in question, as all symbols are. 
 In such a constructivist approach, sexualities refer to the social 
rules, economic structures, political battles, and religious ideologies 
which determine people’s physical expressions of intimacy and their 
relationships (Cornwall et al. 2008). Since women and men have been 
affected by general power relations in strikingly different ways, the 
concept of gender is crucial in my research.
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Gender
Although ‘gender’ is not at all synonymous with ‘women’, particularly 
in development work, gender often tends to be narrowly identified 
with women’s issues. In the 1970s, feminists started to use the term 
gender as a way of referring to the social and cultural expectations of 
women and men, girls and boys, and people of alternative gender 
identities and constructions of femininity and masculinity. Gender 
refers to the attitudes, feelings, and behaviours that are culturally 
associated with a person’s biological sex. 
 As Simone de Beauvoir, applying existentialism to women’s life 
experiences pointed out: ‘One is not born a woman, one becomes one’ 
and that ‘social discrimination produces in women moral and 
intellectual effects so profound that they appear to be caused by nature’ 
(Beauvoir 1972:18 [original 1949]). 
 Feminism aims to create a ‘genderless (though not sexless) society, 
in which one’s sexual anatomy is irrelevant to who one is, what one 
does, and with whom one makes love’ (Rubin 1975: 204). Gender thus 
involves the social construction of ideas about the appropriate ways of 
being women and men, and how women and men are supposed to 
behave. 
 Overall, gender arrangements are dynamic and influenced by 
power structures, which are shaped by and shape individual actions 
(Connell 1987). When people consider gender differences as natural, it 
makes the structural and systemic bases of power invisible, although 
they are at work in all human relations (Gorman 1992). 
 Many existing political theories do not challenge the dominant 
values of gendered human behaviours which are at work in patriarchal 
societies (Persram 1994; Peterson et al. 1998; Schwartz et al. 2001). 
Therefore in this study I view gender relations as being power relations, 
relations as being always gendered, not power-neutral. Global health 
policies actors who are tasked with decision-making and setting 
priorities ‘do gender’ like all other human beings (West et al. 1987). The 
different ways in which they ‘do gender’ in this process will be 
uncovered in this thesis.
Theories on political prioritization in global health
To critically investigate political prioritization in global health, the 
literature provides some interesting studies: Joachim (2003); Carpenter 
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(2007); Rushton (2010) and Shiffman & Smith (2007). Joachim (2003) 
studied how non-governmental organisations advocated and successfully 
drew the attention of the United Nations and its member states to their 
concerns about violence against women, which is considered a violation 
of their sexual and reproductive health and rights. These rights include 
the freedom of women, and thus implies that women should be free, 
without the threat of violence, to choose the type of protection they 
prefer to make their sexual acts safer, protecting them against an 
unplanned pregnancy or a sexually transmitted disease (Petchesky et 
al. 1998). Joachim’s conceptual framework (2003) lays out a step-wise 
process of gaining global political interest at the UN level. However, in 
the case of the female condom, a step-wise process of political 
prioritisation will not help, since the topic already seems fully 
integrated in the official UN agenda (UNGASS 2001:7) and features in 
many official donor policies. Because getting an issue on the agenda is 
not enough, as it already is mentioned on the agenda, I therefore need 
theoretical frameworks which go beyond agenda setting to clarify 
political prioritization.  
 Carpenter (2007) suggested another theoretical framework about 
political prioritisation. She states that, although the impact of global 
advocacy networks on global public policy making has frequently been 
studied in-depth, little is known about how these networks select the 
issues around which they organize themselves and mobilize resources. 
Based on empirical data, Carpenter argues that there is considerable 
variation in the emergence and prominence of global issues. 
Understanding this variation is especially relevant for those who study 
processes of social change in a global context. Carpenter (2007) 
concludes that little is known about the initial stages of political 
prioritisation, which determine whether or not a particular problem is 
defined as an issue that merits attention, how it is articulated and 
adopted, and, most importantly, whether it actually emerges and is 
judged worth advocating for. Carpenter argues that advocacy networks 
are often not transparent about their selection criteria. Her research 
was exceptional, in the sense that she compared two global problems in 
the context of armed conflict that are related, and apparently equally 
relevant and widespread: child soldiers in war areas and children born 
as a result of rape during wartime. The first one has gained high 
prominence in the global advocacy sphere, while the second one is 
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absent. The problem of children born of rape during wartime has never 
become a significant issue for transnational advocacy, although it is as 
problematic as the issue of child soldiers. By comparing these two 
problems, she discovered how crucial the selection criteria are at the 
early stages of the process of advocacy. These are often not transparent 
or justified, seldom studied, and thus not understood. Carpenter 
recommended that future studies should focus on analysing issues 
which are silenced in the global sphere. I have taken up this challenge 
by looking at the silencing mechanism. Why has the female condom 
failed to become a high-priority global health issue, even though it is a 
clear preventive to AIDS whose epidemic is seen as a prominent global 
health problem? If it is not about the size of the problem, what is 
important in theories about political prioritization? 
 Rushton’s theory (2010) about political prioritisation focuses on 
analysis of the process of interest formation. Although there are 
multiple ways in which a global problem may be framed, the selection 
of the ‘right frame’, or the frame which potentially has the most 
influence, appears to be crucial in explaining the successes and failures 
of global interest formation in an issue. Circumstances determine 
which framings are most influential, as certain frames raise the profile 
of the problem at hand more than others. Rushton analyses different 
types of frames that have been used to make AIDS the most widely 
prioritised global health issue in the past decade. He identifies the 
critical moments in the ascendancy of HIV and AIDS to the top level of 
political attention. And he further identifies the three most influential 
framings that have helped to portray and lift AIDS to the position of a 
global issue: AIDS as a development issue, as a human rights issue, and 
as a security threat. He concludes that the development frame is by far 
the most frequently used frame in AIDS policy documents; that framing 
AIDS as a security threat is less used; and that the human rights frame 
appears largely in the context of the modality of the global response to 
AIDS, rather than as a justification for the prioritisation of AIDS in its 
own right. Following this approach of Rushton, I will study the nature 
of the ‘frames’ global actors use in their policies in addressing HIV 
prevention and the relative role of the female condom therein, and how 
this is informed by notions of gender and sexuality (chapter 6). 
 In his conclusion, Rushton (2010:13) states: ‘It is clearly problematic 
to draw a direct link between the prevalence of a frame, and its actual 
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influence on subsequent actions.’ He further notes that the practical 
implications of the existence of competing frames are not known. He 
concludes that both agency and the institutional context are found to 
be important in determining whether an issue gets prioritised and 
decision makers are willing to act. In a similar way, it is problematic to 
draw a direct link between the framing of the female condom issue and 
its active availability and use. There is a need to study the power and 
actors involved in the allocation of funding for the female condom as 
well (chapter 5), and real life attitudes behind the official framing of 
AIDS prevention and the female condom in an institution responsible 
for implementing policies supporting the female condom (chapter 7). 
 The power of the actors, including the power of actors’ ideas, is an 
important category in the theoretical framework of Shiffman and 
Smith (2007). They developed a theoretical framework which 
prominently includes the concept of power, and is classified as a 
political process theory (Bevington et al. 2005), based on a rational view 
of collective action and institutional power (Bergman 2004; Della Porta 
et al. 1999). Shiffman and Smith (2007) applied this framework to the 
case of the global health initiative to reduce maternal mortality and 
came up with four categories of factors, considered equally important 
to political prioritisation in global health; actor power, the ideas used 
to describe the issue, the context within which the actors are operating, 
and the characteristics of the issue itself.
 Actor power in this framework consists of leadership, a guiding 
institution - either an organization or a more informal network, but 
one connected by similar values and goals; and the mobilization of civil 
society in order to advocate at national and international level. Ideas in 
this framework refer to how the issue is characterised and described in 
trying to draw attention to it. Shiffman and Smith argue that some 
health campaigns are easier to promote than others because the 
diseases they address are seen to be more harmful (for example, 
neonatal mortality, with 4 million global deaths per year) and have 
more cost-effective and simple evidence-based solutions. Context in the 
Shiffman and Smith framework is the environment in which the actors 
operate and includes the ability of the global actors to take advantage 
of policy windows to influence decision makers. Characteristics of the 
issue being addressed include the extent to which there are credible 
indicators that can be used to assess severity and to monitor progress 
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and the size of the burden, as well as an evidence base on cost-effective 
interventions that can be implemented at scale. In table 1.2 the 
framework is summarised. 
I used this framework to build my thesis and to split my central research 
question into six sub questions.
 
1.6  Sub-questions
In the following section, I explain how I divided the central question, 
Why has the female condom remained a low priority product on the global 
health agenda in the response to AIDS?, into six sub questions, inspired by 
the theoretical framework of political prioritisation by Shiffman and 
Smith (2007). To answer this central question I decided to foreground 
two of the four categories identified by Shiffman and Smith (2007) - 
issue characteristics and actor power - but in an adapted sequence. 
 I integrated the category ‘power of ideas’ into ‘actor power’ as it 
was impossible to analyse the power of ideas as independent from its 
actors and the different discourses. The other category, ‘political 
Table 1.2  Theoretical framework of Shiffman and Smith about 
political prioritisation in global health 
Categories Description Additional features
1 Actor power The strength of the 
individuals and 
organisations concerned 
with the issue
Coherence between actors,  
in institutions and in civil 
society and leadership
2 Power of ideas The ways in which actors 
understand and portray 
the issue
Resonances of the frame 
internally and externally
3 Political 
context
The environments in 
which the actors operate
Global conditions and  
global governance
4 Issue 
characteristics
Features of the problem The scale of the problem,  
the severity of the problem 
itself, and the existence of 
effective interventions
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context’, was studied as the total of political factors that influence both 
the issue characteristics as well as the actor power and the power of 
ideas. Thus I structured my research into two parts: researching the 
issue characteristics and researching the power of actors. 
 The chronological order in which different studies were carried 
out, researching either an issue characteristic or an actor power, was 
different from the order presented in this thesis. Only at a later stage of 
my PhD, I developed a new structure, which means that the sequencing 
of the data might sometimes be perceived as illogical, as for example 
chapter 4 was the first study published (2010) though not presented as 
such in this thesis.
 The main question regarding the low priority for the female 
condom is researched step by step by analysing those factors that are 
generally perceived as characteristics of the female condom that block 
its success as a HIV prevention tool: its perceived unacceptability, high 
price, and neglect by global AIDS policy actors. 
 The first sub-question is therefore related to the issue that the 
acceptability of the female condom is often questioned. Frequently, 
this device evokes spontaneous negative reactions or a kind of dissatis-
faction, including among AIDS policy makers. People generally seem to 
doubt the acceptability of the device by its potential users. My first set 
of sub-questions are therefore: How has the concept of acceptability been 
operationalized in recent female condom acceptability studies, and how do any 
differences in the way acceptability is operationalized relate to the results of 
these studies in terms of whether women in sub-Saharan Africa accept or reject 
the female condom? These questions are answered in chapter 2. 
 The second set of sub-questions relate to the economic characteris-
tics of the female condom, its price and affordability, since the high 
price is currently used by global AIDS policy makers as the rationale for 
not promoting the female condom, as they fear low cost-effectiveness of 
AIDS prevention programmes. I would like to obtain a better 
understanding of how public and private sector measures are usually 
taken to make public health products universally accessible, and 
explore how this has functioned with respect to the female condom. 
The sub-questions are therefore: How do global measures to create access to 
the female condom or to improve the product compare to global measures that 
are taken for two other, though similar, public health products and what are the 
consequences for the affordability and demand of these products, both generally, 
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and with a focus on the region of sub-Saharan Africa? The results of this 
study can be found in chapter 3.
 The third sub-question in this category is related to the female 
condom’s perceived potential. I studied how different stakeholders 
view the potential of the female condom, in order to understand the 
complexity of the network of stakeholders and their different opinions 
of, and stakes in, the issue. Therefore the third sub-question is: What 
positions do the different stakeholders – female condom users, providers, 
manufacturers, national governments, international development organisations 
and donor agencies – take towards the acceptability, availability and affordability 
of the female condom, and what roles do they play? The full study can be read 
in chapter 4.
 The next step in my thesis about the low priority for the female 
condom will be answered by unravelling and studying different types 
of actor power, and the ways in which global AIDS policy makers 
exercise their power. The first and most visible way is funding power. 
I analysed the trends in funding for the female condom and relevant, 
comparable products being considered in the global fight against AIDS. 
The fourth set of sub-questions read as follows: How is the public funding 
divided over research on HIV preventive vaccines and microbicides compared to 
integrated condom programming in the period 2000 to 2008? And is there a 
difference in public donor funding within HIV prevention between the EU and 
the USA? These questions are examined in chapter 5. 
 Another way actors exercise power is by ideas, the power of framing. 
I am interested in how global AIDS policy actors frame the problem of 
AIDS in their policy papers, how they view sexual and reproductive 
health and rights, and how they frame the female condom. The fifth 
research sub-question is therefore: In what ways did global AIDS policy 
actors frame the AIDS problem, considering women’s sexuality and sexual rights, 
and in particular, the female condom, and which AIDS prevention technologies 
did they prioritise in their policy papers? The results of the study are 
presented in chapter 6.
 Although written AIDS policies were found important to research 
the dynamics which made the female condom a low priority in the 
global response to AIDS, another more implicit type of actor power 
needed to be taken into consideration. Policy actors are part of an 
organisation and in their daily work; these actors share their personal 
ideas, values and opinions with each other. Therefore I researched this 
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aspect too, guided by the research sub-questions: Do the staff narratives 
in this case study contribute to an organisational context that is an enabling, 
neutral or disabling environment to facilitate the implementation of the female 
condom as stated in the organisation’s policy, and why? These questions are 
answered in chapter 7. 
 Last but not least in chapter 8 I answer the central research question 
and add more depth to the theorisation about political prioritization in 
global health. First I explain the different research methodologies used 
in this thesis. 
1.7  Methodology
In conducting this research, I used insights from different disciplines: 
public health, sociology, anthropology, psychology, political science, 
development studies, international relations, and gender studies. 
Combining different disciplines is an advantage in the context of a 
complex and fast changing global society, and also in relation to an 
issue concerning HIV and AIDS and sexuality, which has many and 
complicated ramifications. This approach also permitted me to consider 
the issue from multiple angles and investigate the dynamics at play 
which made the female condom into a low priority in global health and 
the response to AIDS. 
 A mix of quantitative and qualitative research methods lent 
themselves to obtaining the answers to these questions. For each of the 
six research sub-questions I used a special research method appropriate 
to answer the sub-questions, and these study methods are fully 
explained at the beginning of each chapter. They included in-depth 
interviews with key stakeholders, observations of policy actors during 
international conferences, financial tracking and trend analysis, 
content analysis of policies, analysis of annual reports of condom 
companies, and diverse literature studies. The following table gives an 
overview of the research questions and related research methodologies. 
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Table 1.3  Overview of the selected methods for each of the six 
sub-questions
Central research question: Why has the female condom remained a low priority 
product on the global health agenda in the response to AIDS?
Sub-questions Methods
1.  How has the concept of 
acceptability been 
operationalized in recent 
female condom acceptability 
studies, and how do any 
differences in the way 
acceptability is 
operationalized relate to the 
results of these studies in 
terms of whether women in 
sub-Saharan Africa accept or 
reject the female condom? 
(chapter 2)
Literature review across multi-disciplinary 
fields using the most relevant electronic 
databases.
In-depth analysis of 15 female condom 
acceptability studies for women in sub-
Saharan Africa. 
2.  How do global measures to 
create access to the female 
condom or to improve the 
product compare to global 
measures that are taken for 
two other, though similar 
public health products and 
what are the consequences 
for the affordability and 
demand of these products, 
both generally, and with a 
focus on the region of sub-
Saharan Africa? (chapter 3) 
Comparative case method: the female 
condom with two similar public health 
products, male condoms and microbicides.
Literature review, annual reports of the 
male and female condom companies, and 
business news articles.
Five elements for analysis: the global 
market, size of investments, the volume of 
the sales and type of clients, the availability 
of subsidies and public private 
partnerships.
3.  What positions do the 
different stakeholders – 
female condom users, 
providers, manufacturers, 
national governments, 
international development 
organisations and donor 
agencies – take towards the 
acceptability, availability and 
affordability of the female 
condom, and what roles do 
they play? (chapter 4)
Literature review.
Comparison of number of references in 
special issue of the Lancet edition on the 
‘state of the art of HIV prevention’.
Observations and interviews with 
representatives of international 
stakeholders during an international 
conference.
Analysis of results with special framework 
developed to assess access to new health 
products in developing countries.
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To keep personal biases in check, I conducted part of the research in 
collaboration with other colleagues interested in the same issues. Such 
collaboration also contributed to the interdisciplinary perspective, 
making the research richer. My own perspective is derived from public 
health and inspired by the ethic of public health: ‘Public health should 
be a way of doing justice, a way of asserting the value and priority of all 
human life’ (Beauchamp 1976:8). I agree with Delobelle’s view (2011) 
Table 1.3  Continued
Sub-questions Methods
4.  How is the public funding 
divided over research on HIV 
preventive vaccines and 
microbicides compared to 
integrated condom 
programming in the period 
2000 to 2008? And is there a 
difference in public donor 
funding within HIV 
prevention between the EU 
and the USA? (chapter 5)
Analysis of secondary data drawn from two 
databases maintained by UNAIDS and 
UNFPA.
Tracking donor government financing for 
HIV vaccines and microbicides.
Computing donor government funding 
levels for integrated condom programming.
5.  In what way did global AIDS 
policy actors frame the AIDS 
problem, considering 
women’s sexuality and sexual 
rights, and in particular the 
female condom, and which 
AIDS prevention technologies 
did they prioritise in their 
policy papers? (chapter 6)
Quantitative and qualitative discourse 
analysis of 16 global AIDS policy papers, 
involving collection of data in the form of 
excerpts from 16 global AIDS policy papers; 
counting and tabulating the frequency of 
different terms used in framing the AIDS 
problem; examining how different 
categories of people are labelled, as part of 
targeting in AIDS prevention programmes; 
analysing how gender is marked in AIDS 
prevention technologies. 
6.  Do the staff narratives in this 
case study contribute to an 
organisational context that is 
an enabling, neutral or 
disabling environment to 
facilitate the implementation 
of the female condom as 
stated in the organisation’s 
policy, and why? (chapter 7)
Data collection through in-depth 
interviews using a pre-tested, semi-
structured interview guide with five staff 
members working in a government 
institutional setting where global AIDS 
policies are developed and guidance for 
implementation provided. 
Qualitative data analysis using coding 
techniques, thematic analysis.
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that political will and power relations influence public health, and this 
thinking has influenced me as researcher.
 Although familiar with the standpoint theory of Harding, which 
prioritises studying the unheard voices of women (Harding 1993), I chose 
not to conduct an empirical study of women’s attitudes to and experiences 
with female condom use. For one thing, quite a few studies have already 
been conducted on this subject and these are reviewed in chapter 2. 
 More importantly, interrogating women on something that is beyond 
their reach now and likely to remain so in the near future was not an 
option to me. I believed that the interrogation of power holders was 
more relevant, based on the maxim that `with great power, comes 
great responsibility .´ As power holders often remain unproblematised 
(Bacchi et al. 2009), I decided to focus my research on those currently in 
power and examine why the female condom remained a low priority 
among global AIDS policy actors. 
1.8  Outline of the thesis 
This first chapter serves as introduction to my research on the female 
condom. Chapters 2 to 7 describe the results, concerning three charac-
teristics of the female condom and three different types of power of the 
actors. This categorisation was inspired by the theoretical framework 
of Shiffman and Smith. As the chapters were published as separate 
articles some overlap is inevitable. The chapters moreover were published 
over a period of time during which the field of research changed. Some 
of the data used in later articles was not yet available when the first 
ones were written, e.g. the introduction of new types of condoms, new 
manufacturers or new data on HIV prevalence. As this did not change 
the overall conclusions I decided to keep the articles as they were 
published. 
 Chapter 2 deals with what a review of the existing literature reveals 
about the acceptability of the female condom. While the first reaction 
of many stakeholders to the female condom is often negative, an analysis 
of the recent acceptability research shows surprisingly different results. 
 Chapter 3 deals with the unaffordability of the female condom, 
which is seen as another barrier for its use. The research shows that the 
affordability of public health products can be successfully changed by 
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some public and private sector measures. It provides a comparative 
analysis of how certain measures have operated in the case of the 
female condom, compared to similar public health products: the male 
condom and microbicides. 
  Chapter 4 deals with the perceptions of the different stakeholders 
about the issue of the female condom in terms of its acceptability, 
availability and affordability. The responses of the different stake - 
holders helps explain the limited access to the female condom for 
women living in sub-Saharan Africa, and puts the role the global public 
sector under scrutiny. 
 Chapter 5 focuses on the amount and nature of international 
funding for HIV prevention and the power of international donors to 
influence the amount of funding invested in certain technologies. 
The findings show that the funding practices of donors are not in favour 
of integrated condom programming and the female condom. 
 Chapter 6 explores the framing power of actors. Here the discursive 
practices of 16 global actors are analysed in order to find out how they 
frame and justify their political priorities in their policy papers. The 
research reveals that an analysis of the framing of the AIDS epidemic 
in terms of gender and sexuality matters significantly. 
 Chapter 7 deals with implicit power. It analyses the narratives 
related to the female condom among policy officers and technical staff 
working in donor agencies in the domain of AIDS and sexual & 
reproductive health and rights. How policies are implemented however, 
also depends on the attitudes and values of personnel responsible, and 
these probably merit closer scrutiny to identify the gaps between policy 
and practice. 
 Chapter 8 presents the overall conclusions, answering the central 
research question of this thesis. These are presented in the context of 
the theoretical framework of Shiffman and Smith about political 
prioritisation in global health, and offer some additional elements and 
deeper insights, plus recommendations.
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ACCEPTABILITY OF  
THE FEMALE CONDOM BY 
SUB-SAHARAN AFRICAN WOMEN:  
A LITERATURE REVIEW2
2 Published as: Peters A, Driel van F, Jansen W. 2014. “Acceptability of the Female  Condom 
by sub-Saharan African Women: A Literature Review.” African Journal of Reproductive 
Health; 18(4): 34-44.
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Abstract
Sub-Saharan African women are affected disproportionately highly by 
AIDS, while experiencing lack of choice for devices which protect them 
against sexual transmitted diseases, including HIV. One should expect 
that global policy makers react positive to the female condom, a 
contraceptive device which offers dual protection. However, those 
policy makers often argue that the female condom is not acceptable to 
its users. Our objective is to find out whether this general statement is 
based on existing empirical data. Through a literature review we 
analysed empirical studies done between 2003 and 2013 and compared 
the extent to which female condoms were acceptable among women in 
sub-Saharan Africa. We found that acceptability was defined in 
different ways, along the line of two types of studies: intervention and 
non-intervention studies. The intervention studies defined acceptability 
as women who agreed to use the female condom several times. The 
non-intervention studies which were not linked to specific interventions, 
operationalized acceptability in terms of women who liked the female 
condom, not necessarily based on practical experience or use. Intervention 
studies led to a high proportion of women using the technology, rating 
the experiences as satisfactory, although recommending technical 
improvements. In contrast, non-intervention studies showed low use due to 
non-acceptability mixed with reasons of unfamiliarity, unavailability 
or unaffordability. We concluded that women in sub-Saharan Africa 
accepted the use of the female condom when potential users were given 
access to the device, and exposed to interventions which supported the 
use of a female condom.
Keywords: acceptability, female condom, sub-Saharan Africa, HIV/AIDS, 
contraception, policy and practice.
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2.1 Introduction
Globally women comprise about half of all people infected with Human 
Immune-deficiency Virus (HIV) leading to Acquired Immune Deficiency 
Syndrome (AIDS), though in sub-Saharan Africa women form the 
majority (58%) (UNAIDS 2012:72). This region accounts for the largest 
proportion of HIV-positive women (76%) and the prevalence among 
women aged 15 - 24 years (3.3%) is more than twice the prevalence rates 
for men (1.4%) (WHO 2011:153). This gender difference originates from 
biological, sociocultural, economic and political factors (Higgins et al. 
2010; Kemboi et al. 2011). Sub-Saharan Africa has the highest percentage 
of women with an unmet need for contraceptive methods (about one 
quarter of women between 15- 49 years: 47 of 195 million) (Darroch et 
al. 2011:35). Under these circumstances, accessibility to both male and 
female condoms appears important, since condoms are the only 
evidence-based technologies that provide dual protection.
 The female condoms allow women to protect themselves (WHO 
2009),  and have proved to help them gain more control over their 
sexuality (Gollub 2000, Mantell et al. 2008; Susser 2001). Although it has 
been on the market since 1993, consumers, especially women in 
sub-Saharan Africa or women with low purchasing power are not in a 
position to access it (Peters et al. 2010a; chapters 3 and 4). The limited 
spread of female condoms is remarkable, given the widespread ambition 
to curb the AIDS epidemic and reduce high fertility rates, and moreover, 
according to the current international agenda, to enhance women’s 
sexual and reproductive rights (Meredith et al. 2012; Peters et al. 2010a; 
chapter 4). While the promotion of the female condom seems obvious 
in this context, global health agencies often express their concern 
about the low acceptability and low usage rates of the female condom 
(Hoffman et al. 2004; Worley 2005). Therefore, this review was 
conducted to find answers to our research questions: How has the 
concept of acceptability been operationalized in recent female condom 
acceptability studies, and how do any differences in the way 
acceptability is operationalized relate to the results of these studies in 
terms of whether women in sub-Saharan Africa accept or reject the 
female condom?
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2.2 Methods
We searched literature in two databases: PubMed biomedical literature, 
and PsycInfo behavioural sciences and mental health; and searched 
‘grey’ literature in relevant mailing lists (RectalMicro IRMA, AVAC, 
ShareNet) and earlier reviews (AIDS institute 2009; Parker et al. 2009), 
by screening titles and abstracts for combinations of the terms ‘female 
condom’, ‘acceptability’ and ‘rejection’. In order not to miss out on 
publications, we included words in our search terms that might indicate 
acceptability or its opposite, such as accept(ance), adopt(ion), attitude 
(attitudinal), convenient (convenience), use (using), reject(ion), fail(ure), 
prefer(ence), perform(ance), skill, experience; terms that might indicate 
pilot interventions, such as introduce (introduction), promote (promotion), 
educate (education); communicate (communication), empower(ment), 
teach(ing), intervention. The review excluded economic analyses, cost- 
effectiveness and impact studies. We also left out female condom 
acceptability studies among men, health providers, (health) policy makers 
and the media, since this is not the focus of our study. All studies used 
a similar type of female condom, the type with the inner ring (Joanis et 
al. 2011; Smit et al. 2006). 
 We searched recent literature published between 2003 – 2013 when 
increased funding was available for the global fight against AIDS (Peters 
et al. 2010; chapter 4). Eligible papers were required to be: (1) retrievable, 
either as a full study or as an article in peer reviewed scientific journals; 
(2) based on empirical studies; (3) have a sound scientific methodology; 
(4) study female condom acceptability of the condom type with the 
inner ring; (5) deal with women in sub-Saharan Africa. 
 These were our five pre-set criteria. We found 30 studies of which 
15 met and 15 did not meet these criteria. This latter group was listed 
with the reasons for exclusion, which ranged from irretrievability, to 
not being based on empirical data, employment of poor quality research 
methodology, not addressing acceptability, and involving men instead 
of women (See appendix 2.1). The remaining fifteen eligible studies 
were subjected to an in-depth analysis.
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2.3 Results
The 15 selected papers cover eight countries in sub-Saharan Africa and 
9 (of 15) principal researchers came from the region. Table 2.1 lists the 
15 studies: 9 intervention studies and 6 non-intervention studies. The 
latter category targeted sexually active women in general, while the 
target groups of the 9 intervention studies varied considerably: two 
studies targeted only commercial sex workers (Mathenjwa 2010; 
Zachariah et al. 2003), while three studies had a mixed group of women, 
including HIV+women, commercial sex workers, married women, and 
women who had undergone an abortion (Wanyenze et al. 2011; Rasch et 
al. 2007; Smit et al. 2006). Almost half (4 out of 9 studies) involved a 
study population of sexually active women, not further categorised 
(Simons 2009; Napierala et al. 2008; Brady et al. 2009; Ezire et al. 2013). 
The data could not be systematically organised and profoundly analysed 
by target group or category of women, as the number of studies for each 
group was too small and the differentiations between the types of 
women within each study not clear enough to reassemble and compare 
the data. The table shows that the study results on female condom 
acceptability are highly variable and the reported acceptability rates 
range from 2% to 98%.
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Table 2.1  Summary of results of 15 female condom acceptability studies  
among women in sub-Saharan Africa 
Researcher(s), title, year of publication Country and Study population Objectives Methodology Results
9 INTERVENTION STUDIES
Simons B. Over the threshold: female 
condom introduction, negotiation and 
use within heterosexual relationships in 
Lagos, Nigeria [dissertation]. Amsterdam: 
University of Amsterdam; 2009.
Nigeria: 12 women, 12 men, 
aged 20-33 years, with sexual 
relationships, who had never used 
female condoms.
To describe the socio-cultural 
factors influencing the 
introduction of, negotiation 
about, and use of the female 
condom between heterosexual 
partners.
Qualitative: in-
depth interviews.
Preference for female condoms 
over currently used method (p 11). 
Good preparation, introduction 
increases acceptability, use (p 71).
Wanyenze R, Atuyambe L, Kibirige V, 
Mbabazi S, Tumwesigye NM, Djurhuus K, 
Namale A.The new female condom (FC2) 
in Uganda: perceptions and experiences 
of users and their sexual partners. Afr. 
J.AIDS Res. 2011; 10(3): 219-224.
Uganda: 8 women, 8 men who had 
used female condoms: female sex 
workers, HIV+ men, women.
Explore acceptance of female 
condoms by women users and 
their sexual partners.
Qualitative: focus 
group discussions, 
in-depth 
interviews.
No problems in using the 
female condom. Its neutral 
smell, strength, lubrication 
and looseness contribute to 
acceptability (p 219). 
Mathenjwa T. Women’s experiences with 
the female condom: a case of Lavumisa 
female commercial sex workers, in 
Swaziland [Dissertation]. Durban: 
University of KwaZulu-Natal; 2010.
Swaziland: 10 female sex workers, 
22-40 years, who used female 
condoms more than five times, 
with sustained access to integrated 
services.
Elicit female sex workers’ 
experiences, perceptions of 
female condoms.
Qualitative: in-
depth interviews 
and focus group 
discussions.
Appreciation for the female 
condom. Prerequisite for using 
female condoms is training on 
and practice with how to insert 
the device (p 32).
Rasch V, Yambesi F, and Kipingili R. 
Acceptance and use of the female 
condom among women with 
incomplete abortion in rural Tanzania. 
Contraception. 2007; 75(1):66-70.
Tanzania: 475 women admitted to 
hospital for incomplete abortion, 
received counselling on female 
condoms. 
Describe the outcome 
of a post-abortion care 
intervention aimed at 
introducing the female 
condom as a means to 
prevent women from having 
unintended pregnancies and 
STI/HIV.
Quantitative: case-
control design.
39% women consented to use 
female condoms (p 68); 79% 
of those who consented were 
satisfied after 3 months of use 
(p 69). This group intended to 
continue using the device.
Napierala S, Kag M, Chipato T, Padian 
N, Van der Straten A. Female condom 
uptake and acceptability in Zimbabwe. 
AIDS Educ Prev. 2008; 20(2):121-134.
Zimbabwe: 379 sexually active
 women who visited family 
planning clinic.
Determine proportion of 
sex acts protected by female 
condoms; identify women 
reporting 100% female 
condom use. 
Quantitative: 
survey.
Increase in users from 1% at 
baseline to 71% at the end (p 121).
Brady M, Austrian K, Geibel S, Mwangi 
D, Sudha S, Kilonzo N, Ngari H, Njoki 
E, Khisa G, Ajema C. Female-initiated 
Prevention: Integrating Female 
Condoms into HIV Risk-reduction 
Activities in Kenya. Nairobi: Population 
Council 2009.
Kenya: 302 Women visiting VCT; 
50 women visiting family planning 
clinic. 
Explore clients’ attitudes, 
knowledge, use female 
condoms.
Quantitative: 
survey.
56% women consented use (p 11); 
60% of those who consented found 
female condoms comfortable to 
use after having gained some 
experience (p 17).
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Table 2.1  Summary of results of 15 female condom acceptability studies  
among women in sub-Saharan Africa 
Researcher(s), title, year of publication Country and Study population Objectives Methodology Results
9 INTERVENTION STUDIES
Simons B. Over the threshold: female 
condom introduction, negotiation and 
use within heterosexual relationships in 
Lagos, Nigeria [dissertation]. Amsterdam: 
University of Amsterdam; 2009.
Nigeria: 12 women, 12 men, 
aged 20-33 years, with sexual 
relationships, who had never used 
female condoms.
To describe the socio-cultural 
factors influencing the 
introduction of, negotiation 
about, and use of the female 
condom between heterosexual 
partners.
Qualitative: in-
depth interviews.
Preference for female condoms 
over currently used method (p 11). 
Good preparation, introduction 
increases acceptability, use (p 71).
Wanyenze R, Atuyambe L, Kibirige V, 
Mbabazi S, Tumwesigye NM, Djurhuus K, 
Namale A.The new female condom (FC2) 
in Uganda: perceptions and experiences 
of users and their sexual partners. Afr. 
J.AIDS Res. 2011; 10(3): 219-224.
Uganda: 8 women, 8 men who had 
used female condoms: female sex 
workers, HIV+ men, women.
Explore acceptance of female 
condoms by women users and 
their sexual partners.
Qualitative: focus 
group discussions, 
in-depth 
interviews.
No problems in using the 
female condom. Its neutral 
smell, strength, lubrication 
and looseness contribute to 
acceptability (p 219). 
Mathenjwa T. Women’s experiences with 
the female condom: a case of Lavumisa 
female commercial sex workers, in 
Swaziland [Dissertation]. Durban: 
University of KwaZulu-Natal; 2010.
Swaziland: 10 female sex workers, 
22-40 years, who used female 
condoms more than five times, 
with sustained access to integrated 
services.
Elicit female sex workers’ 
experiences, perceptions of 
female condoms.
Qualitative: in-
depth interviews 
and focus group 
discussions.
Appreciation for the female 
condom. Prerequisite for using 
female condoms is training on 
and practice with how to insert 
the device (p 32).
Rasch V, Yambesi F, and Kipingili R. 
Acceptance and use of the female 
condom among women with 
incomplete abortion in rural Tanzania. 
Contraception. 2007; 75(1):66-70.
Tanzania: 475 women admitted to 
hospital for incomplete abortion, 
received counselling on female 
condoms. 
Describe the outcome 
of a post-abortion care 
intervention aimed at 
introducing the female 
condom as a means to 
prevent women from having 
unintended pregnancies and 
STI/HIV.
Quantitative: case-
control design.
39% women consented to use 
female condoms (p 68); 79% 
of those who consented were 
satisfied after 3 months of use 
(p 69). This group intended to 
continue using the device.
Napierala S, Kag M, Chipato T, Padian 
N, Van der Straten A. Female condom 
uptake and acceptability in Zimbabwe. 
AIDS Educ Prev. 2008; 20(2):121-134.
Zimbabwe: 379 sexually active
 women who visited family 
planning clinic.
Determine proportion of 
sex acts protected by female 
condoms; identify women 
reporting 100% female 
condom use. 
Quantitative: 
survey.
Increase in users from 1% at 
baseline to 71% at the end (p 121).
Brady M, Austrian K, Geibel S, Mwangi 
D, Sudha S, Kilonzo N, Ngari H, Njoki 
E, Khisa G, Ajema C. Female-initiated 
Prevention: Integrating Female 
Condoms into HIV Risk-reduction 
Activities in Kenya. Nairobi: Population 
Council 2009.
Kenya: 302 Women visiting VCT; 
50 women visiting family planning 
clinic. 
Explore clients’ attitudes, 
knowledge, use female 
condoms.
Quantitative: 
survey.
56% women consented use (p 11); 
60% of those who consented found 
female condoms comfortable to 
use after having gained some 
experience (p 17).
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Table 2.1  Continued 
Researcher(s), title, year of publication Country and Study population Objectives Methodology Results
9 INTERVENTION STUDIES
Zachariah R, Nkhoma W, Harries AD, 
Arendt V, Chantulo A, Spielmann MP, 
Mbereko MP, Buhendwa L. Acceptability 
and technical problems of the female 
condom amongst commercial sex 
workers in a rural district of Malawi. 
Trop. Doct. 2003; 33(4): 220-224.
Malawi: 90 female sex workers 
were trained, requested to use 
female condoms.
Assess acceptability of 
female condoms; identify 
common technical problems, 
discomforts associated with 
its use.
Quantitative: 
survey.
88 of 90 sex workers (98%) 
consented to use female condoms. 
98% of the users were satisfied (p 
220).
Smit J, Beksinska ME, Vijayakumar G, 
Mabude Z. Short term acceptability 
of the Reality polyurethane female 
condom and a synthetic latex prototype: 
a randomized crossover trial among 
South African women. Contraception. 
2006; 73(4):394-398.
South Africa: 
276 young sexually active women: 
family planning clients, students, 
STI clients, commercial sex 
workers.
To explore the short-term 
acceptability of the synthetic 
latex female condom and the 
polyurethane female condom.
Quantitative 
survey.
All agreed beforehand to try the 
female condom. About 50% rated 
female condoms satisfactory (p 
394). 
Ezire O. Oluigbo O, Archibong V, Ifeanyi 
O and Anyanti J. Barriers to repeated use 
of female condom among women and 
men of reproductive age in Nigeria. J. 
AIDS HIV Res. 2013; 5 (6): 206-213.
Nigeria: men and women of 
reproductive age who are currently 
using and/or have previously used 
female condom.
Study possible reasons 
for low levels of repeated 
use of female condom 
among women and men of 
reproductive age, and options 
to address issues related 
to repeated use of female 
condom
Qualitative: 
16 focus group 
discussions 
and 16 in-depth 
interviews.
Major solution of low repeated use 
of female condoms lies primarily 
in awareness creation through 
more education on how to use (p 
209).
6 NON INTERVENTION STUDIES
Okunlola MA, Morhason-Bello IO, 
Owonikoko KM, Adelkunde AO. Female 
condom awareness, use and concerns 
among Nigerian female undergraduates. 
Journal of Obstetrics and Gynaecology 
2006; 26(4): 353-356.
Nigeria: 879 female university 
undergraduates.
Find out knowledge about, 
attitude to, and use of female 
condoms.
Quantitative 
survey.
11% ‘ever used’ a female condom. 
Major concern: difficult insertion. 
Even though the use was low, the 
high acceptance level in terms of 
willingness to use the device was 
seen as positive (p 353).
Meekers D, and Richter K. Factors 
associated with use of the female 
condom in Zimbabwe. Int. Fam. Plan. 
Perspect. 2005; 31(1):30-37.
Zimbabwe: 1740 sexually active 
consumers visiting retail outlets 
selling male and female condoms
Assess factors associated with 
ever-use and consistent use 
(always or often) of the female 
condom among marital and 
non-marital partners.
Quantitative 
survey.
2% ‘ever used’ a female condom. 
Perceived ease of use, affordability 
of the product, prior use were 
factors associated with women’s 
ever-use (p 30). 
Francis-Chizororo M, and Natshalaga 
NR. The female condom: acceptability 
and perception among rural women in 
Zimbabwe. Afr. J. Reprod. Health. 2003; 
7(3)101-116.
Zimbabwe: 700 women visiting 
health clinic.
To generate data for 
developing an action plan for 
accessing the female condom 
through primary health care 
centres in Zimbabwe.
Quantitative 
survey.
2% ‘ever used’ a female condom. 
Sexual satisfaction, the fact 
that the female condom can be 
inserted before sexual intercourse, 
and the dual role of preventing 
pregnancies and STIs were greatly 
appreciated (p 101). 
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2.4 Discussion 
The concept of acceptability 
Intervention studies operationalized acceptability in terms of women 
who are prepared to use the female condoms (Brady et al. 2009; 
Napierala et al. 2008; Rasch et al. 2007; Smit et al. 2006; Wanyenze et al. 
2011) and or who have already used it (Ezire et al. 2013; Mathenjwa 
2010; Simons 2009; Zachariah et al. 2003) and who are thus in a position 
to rate their experiences as being satisfactory or unsatisfactory. 
Intervention studies operationalized acceptability that women who 
accept the female condom are the ones who have a positive attitude 
and/or willingness to use female condoms. Non-intervention studies 
assessed mixtures of general attitudes, perceptions and fears towards 
the female condom, which were often grounded on hearsay and myths, 
rather than user experiences. Acceptability (or rejection) of the female 
condom is difficult to measure when society is not familiar with the 
female condom and when women, who generally lack the information 
about the device, are asked to judge its acceptability. We will therefore 
discuss these two groups separately.
Table 2.1  Continued 
Researcher(s), title, year of publication Country and Study population Objectives Methodology Results
Dube CC. Exploring women’s 
perceptions on the use of the female 
condom among female attendees at 
an inner-city family planning clinic in 
Durban, South Africa [Dissertation]. 
Durban: University of Kwazulu Natal; 
2011.
South Africa: 30 women aged  
18-35 visiting clinic, sexually 
active, users, non-users.
Describe perceptions, 
general information, myths, 
misconceptions, experiences, 
difficulties with female 
condoms.
Qualitative: In-
depth interviews, 
focus group 
discussions.
Acceptance of the female condom 
depends on personal, cultural, 
societal, programmatic aspects of 
sexual decision-making (p 75).
Gwebu N. Knowledge and attitudes of 
women attending the antenatal care 
clinic at Piggs Peak government hospital 
as regards the female condom in HIV 
prevention [Dissertation]. Stellenbosch: 
University of Stellenbosch; 2012.
Swaziland: 28 women attending 
antenatal care clinic aged 18-49 
who were pregnant or had come 
for contraception.
To find out the attitudes to 
and knowledge concerning 
female condom use in HIV 
prevention.
Qualitative: In-
depth interviews 
and focus group 
discussions.
Acceptance can be high and use 
low due to lack of training on use 
and little marketing of the device 
(p iii). Women who didn’t like the 
design did not want to try (p iii).
Naidu M. Perceptions around 
second generation female condoms: 
reporting on women’s experiences. 
Anthropological Notebooks. 2013; 
19(1):25-34.
South Africa: 1220 (originally 
1290) sexually active women 
(18–52 years) in heterosexual 
relationships.
Conduct an empirical study 
on the knowledge and 
perceptions of the female 
condom.
Quantitative:
A survey with 
semi-open ended 
interviews.
3-4% used the female condom 
(43 of 1220). The rest had almost 
no exposure and knowledge of 
female condoms (p 29).
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Intervention studies 
Intervention studies (Brady et al. 2009; Ezire et al. 2013; Mathenjwa 
2010; Napierala et al. 2008; Rasch et al. 2007; Simons 2009; Smit et al. 
2006; Wanyenze et al. 2011; Zachariah et al. 2003) reported the results 
from pilot projects that actively invited sexually active women to 
participate in the project activities, and to be counselled and trained 
on whether and how to use the female condom. Some intervention 
studies recruited women who already had some experience with the 
female condom, that is, women who had used it at least five times 
(Mathenjwa 2010), or sexually active women who agreed in advance to 
use the female condom, even before the intervention commenced (Smit 
et al. 2006; Wanyenze et al. 2011). Four of the 9 intervention studies 
(Ezire et al. 2013; Mathenjwa 2010; Simons 2009; Wanyenze et al. 2011) 
used qualitative methods to assess acceptability, while another four 
(Brady et al. 2009; Napierala et al. 2008; Rasch et al. 2007; Zachariah et 
al. 2003) used quantitative methods to calculate acceptability rates. 
One study used both methodologies (Smit et al. 2006). 
 The majority of the participants in the intervention studies (71% in 
Napierala et al. 2008; 56% in Brady et al. 2009; and 98% in Smit et al. 
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female condoms (p 29).
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2006) consented to use the female condom. The study with the highest 
percentage of women (98%) willing to use the device involved 
commercial sex workers (Zachariah et al. 2003). The study with the 
lowest percentage of women willing to use the device consisted of 
women who visited a clinic for the purpose of post abortion care and 
family planning and among these, more than one-third (39%) chose to 
use the female condom (Rasch et al. 2007). The findings about the satis-
factoriness of the female condom, according to the women who used 
the device were also clear: between 50% to 98 % of these users (50% in 
Smit et al. 2006, 60% in Brady et al. 2009, 79% in Rasch et al. 2007, and 
98% in Zachariah et al. 2003) rated their experiences as satisfactory 
after having used it several times. The highest satisfaction rate (98%) 
was found in the study done among commercial sex workers (Zachariah 
et al. 2003), though the proportion of women in the other studies who 
found the female condom to be satisfactory was also consistently above 
50%. About the same percentages were found in earlier pilot intervention 
study in Uganda: about half of the women were interested in trying out 
the female condom, and three quarters rated it as satisfactory (Green 
et al. 2001). The evidence suggests that through the implementation of 
well-planned interventions, normalisation of the female condom is 
possible and improves with practice (Gollub 2000).
 Before the demonstration many feared the inner ring might cause 
pain to the woman or damage a man’s penis, but afterwards this no 
longer seemed to be the case. There was also not any negative talk 
of the large size of the female condom anymore (Simons 2009:36).
The project interventions helped to remove some of the initial fears of 
the women about using a female condom,
It should be just the same thing as the male condom because the 
male condom is more or less like the shape of the penis and I believe 
the one for the female will be like the shape of the vagina (Simons 
2009:35).
Some participants did not experience any hesitation to try out the use 
of the female condom, even after a false start, 
You try it and it is uncomfortable or it hurts, but you have to try 
again. You do not have to say: well it is difficult, and then give up 
(Mathenjwa 2010: 58). 
Women who had used the female condom frequently (defined as more 
than five times in Mathenjwa 2010) stressed that adaptation to the 
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female condom is a gradual process of gaining confidence in inserting 
the female condom. This shows how important support and opportunities 
to gain experience are in the process of getting used to the female 
condom.
Non-intervention studies 
Non-intervention studies (Dube 2011; Francis-Chizororo et al. 2003; 
Gwebu 2012; Meekers et al. 2005; Naidu 2013; Okunlola et al. 2006) 
assessed acceptability at one point in time and asked whether women 
had ever seen or used a female condom, at least once in their lives. In 
contrast to the intervention studies, considerably lower rates of women 
had used female condoms. In four of the six non-intervention studies in 
which the user rates were measured, these were 11% (Okunlola et al 
2006), 3-4% (Naidu 2013), 2% (Meekers et al. 2005) and 2% (Francis-Chizo-
roro et al. 2003) respectively. The other two non-intervention studies 
(Dube 2011; Gwebu 2012) were small-scale qualitative studies, involving 
too small a number of respondents to calculate user rates. The generally 
lower rates in this type of studies might be attributed to factors other 
than rejection, such as unavailability, unaffordability and unfamiliarity, 
since these studies were not embedded in a project.
Reasons for satisfaction 
Women who evaluated the female condom as satisfactory did so for a 
variety of reasons. Generally, the condoms made them feel well protected. 
A participant in a study in South Africa said, 
I use female condoms as often as possible. I prefer them over male 
condoms. They are nice and big, impossible to burst and break like 
it always happens with male condoms (Naidu 2013:32). 
Women liked the flexibility of the female condoms that they are long 
lasting and safe enough to protect from contracting HIV/AIDS and 
unintended pregnancy. Three studies of the 15 resulted in female 
condom preference by women who experienced negative side effects to 
hormonal contraceptives (Mathenjwa 2010; Naidu 2013; Wanyenze et 
al. 2011) and perceived female condoms as being the best solution to 
preventing pregnancies and giving them control: 
The female condom came to free us from being controlled by men. 
Now I do not have to keep asking a man for protection. I ask him, 
if he refuses I just wear my [female] condom (Naidu 2013:51). 
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Or: 
It is difficult to insist on condom use with your steady partner 
when you have been in the relationship for a long time, because it 
always comes across as a question of trust and is always accompanied 
with accusations. But the female condom helps you avoid all that 
drama because you do not have to ask him for anything. You just 
tell him that you are using a new method of contraception that has 
no side effects (Naidu 2013:66). 
These studies showed that women were satisfied with the female 
condom as it empowers them and provides them with more freedom, 
greater autonomy and makes them less dependent on the cooperation 
of men. Women who agreed to use the female condom seemed 
unworried about a negative reaction from their partners: 
My husband said he likes it (Ezire et al. 2013:209). 
Or: 
The lubrication is good and you do not get bruised. My husband 
said it felt like we had unprotected sex; it seems he liked it more 
than the male condom which is tight (Wanyenze et al. 2011:221). 
One study recorded various ways in which the women introduced the 
new device to their partners, showing a lot of creativity (Simons 2009). 
The intervention studies which measured acceptability on the basis of 
real users’ experiences showed that women did not mention complaints 
from men. Apparently this was not a reason for dissatisfaction. 
Reasons for dissatisfaction 
Women who found the female condom unsatisfactory cited reasons for 
their lack of acceptance. In particular, the first impression of the 
appearance of the female condom was a trigger to reject the device: 
There is a need for a different model. This one is not appetising. 
When you see it, all desire disappears (Gwebu 2012:27). 
Or: 
Female condom does not look ’decent’ or ’charming’ because of its 
size (Francis-Chizororo et al. 2003:42). 
Some women commented that the outer ring looked too big, sending 
negative impressions to their sexual partners about the size of their 
vaginas (Naidu 2013:30). Others were of the opinion that the inner ring 
looked ‘painful’ and feared it would not fit into the vagina (Fran-
cis-Chizororo et al. 2003:39). The first literature review of female 
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condom acceptability studies by World Health Organization in 1997 
documented exactly the same findings: namely, that the appearance 
and the big size of the female condom are the most common reasons for 
rejection (WHO 1997). Occasionally, some women reported negatively 
about an aspect that others were positive about. For example, some 
perceived the lubrication of the female condom as negative: 
Often the ring slipped out of their fingers, which was attributed to 
the slipperiness of the inner ring caused by the lubrication (Simons 
2009:38). 
Or: 
Although a fourth of the participants did not experience any 
difficulties during the insertion, most participants found it 
difficult to squeeze the inner ring and hold it firmly in order to be 
able to insert it (Simons 2009:39). 
While others perceived the lubrication of the female condom as 
positive: 
...there is no time to make you wet. So the female condom has got a 
lot of oil that compensates for the fact that you are not turned on, 
so it does not hurt (Mathenjwa 2010:53). 
Lubrication appears to be a personal preference. Extra lubrication 
might be useful for groups like sex workers and teenagers. However, 
acceptability of the female condom among teenagers has never been 
researched. Aversion to the process of inserting the female condom was 
often mentioned as another reason for not liking it (Ezire et al. 2013). 
When women used the female condom for the first time, they often 
experienced insertion difficulties and commented negatively about the 
amount of time it took them to insert it. Moreover, women were afraid 
of the possibility that it might slip inside the vagina when they used it 
for the first time (Ezire et al. 2013). The data suggests that interventions 
which support women in the process of getting used to the female 
condom are crucial for acceptability of the device. Consequently, we 
analysed the studies to try and understand the interventions which 
seemed to be key for increasing acceptability. 
Key interventions 
Interventions enhanced acceptability and use of the female condom. 
Informed and supported female condom users were willing to repeat 
its use (Rasch et al. 2007). Well-trained providers were essential to 
501567-L-bw-Peters
66
CHAPTER 2
counsel or train women to overcome their initial aversion to the female 
condom, and their perceptions about the difficulties in using it. In one 
study which reported high user rates:  
The counsellors were well trained and equipped with skills to 
empathically listen to their clients (Rasch et al. 2007:67). 
Another study noted: 
The best predictors of female condom uptake were measures taken 
after the counselling intervention (Napierala et al. 2008:130). 
Four of the nine intervention studies clearly and specifically emphasised 
the importance of a personal approach to women, through attentive 
listening to the experiences of the users (Mathenjwa 2010; Napierala et 
al. 2008; Rasch et al. 2007; Simons 2009). These findings are in line with 
findings from studies on contraceptive acceptability and use, where 
poor service quality and lack of empathy by service providers precludes 
the successful introduction of new contraceptives (Cleland et al. 2006b; 
Vijayakumar et al. 2006). The World Health Organisation has warned 
that technological innovations never fulfil all requirements of ‘us-
er-friendliness’ and points out that each time there is a technological 
innovation, users and providers will need to consider different sets of 
trade-offs to satisfy user needs and create market demand (WHO 2004). 
Pre-conceived ideas about condom use 
Consumers’ acceptance and use of contraceptives is complex, accentuated 
by the fact that many people would prefer not to use any protective 
method at all during sex (Severy 2001). For example, there is evidence 
that many men often dislike the male condom or some of its features, 
while others may still accept and use it (Albarracin et al. 2001). If the 
level of provision, ease, cost and education related to the female condom 
is stepped up for women, as it has been over the past decade for men 
with respect to the male condom, the same higher levels of acceptance 
might result. Another comparison could be made with the acceptability 
of the technological innovation of the tampon which is designed to be 
easily inserted into the vagina during menstruation and absorb the 
user’s menstrual flow. 
 Latka (2001) studied the history of the gradual acceptance of the 
use of tampons, which also require vaginal insertion. The tampon 
became successful only after at least 30 years of intensive promotion 
and adaptation. Technical improvements to female condoms are 
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currently taking place and might increase choice, and also overall 
acceptability and use, aspects strongly related to personal preferences 
(Beksinska et al. 2012; Vijayakumar et al. 2006). Female condoms are 
concerned not only with social norms about women’s personal hygiene 
and vaginal insertion, but also with norms about sexual relations (Sen 
et al. 2007; Tanner et al. 2009). Unlike the tampon, the female condom 
needs acceptance by both partners. However, current dominant social 
and gendered norms on sexuality often expect women not to be active, 
carrying a female condom and making autonomous decisions on 
sexuality. Married women, especially, are often thought to have no 
agency. The idea of women using a condom on their own initiative is 
generally perceived as socially unattractive, appearing strange, even to 
some women themselves (Alexander et al. 2011; Mantell et al. 2005; 
Marshall 1977; Morrow et al. 2008; Sarkar 2008). In this context, it 
appears that when respondents are not given the opportunity to 
experience use of the female condom, and acceptability is measured 
without providing an intervention to assist with this, the resulting 
data might be misinterpreted, as pre-conceived ideas may be measured. 
Pre-conceived ideas are often gendered as societies base them on typical 
gender roles (West et al. 1987). 
 In sub-Saharan Africa, condom use is often equated with promiscuity, 
making it difficult to negotiate condom use within marriage (Caldwell 
2000; Chimbiri 2007; Shai et al. 2012; Scott 2010). It is also associated 
with limiting sexual pleasure or sexual performance (Measor 2006). 
The metaphors of ‘eating a sweet in a wrapper’ or ‘farming with your 
hoe in a sack’, typify some of these gendered ideas about (male) condom 
use in sub-Saharan Africa (Plummer et al. 2006; Tavory et al. 2009). 
Such socially constructed ideas about female condoms have not been 
explicitly researched for this article. However, evidence suggests that 
these can be restrictive and negative (Kahari et al. 2014; Measor 2006; 
Muula 2006). Such socially constructed ideas can also, depending on 
how the concept of acceptability is operationalized in these studies, 
influence the outcomes of acceptability studies. 
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2.5 Conclusion 
The way the concept of acceptance has been operationalized is a key 
factor influencing the results of acceptability of studies on the female 
condom. A person who has never used, tried or tested it may find it 
difficult to accurately judge whether it is comfortable and efficacious. 
Non-intervention studies which gave the respondents no opportunity 
to experience or use the female condom tended to conclude negatively 
about its overall acceptability, as these studies measured existing 
pre-conceived ideas, rather than perceived satisfaction based on actual 
experience. Intervention studies showed opposite results concerning 
acceptability. When programmes created free access to the female 
condom accompanied by key interventions such as empathic support to 
women by skilled providers in the period during which women became 
accustomed to the device, acceptability rates were high. This was true 
for women with varied backgrounds, with consistently more than half 
rating their experiences as satisfactory. Resistance from men was not 
a significant factor, though the women do suggest that technical 
improvements be made to the design of the device. Based on our 
literature review we concluded that women in sub-Saharan Africa 
accepted the use of the female condom when potential users were given 
access to the device, and exposed to interventions which supported the 
use of a female condom.
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Appendix 2.1   List of 15 female condom studies in sub-Saharan Africa  
excluded from in-depth review and reasons for exclusion 
Name of researcher, title of study, year. Reason for exclusion
1 Agbiboa D. Female condoms in sub-Saharan Africa: Unanswered calls for 
normalisation. Discussion paper. Pretoria: Consultancy Africa Intelligence 
2010.
Criterion 2: not based on empirical studies.
2 Beksinska ME, Smit JA, Mantell JE. Progress and challenges to male and female 
condom use in South Africa. Sexual Health 2012; 9(1):51-8.
Criterion 2: not based on empirical studies but literature review
3 Bisika T. Female controlled methods of contraception and sexually transmitted 
infections including HIV in Malawi: examining the role of the female condom 
and microbicides. East African Journal Public Health 2009; 6(2): 223-5. 
Criterion 1: The full study could not be retrieved; only an abstract.
4 Limbani FV. Acceptability of female condom in HIV and STI prevention in 
Malawi. Dissertation. University of Malawi. College of Medicine 2011. 
Criterion 3: The research methodology of this qualitative study was hardly made 
explicit.
5 Koster W, Groot Bruinderink M. Male views on female condoms. A study of 
male acceptance of female condoms in Zimbabwe, Cameroon and Nigeria. 
Amsterdam Institute of Global Health and Development 2012.
Criterion 5: The study population were men instead of women.
6 Mantell JE, Smit JA, Beksinska M, et al. Everywhere you go, everyone is saying 
condom, condom. But are they being used consistently? Reflections of South 
African male students about male and female condom use. Health Education 
Research 2011; 26(5):859-871. 
Criterion 5: The study population were men instead of women. 
7 Beksinska M, Smit J, Mabude Z, et al. Male partner involvement and 
assistance in female condom use. The European Journal of Contraception and 
Reproductive Health Care 2008; 13(4):400-403. 
Criterion 4: Topic of study was male involvement rather than acceptability of the 
female condom.
8 Coffey PS, Kilbourne-Brook M, Austin G, et al. Short-term acceptability of the 
PATH woman’s condom among couples at three sites. Contraception 2006; 
73(6):588-593. 
Criterion 5: The acceptability of the female condom by African women was mixed 
with that of women from other continents.
9 Mung’ala L, Kilonzo N, Angala P, et al. Promoting female condom in HIV 
voluntary counselling and testing centres in Kenya. Reproductive Health 
Matters 2006; 14(28):99-103.
Criterion 5: Study population was health providers instead of women.
10 Beksinska M, Smit J, Mabude Z, et al. Performance of the Reality polyurethane 
female condom and a synthetic latex prototype: a randomized crossover trial 
among South African women. Contraception 2006; (73):386-93.
Criteria 4 and 5: The study focussed on product characteristics of female condoms, 
for example breakage instead of acceptability by women.
11 Beksinska M, Smit J, Joanis C, et al. Practice makes perfect: reduction in 
female condom failures and user problems with short-term experience in a 
randomized trial. Contraception 2012; 86(2):127-31. 
Criteria 4 and 5: This study dealt with product characteristics, such as breakage not 
with acceptability by women. 
12 Joanis C, Beksinska M, Hart C, et al. Three new female condoms: which do 
South-African women prefer? Contraception 2011; 83:248-254
Criterion 4: This study reported on differences in types of female condoms, 
including the V-amour female condoms which model was not part of our research. 
13 Hoke, TH, Feldblum PJ, Van Damme K, et al. Temporal trends in sexually 
transmitted infection prevalence and condom use following introduction of 
the female condom to Madagascar sex workers. Int. J. STD&AIDS 2007; 18:461-
466.
Criterion 4: Study of effectiveness, not on acceptability.
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Appendix 2.1   List of 15 female condom studies in sub-Saharan Africa  
excluded from in-depth review and reasons for exclusion 
Name of researcher, title of study, year. Reason for exclusion
1 Agbiboa D. Female condoms in sub-Saharan Africa: Unanswered calls for 
normalisation. Discussion paper. Pretoria: Consultancy Africa Intelligence 
2010.
Criterion 2: not based on empirical studies.
2 Beksinska ME, Smit JA, Mantell JE. Progress and challenges to male and female 
condom use in South Africa. Sexual Health 2012; 9(1):51-8.
Criterion 2: not based on empirical studies but literature review
3 Bisika T. Female controlled methods of contraception and sexually transmitted 
infections including HIV in Malawi: examining the role of the female condom 
and microbicides. East African Journal Public Health 2009; 6(2): 223-5. 
Criterion 1: The full study could not be retrieved; only an abstract.
4 Limbani FV. Acceptability of female condom in HIV and STI prevention in 
Malawi. Dissertation. University of Malawi. College of Medicine 2011. 
Criterion 3: The research methodology of this qualitative study was hardly made 
explicit.
5 Koster W, Groot Bruinderink M. Male views on female condoms. A study of 
male acceptance of female condoms in Zimbabwe, Cameroon and Nigeria. 
Amsterdam Institute of Global Health and Development 2012.
Criterion 5: The study population were men instead of women.
6 Mantell JE, Smit JA, Beksinska M, et al. Everywhere you go, everyone is saying 
condom, condom. But are they being used consistently? Reflections of South 
African male students about male and female condom use. Health Education 
Research 2011; 26(5):859-871. 
Criterion 5: The study population were men instead of women. 
7 Beksinska M, Smit J, Mabude Z, et al. Male partner involvement and 
assistance in female condom use. The European Journal of Contraception and 
Reproductive Health Care 2008; 13(4):400-403. 
Criterion 4: Topic of study was male involvement rather than acceptability of the 
female condom.
8 Coffey PS, Kilbourne-Brook M, Austin G, et al. Short-term acceptability of the 
PATH woman’s condom among couples at three sites. Contraception 2006; 
73(6):588-593. 
Criterion 5: The acceptability of the female condom by African women was mixed 
with that of women from other continents.
9 Mung’ala L, Kilonzo N, Angala P, et al. Promoting female condom in HIV 
voluntary counselling and testing centres in Kenya. Reproductive Health 
Matters 2006; 14(28):99-103.
Criterion 5: Study population was health providers instead of women.
10 Beksinska M, Smit J, Mabude Z, et al. Performance of the Reality polyurethane 
female condom and a synthetic latex prototype: a randomized crossover trial 
among South African women. Contraception 2006; (73):386-93.
Criteria 4 and 5: The study focussed on product characteristics of female condoms, 
for example breakage instead of acceptability by women.
11 Beksinska M, Smit J, Joanis C, et al. Practice makes perfect: reduction in 
female condom failures and user problems with short-term experience in a 
randomized trial. Contraception 2012; 86(2):127-31. 
Criteria 4 and 5: This study dealt with product characteristics, such as breakage not 
with acceptability by women. 
12 Joanis C, Beksinska M, Hart C, et al. Three new female condoms: which do 
South-African women prefer? Contraception 2011; 83:248-254
Criterion 4: This study reported on differences in types of female condoms, 
including the V-amour female condoms which model was not part of our research. 
13 Hoke, TH, Feldblum PJ, Van Damme K, et al. Temporal trends in sexually 
transmitted infection prevalence and condom use following introduction of 
the female condom to Madagascar sex workers. Int. J. STD&AIDS 2007; 18:461-
466.
Criterion 4: Study of effectiveness, not on acceptability.
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Appendix 2.1   Continued 
Name of researcher, title of study, year. Reason for exclusion
14 Hoke TH, Feldblum PJ, Van Damme K, et al. Randomised controlled trial of 
alternative male and female condom promotion strategies targeting sex 
workers in Madagascar. Sexually Transmitted Infections 2009; 83(6): 448-453.
Criterion 4: Study of effectiveness, not on acceptability.
15 Thomsen SC, Ombidi W, Toroitich-Ruto C, et al. A prospective study assessing 
the effects of introducing the female condom in a sex worker population in 
Mombasa, Kenya. Sex Trans Infect. 2006; 82(5): 397-402. 
Criterion 4: The study investigated user cost rather than acceptability.
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Appendix 2.1   Continued 
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14 Hoke TH, Feldblum PJ, Van Damme K, et al. Randomised controlled trial of 
alternative male and female condom promotion strategies targeting sex 
workers in Madagascar. Sexually Transmitted Infections 2009; 83(6): 448-453.
Criterion 4: Study of effectiveness, not on acceptability.
15 Thomsen SC, Ombidi W, Toroitich-Ruto C, et al. A prospective study assessing 
the effects of introducing the female condom in a sex worker population in 
Mombasa, Kenya. Sex Trans Infect. 2006; 82(5): 397-402. 
Criterion 4: The study investigated user cost rather than acceptability.
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MARKETING MEASURES  
AND DEMAND CREATION IN  
GLOBAL HEALTH AND HOW  
THESE AFFECT THE AFFORDABILITY 
OF THE FEMALE CONDOM:  
A COMPARATIVE CASE STUDY
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Abstract 
The task of the global health sector is to monitor, maintain and improve 
public health, taking measures to create accessibility to public health 
products worldwide. The affordability of these products is a key factor 
affecting access, and this is influenced by different measures initiated 
by the public and/or private sectors to create demand and market the 
product. These measures are under scrutiny in this study as the female 
condom is a public health product with a problematically high price, 
and is basically unaffordable for women living in sub-Saharan Africa, 
a region highly affected by the AIDS epidemic and in addition, with 
a large unmet need for contraceptives. This study compares three 
public health products that prevent HIV infection (female condom, 
male condom and microbicides),  examining how global measures such 
as demand creation, product development and marketing measures 
differ across the three products; and it analyses what this means for 
the price and demand of each product, both generally, and with a focus 
on the region of sub-Saharan Africa. The comparative case study 
method was used on the basis of an analysis of secondary data. It was 
found that current global measures for the three products were 
comparable to a great extent in respect to type, based mainly on 
whether the major actors belonged to the public or private sectors; but 
these global measures differed significantly in size. The global measures 
for the female condom were assessed as too small to be able to positively 
influence the problematically high price of the product. The analysis 
raises questions about what criteria are used by the global health sector 
to politically prioritise certain public health products to the detriment 
of others like the female condom, ignoring existing user demand and 
paying little attention to increasing demand. 
Keywords: Global health, HIV prevention products, marketing, subsidies 
and public-private partnerships.
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3.1 Introduction 
The number of female condoms available on the global market is less 
than 0.5 percent of male condoms (Friel 2005:4) while the market price 
is about 20 times higher: on average 0.59 US$ for a female condom 
versus 0.03 US$ for a male condom bought by wholesale purchasers, 
such as international agencies and national governments. The price of 
the female condom for individual customers depends greatly on the 
country, but on average is about 1 US $ per piece (Marseille et al. 2008:17; 
UNITAID 2013:34). From the time when they have been on the global 
market since 1993, these prices have hardly come down, access has 
remained low and price high (UNITAID 2013:44; WHO 2012:5). This is 
especially problematic in sub-Saharan Africa, where women generally 
have low purchasing power and are highly affected by the AIDS epidemic 
and most in need of preventative measures. Throughout sub-Saharan 
Africa, HIV prevalence among young women aged between 15 and 24 
years is more than double that of young men of the same age range 
(UNAIDS 2013:17), suggesting that young women are especially in need 
of protection and a woman-friendly product. 
 When female condoms became available in sub-Saharan Africa, 
women’s levels of comfort with the product increased considerably 
when the distribution was embedded in counselling and educational 
activities and women were given the opportunity to use them (Brady et 
al. 2009; Ezire et al. 2013; Mathenjwa 2010; Napierala et al. 2008; Rasch 
et al. 2007; Simons 2009; Wanyenze et al. 2011). Acceptability studies 
showed that, when combined with pilot interventions, about three- 
quarters of the women were satisfied with the female condom, though 
women who did not have the opportunity to practise with it rated its 
acceptability much lower (Peters et al. 2014). 
 Marketing campaigns and the branding or positioning of the 
product in the market are  important for increasing demand and access 
for consumers, sales profit for the commercial sector, cost-effectiveness 
for the public sector and affordability for the consumers. This article 
offers an initial exploration of how such type of market measures have 
operated in the case of the female condom and how this influences its 
price when compared to other relevant public health products.
 Competition is one of the most prevalent and conceptually simple 
market measures. Free competition assumes a market, defined as a 
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non-restricted and non-subsidised commercial market, in which it is 
understood that the supply almost automatically matches the demand 
(Posner 1974:122). In the case of standard products, companies compete 
with each other for clients, using marketing strategies to stimulate 
the demand for their products and increase their sales and profit. 
The position of the market measures for private enterprises which 
manufacture public health products is somewhat different when compared 
to private enterprises which manufacture standard products. This is 
because the initial demand for public health products, particularly 
new or unfamiliar ones, is often limited, and needs promotion and 
motivation. For clarity, I will first briefly touch on the concepts of public 
health and social marketing before analysing the special position of 
public health products on the market, as a prelude to considering the 
comparative case of the female condom in greater detail.
 According to the World Health Organization, ‘Public health refers 
to all organized measures (whether public or private) to prevent disease, 
promote health, and prolong life among the population as a whole’ 
(WHO 2014:1). Fried et al. (2010) argue that there is no distinction 
between public health and global health and suggest that ‘public health 
is global health for the public good’. Public health products are 
commodities that enable people to take more control over the process 
of staying healthy (Nutbeam 1998). Unlike standard products, public 
health products empower people to fulfil their health needs and these 
health products often demand extra measures from the public sector to 
create demand or rectify market measures which may otherwise block 
access to them (George 2009). Marketing such public health products is 
often done through social marketing which might be defined as the 
application of commercial marketing principles and tools to promote 
health (Donovan 2011), with for example global agencies contracting 
private companies to do the marketing of these public health products. 
The consumer price of such products is different from those of standard 
products. Since the use of these products contributes significantly to 
the public health of the society, there is a special role for the public 
sector (Cottingham et al. 2011:70; Figueras et al. 2009: 62). Both 
governments and international agencies may decide to intervene in the 
market and preserve the health of the population by ensuring access to 
public health products and other additional measures (Figueras et al. 
2009:127-128). For example, national governments may decide to 
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provide vaccines for free and make these widely accessible to all 
through systematic vaccination campaigns. In the case of sexually 
transmitted infections, international agencies such as UNFPA may 
intervene to make subsidised condoms available for a lower price than 
the commercial market offers. Overall, such measures tend to stimulate 
demand and motivate people to use these products, so that public 
health might be better preserved. 
 Due to the increased globalisation of markets, certain additional 
economic measures may be taken at the international level specifically 
to address the public health concerns of people living in poverty, whose 
overall purchasing power may be low. For example, the World Trade 
Organization (WTO) agreed in the so-called Doha declaration to give 
primacy to health over private intellectual property, and called on 
WTO members to use safeguards to make the price of anti-retroviral 
treatment (ART) affordable for low and middle income countries (Hoen 
2003:39). Governments and international agencies can thus influence 
markets, and the prices of medicines as well as public health products, 
in different ways. One way is through direct participation as a buyer or 
supplier of products; for example, the UNFPA buys and supplies male 
and female condoms for developing countries. Another way is through 
indirect participation in private markets by subsidisation (George 
2009:2). Government subsidies to reduce consumer prices for public 
health products are common measures to encourage people towards 
greater use of such products. Further, when international agencies 
supply public health products or when governments subsidise them, 
they often make sure that these products are embedded in larger 
health promotion programmes or social marketing campaigns, for 
which they may contract specialised social marketing companies, 
which in turn use marketing strategies borrowed from the private 
sector to increase overall demand and motivate potential users (Cusot 
et al. 2012; Patty et al. 2003).  
 Another measure that is often applied to enhance the demand for and 
use of certain public health products in developing countries is research 
and development (R&D), aimed at improving product design or 
exploring possibilities for innovations to increase choices, and thus the 
demand for and use of new products. At the global level, governments of 
high-income countries often participate in public-private partnerships for 
product development. For this article, I define public-private partnership 
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as being a voluntary strategic partnership between at least one public 
sector actor and one private actor both interested in reaching the same 
goal (Asante et al. 2007; Buse & Harmer 2007; Caines et al. 2004). In the 
case of public-private partnerships for product development, the matching 
goal is to develop a new or better product to create and satisfy the 
potential demand, though the majority of public-private partnerships 
in global health directly aim at creating access to public health products 
in developing countries (Labonté et al. 2010; Buse & Walt 2000). 
 Accessibility to public health products in developing countries is 
not only influenced by affordability; factors such as availability and 
acceptability also play a role and are linked with each other (Frost et al. 
2009). Some factors that influence access to the female condom were 
separately analysed in earlier studies, especially factors related to 
acceptability among women users as mentioned earlier (Peters et al. 
2014), and factors related to the policy discourses used at global level 
(Peters et al. 2013). The current study focuses on issues of access that are 
specifically related to price and/or affordability.
 Compared to the pricing and marketing of a standard product, 
those of a public health product are more complex due to the explicit 
concern with public health. Thus marketing of public health products 
is not left to the private sector alone, as the public sector often has to 
create extra support measures for marketing and demand creation to 
increase the use of public health products (Frost et al. 2009). Extra 
promotion measures for newly developed preventive health products 
are indispensable for public health, at least until strong levels of 
demand for the product are created and maintained. This article is 
based on this public health perspective that, unlike standard products, 
public health products need extra measures to promote and balance 
demand and supply. Another premise of this study is that an initial 
demand for the female condom exists among women in sub-Saharan 
Africa, although its acceptability largely depends on the support which 
women receive when getting accustomed to the use of the product.
 Given this context, my research question is: How do global measures 
to create access or to improve the product of the female condom 
compare to global measures that are taken for two other though similar 
public health products, and what are the consequences for the 
affordability and demand of these products, both generally, and with a 
focus on the region of sub-Saharan Africa. 
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3.2  Methodology
In this exploratory research, the comparative case study has been used 
(Byrne et al. 2009; Collier 1997; Yin 2014). Comparative case studies 
emphasize comparison within and across contexts and are undertaken 
when it is not feasible to organise an experimental design and/or when 
there is a need to understand and explain how features within the context 
influence the success of certain measures. This descriptive methodology 
was believed to be best to examine the global marketing and demand 
creation measures currently in place for the female condom, and to 
compare these with the measures in place for two other public health 
products, similar in terms of either their potential to prevent HIV 
infection - the male condom, or future perceived potential - microbicides. 
 The male condom is a product which has been available on the 
global market much longer than the female condom. Microbicides are 
new topical vaginal agents that might potentially prevent HIV infection 
in future. The product of microbicides is still in the development or 
testing phase, and has not yet been found effective enough to be sold or 
promoted in the global market (Naswa et al. 2012; Obiero et al. 2012). 
Nevertheless, as a product that absorbs a significant proportion of the 
global funding available for AIDS prevention (Peters et al. 2010), 
measures to promote microbicides can be used for comparison with 
measures to promote the female condom for the purposes of this 
analysis. 
 Secondary data available in the public domain were the main 
source for data collection for this study. The choice to use secondary 
data rather than primary data had to be made because collecting 
primary data from the private sector proved impossible as representa-
tives of relevant private-for-profit making companies were reluctant to 
be interviewed for the purpose of this study. Primary data on public- 
private partnerships were also found difficult to collect and generally 
data on public-private partnerships are seen to lack transparency, as 
previously experienced by other researchers (Buse et al. 2000; Roehrich 
et al. 2015). Therefore, I collected existing data about the major 
companies associated with the manufacture and/or sale of male and 
female condoms, and on the initiatives to develop micro bicides, including 
annual reports of commercial companies and/or academic or research 
institutions, as described below.
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 The companies currently involved in marketing the female condom 
are well defined on the website of the single extant public-private 
partnership on the female condom (http://www.fcmi.org or http://www.
condoms4all.org/). Of the existing five companies, the Female Health 
Company stands out as the largest in terms of sales, with the other four 
companies much smaller players and at the moment of writing this 
analysis, playing a minimal role at the global level. This is also because, 
until recently, the female condoms manufactured and marketed by the 
Female Health Company were the only ones which enjoyed the WHO 
pre-certification which is essential for these products to be sourced by 
major global public health agencies, and consequently, they enjoyed a 
near monopoly position in the female condom market (Oxfam 2008). 
Therefore, only data pertaining to the Female Health Company, as the 
most significant manufacturer and seller of the female condom, could 
be collected and analysed for this research. 
 For male condoms I collected data from two top global manufacturing 
companies out of a total of 70 companies worldwide (Höllensen 2007:308). 
In terms of sales, the Reckitt Benckiser Group and the Durex brand, 
which is leading the European market (annual report 2012) and the 
Church and Dwight Company and the Trojan brand, which is leading 
the American market (annual report 2012) held about 33% of the global 
market share in 2005. Studying the annual reports of these companies, 
with their large and diverse range of products which were often not 
differentially presented in the reports, was complex. Also I traced 
recent business news articles on the global condom industry, using the 
following search terms on Google: ‘condom industry’, ‘condom marketing’, 
and ‘condom manufacturing’; and adding search terms on Google 
Scholar: ‘condom cost-effectiveness’, and ‘condom subsidies’. 
 For microbicides, the information presented about their development 
as HIV prevention products was collected by using two recent reviews 
published in academic journals: Obiero et al. 2012 and Naswa et al. 
2012. I also checked for additional information using the search term 
‘microbicides public private partnerships’ on Google. 
 To establish the nature and size of the measures to create access, 
demand and supply for the three products undertaken by both the 
public and private sector, the collected data were analysed and 
categorised using an analytical framework on access to new health 
technologies in developing countries (Frost et al. 2009). Measures to 
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increase access were operationalised as demand creation and increasing 
supplies; these jointly influence price, and are considered particularly 
important in global marketing (Höllensen 2007). It is recognised that 
global marketing is a complex arena to research, especially the 
increasingly blurred responsibilities between public and private sectors 
(Tulder et al. 2006). 
 The following paragraph describes the results of the comparison 
between the three products considering: 1. product history, 2. type of 
clients, 3. product innovations, 4. sales, 5. marketing and 6. subsidies. 
3.3  Results
1. Product history
The female condom
The female condom (FC1) was introduced into the global market in 
1993 by pioneer Wisconsin Pharmacal Co Ltd., which later became the 
Female Health Company. More than a decade later, in 2009, a successor 
to FC1 was developed by the company, with a nitrile sheath instead of a 
polyurethane sheath, and was labelled FC2. The change in material 
from polyurethane to nitrile had two main advantages: firstly, nitrile is 
cheaper than polyurethane. Secondly, nitrile, an artificial rubber, does 
not ‘crackle’ like polyurethane, which has some characteristics of 
plastic, and which, in FC1, caused for some people certain typical noises 
when it was used during sexual intercourse. The Cupid1 produced by 
the Indian company Cupid Ltd. was only recently (2012) approved by 
WHO and has a slightly different design from the female condom of the 
Female Health Company since it has an octagonal outer frame instead 
of a round one and is inserted using a sponge instead of a plastic ring, 
and this also holds the condom in place during use. The Cupid1 condom 
is available in a limited way in a few countries (UAFC 2013). Other 
female condoms are currently being developed and tested, and have 
limited availability in a few countries: Phoenurse, V’Amour, Woman’s 
Condom, Cupid 2 and Velvet (www.fcmi.org). For the purpose of this 
study, the primary focus is on the Female Health Company and FC2 as 
its global market share is more than 80% (personal communication, 
Saskia Husken, programme officer, UAFC: female condom public private 
partnership, March 2015).  
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The male condom
The male condom has a long history and is a well-established product 
on the global market (Wong 2013). By the mid-1930s, latex condoms 
were industrially produced and this greatly expanded the market 
(Lewis 2000). Condom production for the market in the USA alone was 
1.4 million daily in 1931 (Edgerton 2006:23). From the early 1960s, the 
use of male condoms as a contraceptive device temporarily declined as 
other contraceptive methods came on the market (Lewis 2000; Kakar 
2002:38). Following the AIDS epidemic in the 1980s, however, the use of 
male condoms went up again, this time serving both as a contraceptive 
and a protective device against the transmission of HIV and other 
sexually transmitted diseases. Except in a few countries such as the 
Philippines where the Catholic Church influenced the government to 
ban the product, male condoms are directly available to consumers in 
pubs, bars, sex shops, grocery stores, and supermarkets, in addition to 
pharmacies, and more recently, can be ordered on the internet (Allen 
2006:25-30; Renaud et al. 2009). Worldwide, male condoms still remain 
the third most frequently used temporary method for contraception 
(Jamison et al. 2006:1080) and the most reliable and effective method 
for protection against HIV and other sexually transmitted infections 
(CDC 2014). The mainstream image of the male condom has been 
acquired over a very long time and after relentless promotion, including 
vast efforts from the public sector on education and social marketing, 
to make it mainstream. The high numbers and reach of the male 
condom should not therefore be considered as somehow ‘natural’, but 
rather as the result of long and ongoing efforts.
Microbicides
In contrast with male and female condoms, microbicides have not yet 
been proven a reliable and effective method for protection against HIV, 
and thus have not entered the global market for sale to the public 
(Obiero et al. 2012). The term “microbicide” refers to substances being 
studied that could be used in the vagina and/or rectum to reduce the 
risk of HIV infection via sexual exposure. There are no licensed 
microbicides available today. Microbicides take many forms - gels, 
creams, suppositories, films, sponges or vaginal rings that slowly 
release the active ingredient. The idea for a microbicide-like product 
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was first proposed about 25 years ago (1990), soon after the female 
condom was invented (1984). Among the first products considered were 
the nonoxynol-9 (N-9) and similar detergent-based spermicides which 
were prophylactic contraceptives for HIV/AIDS; but they used to cause 
lesions in vaginal and cervical epithelia, leaving women more 
vulnerable to HIV infection. Thus their use as microbicides was 
abandoned. Other first generation microbicides that included products 
intended to strengthen natural defences in the vagina or create a 
barrier to protect target cells in the vagina also proved unsuccessful 
(Naswa et al. 2012). Microbicide research has had disappointing outcomes 
during the last two decades. However, a recent small preliminary study 
suggests that microbicides containing the antiretroviral drug tenofovir 
may prevent acquisition of HIV and herpes simplex virus infection in 
women; but further research is needed to assess the generalisability of 
these findings. Therefore, there is not enough evidence to recommend 
topical microbicides for HIV or STI prevention at present (Obiero et al. 
2012:2) and to bring them on the market. Overall, of the three products 
that are compared in this article, the male condom is by far the most 
familiar among clients.
2. Type of clients
Female condom
The Female Health Company strategically views global public sector 
customers as their principal clients, as the chairperson of their board 
clearly stated in 2012 in a press release (Parrish 2012). The two main 
clients of the Female Health Company, UNFPA and USAID, provided no 
in-depth data about price deals with the company, which might indicate 
that the value that these public sector clients hold for the Female 
Health Company has been leveraged to obtain appropriate price advantages 
for the benefit of the consumer. But also, as noted above, the Female 
Health Company was until recently the only company which could 
supply to these major global public health customers, and this has 
helped it keep prices of the female condom high. Almost three-quarters 
of female condom sales (72%) are purchased by the global public sector 
or institutional clients (Female Health Company 2013:10; Reproductive 
Health Supplies Coalition 2014a:6).
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Male condom
In sharp contrast, only a small minority of male condoms (1.9%) is 
purchased by clients from the global public sector (UNFPA 2012:115). 
The majority of male condoms are sold to individual clients through 
the above mentioned diversity of channels. However, the prevalent 
global pattern is inverted in sub-Saharan Africa, where the private 
commercial sector was found to account for only about 2% of male 
condom sales (UNFPA 2013:5 ), and commercial marketing measures for 
male condoms by the private sector were found to be generally lacking 
in this region (UNFPA 2013:18), where the public sector is the main 
client. 
Microbicides
As microbicides are not yet at the stage of being commercially marketed, 
there are no direct clients or real product users as of yet. However, 
‘hidden marketing’ or ‘demand creation’ takes place for microbicides, 
as like some other new products they are readied for marketing before 
they are actually made available to clients. The process of marketing is 
thus not done by commercial companies who market the product to 
potential clients; currently other types of networks are involved which 
mediate relationships between technological producers, scientists and 
clients (Fishman 2004). For example a number of networks on micro - 
bicides exist, whereby scientific researchers promote the technologies 
they study and suggest the benefits they might have in future (for 
example Microbicides Trial Network, International Partnership for 
Microbicides, Alliance for Microbicide Development, Global Campaign 
for Microbicides). These academic researchers and the journalists they 
talk with are allowed to promote the future product to the public 
sector, as it concerns public health. As long as the product is off-label, 
not officially tested and approved, the private commercial sector is not 
allowed to do this type of promotion (Moffatt et al. 2007), although the 
above named networks do ‘hidden marketing’. The process of innovation 
(R&D) is increasingly blurred with the process of marketing, and often 
reaches mainly institutional public sector clients that are ‘seduced’ to 
fund the research.
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3. Product innovations
Female condom
According to a special resource tracking working group officially 
endorsed by UNAIDS, R&D for the female condom received a total 
budget of US$ 2 million from the global public sector (HIV/AIDS 
resource tracking working group. 2012). Moreover, the annual report of 
the Female Health Company did not reveal any investments in 
innovations or R&D by the company in 2012 (Female Health Company 
2013), although in 2009 they launched a new type of female condom 
(FC2). There is only one global public-private partnership on female 
condoms, which was officially established in 2009 (UAFC 2013). Though 
this single public-private partnership has an R&D element, it did not 
include any university or research institute. According to an official 
evaluation of this partnership, it experienced serious problems in 
finding technical expertise, consultants or academics that showed 
interest in working on R&D to improve the female condom (Phlix et al. 
2011). This finding might indicate that academic interest in the female 
condom product is generally low. PATH, a USA-based private organisation 
for applied technological research, received small amounts of research 
and development (R&D) funding to develop a new design for the female 
condom, although this never led to an official public-private partnership 
in which both the public and private sectors committed to a common 
long-term goal to improve this product. The process of developing a 
new design took PATH more than 10 years. The designers had to stop 
the development process from time to time due to lack of sustained 
funding (personal communication with the director of PATH, June 
2007). These examples generally reflect the lack of commitment to 
invest in R&D for the female condom at a global level. In this regard, it 
is also interesting to note that only one male condom manufacturing 
company (Cupid Ltd. in India) of the 70 in total had recently diversified 
into the production of female condoms (UAFC 2013). It appears that 
interest among male condom companies to enter the female condom 
market is very limited.
Male condom
In the annual report of the Church and Dwight Company, its 
investments in R&D were found to total 62 million US$, which is about 
2% of net revenue (Church and Dwight 2013:34). The other companies 
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did not show data about the budget for R&D. However, in business news 
articles, the male condom market was described as being ‘flooded with 
different styles of condoms’ and companies tried many ways to develop 
and design the best styles so that consumers will keep using the items 
ensuring continuous growth of condom sales (Brower 2008). Research 
and development for the male condom is financed by the private sector 
companies themselves, who see it as a way to increase sales (Brower 
2008). The desire and drive for innovation was found to come from 
within these companies (SSL International 2009:30). In the last two 
decades, extensive product differentiation has occurred to create male 
condoms that are ribbed, dotted and striated; coloured, patterned and 
flavoured; to appeal to more and different classes of consumers, with a 
consequent expansion of demand and the market.
Microbicides
By 2007, 11 global public-private partnerships on microbicides, involving 
more than 200 different universities or research schools, had been 
established (Alliance for Microbicide Development 2007:47-53). More 
recent data on the number of global public-private partnerships on 
microbicide development were not retrievable. The development of 
microbicides is embedded in and debated within a dense network of 
academic researchers, known to contribute to increased status of the 
product in general. Demand for products, including public health 
products, is influenced by efforts to make them more attractive and 
user-friendly. The global R&D budget for microbicide development 
included USD 218 million of public sector funding in 2012, 109 times 
what was allotted to the female condom (HIV Vaccines and Microbicides 
Resource Tracking Working Group 2013:28). 
 Comparing these three products, the measures and product innovation 
are smallest in size for the female condom. 
4. Sales 
Female condom
Worldwide sales of the female condom were found to be in the millions: 
61.5 million units in 2012 (Falkner 2013:6). The annual female condom 
market in 2012 was assessed at US $ 36 million (calculated as 61.5 million 
units x 0.59 US$) and the expected growth is not known, although calculated 
by Global Industry Analysts Inc in 2010 in a report called ‘Condoms: 
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A global strategic business report’. This report was prohibitively expensive 
for the researcher and thus not used as a data source. 
 There are a total of five companies producing seven types of female 
condom: Phoenurse by Tianjin Condombao Medical Polyurethane Tech. 
Co. Ltd Tianjin in China; Woman’s Condom by Shanghai Dahua Medical 
Apparatus Company in China; Cupid and Cupid 2 by Cupid Ltd in India; 
FC1 and FC2 by Female Health Company Chicago USA; and Velvet by 
Hindustan Latex Limited (HLL) in India (www.fcmi.org). The Female 
Health Company has more than 80% market share worldwide (personal 
communication with Saskia Husken, programme officer UAFC, public 
private partnership on female condoms, March 2015). The monopoly of 
the Female Health Company as the sole possible supplier of female 
condoms to international public sector purchasers persisted until 2013. 
Only then was it theoretically broken, when Cupid Ltd successfully 
completed the WHO pre-qualification process for their version of the 
female condom. Although UNFPA appeared to now be in the process of 
pre-qualifying the factory of Cupid Ltd, it had so far bought this product 
only from the Female Health Company (WHO 2014). USAID continues 
only to buy the female condom (FC2) of the Female Health Company. We 
found that negotiations about the price of the female condom between 
the public and private sector were lacking, although negotiations 
between public and private sector partners are found crucial for the 
public interest (Thia et al. 2012). 
Male condom
Worldwide sales of the male condom were found to be in the billions: 
22.8 billion units in 2012 (Bernama 2014:1). The annual male condom 
market in 2012 was valued at US$ 3.7 billion, and is expected to grow to 
US $5.4 billion by 2018, mainly by increasing sales through private 
retail channels to individual clients (Tsuru 2013:1). There are a total of 
about 70 companies producing hundreds of types and brands of 
condom. Company shares of the world market for male condoms in 
2005 are as follows: Durex by Seton Scholl London UK (SSL), 25%; 
LifeStyles by Ansell Limited, 13%; Trojan by Church & Dwight Co., 8% 
and Beyond Seven by Okamoto Industries, 10% (Höllensen 2007:307) 
These four companies hold 56% of the total market share. New entrants 
to the male condom industry are scarce, as factors such as economies of 
scale, high capital investment and accessing industrial distribution 
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channels constitute serious barriers to new companies wanting to 
enter this market. 
Microbicides
As microbicides are not at the stage of being commercially marketed, 
there are no manufacturing companies yet as they are only developed 
in laboratories. Of these three products, the existing supply is by far 
highest for the male condom.
5. Marketing
Marketing investments form a key driver of demand and sales of most 
products, including public health products. To be able to compare 
marketing investments, I selected one type of standard - ‘what should 
you spend on advertising’, proposed by McKee in 2009, who claims that 
investing ‘5% of a company’s net revenue’ into marketing is regarded as 
the minimum allocation standard to maintain the sales of products 
(McKee 2009:1-2). 
Female condom
The annual report of 2012 of the Female Health Company declared that 
USD 53,000 was invested in advertising and marketing campaigns (FHC 
2012:11). This is a mere 0.15% of the company’s total net revenue in the 
equivalent period, which was USD 35 million (FHC 2012:11), a figure 
markedly lower than the McKee minimum standard. Moreover, given 
that the product is currently sold in 143 countries, this investment in 
2012 of USD 53,000 works out to an average annual expenditure on 
advertising and marketing of about USD 370 per country. 
Male condom
The annual reports of the male condom marketing companies showed 
marketing investment percentages of 13% (USD 2.087m of USD 16.056m) 
for the Reckitt Benckiser Group (2013:15), and 12.5% (USD 400m of USD 
3,194m) for the Church and Dwight Company (2013:34). These are much 
higher than the minimum 5% proposed by McKee, showing that the 
male condom companies find it profitable to push demand and sales by 
investing considerably in marketing. ‘Today the condom is morphing 
beyond its utilitarian functions—protecting against pregnancy and 
disease—into a kind of entertainment product, setting the stage for 
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growth’ (Coleman-Lochner 2012:1). The marketing of the male condom 
is perceived by the companies as a specialised activity. 
Microbicides
As microbicides are still at the development stage, the issue of companies 
having to invest in marketing the product is yet to arise. 
6. Subsidies
Female condom
Although several studies have proven that female condom distribution 
programmes are cost-effective and gender-responsive ways of HIV 
prevention (Dowdy et al. 2006; Holtgrave et al. 2012; Remme et al. 2014), 
large scale subsidies/programmes in countries to create more demand 
and uptake have not taken place so far (UNITAID 2013:36). Although 
72% of all female condoms are bought and distributed by the global 
public sector, the total amount is relatively small and distributed across 
countries. With female condom donations in kind from UNFPA or USAID, 
several low and middle income countries have started temporary, 
small-scale pilot projects for the promotion of the female condom, 
mostly for specific target groups of women such as female sex workers, 
and often implemented by specialised social marketing companies. 
While these projects have produced some anecdotal outcomes (PSI 2014), 
their limited coverage and the limited evidence-based research on 
their effects have failed to create the substantial evidence that could 
convince international donors and agencies to question the female 
condom’s current high price and negotiate with the private sector, the 
manufacturing companies, to lower the price and improve affordability 
for potential users. Several activist public health researchers in Africa 
(Vijakumar et al. 2006) have expressed disappointment at the absence of 
any large-scale distribution programme for female condoms, as this 
precludes the building up of evidence of any positive public health 
impacts that female condoms might have in society. Another consequence 
of the finding that 72% of female condoms are being taken up by the 
public sector, is that low numbers of female condoms are left available 
for retail sale. The public sector’s current dominance as a purchaser of 
the female condom reduces incentives on producers to make it more 
widely available, for example, in grocery stores and supermarkets, 
where women could easily access it, in the way that the male condom is 
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available. So on the one hand, the low numbers of female condoms 
prevent women getting access to them easily; on the other hand, at the 
current stage of market development, where not enough work has been 
done to create sufficient demand to generate high profits from small 
margins on high volume sales, it is to the advantage of the manufacturer 
to keep supplies sufficiently low so as to keep costs up.
Male condom
A meta-analytical study (Sweat et al. 2012:620), which systematically 
reviewed all measures, whether public or private, undertaken between 
1990 and 2010 in developing countries concluded that the chances of 
people having used a male condom during their most recent sexual 
encounter with a casual partner was found to be 3.5 times higher 
among those who had been exposed to marketing interventions than 
among those who had not been exposed to any marketing interventions. 
Subsidies are judiciously used by governments as a measure to promote 
socially desirable public products. Some national governments provide 
subsidies for male condoms, bringing them onto the market for free or 
at low prices. Recent research showed that the condom markets in six 
sub-Saharan countries are heavily reliant on government or donor- 
funded products: Botswana (85%), Lesotho (70%), Mali (98%), South 
Africa (83%), Swaziland (85%), and Uganda (98%) (Pallin et al. 2013:8); all 
six countries demonstrate improvements in condom use. These subsidies 
combined with strong, ongoing marketing efforts have considerably 
increased the demand for and use of male condoms. Large-scale condom 
subsidy programmes for male condoms initiated by public sector actors 
have been researched and generally proven cost-effective (Weller et al. 
2002), and moreover, have received positive evaluations in terms of the 
health impact on society, for example in the USA (Bedimo et al. 2002; 
Cohen et al. 1999; Harvey 1994), in Thailand (Levine 2004),  and in India 
(Chauhan 2012). 
Microbicides
As microbicides are still at the development stage, the issue of 
subsidising them to decrease price and increase access, is yet to arise. 
Overall, the measures to increase supply, including subsidisation, are 
much higher for the male condom than for the female condom, and not 
yet applicable for microbicides. 
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3.4 Discussion
Why and how some public health products get under- or over-rated has 
been described by several other researchers, drawing attention to and 
analysing the failure of global health governance to rectify some of 
these trends (Cottingham et al. 2011:74; Fishman 2004; Wesenbeeck 
2011; Ziemba 2005). In this study we found that male condom companies 
are generally not interested in the development of the female condom. 
This might be related to the fact that the marketing of the female 
condom demands social change, which is not the core business of the 
private commercial sector. Marketing seems to succeed best when it holds 
on to the status-quo of a society and for example by re-enforcing gender 
stereotypes, for example men should take the initiative for sex (and for 
condom use) and as such condoms for women are not needed or in demand. 
Public health activists might reason differently when using the public 
health perspective, to create more social justice and promote health. 
 Recently the director of the Reproductive Health Supplies Coalition, 
John Skibiak advised that ‘the major players in global health governance, 
especially public sector donors, should expand their efforts to promote 
competition among manufacturers, to address gaps in supply chain 
management that constrain access, and to engage all relevant actors to 
create a better understanding of how to work for the public interest in 
a holistic way, as activities to promote one product will necessarily 
influence the supply and demand of alternative methods’ (Reproductive 
Health Supplies Coalition 2014b:3). Such a holistic way would stop the 
female condom being seen as ‘exceptional’ and unnecessarily perceived 
as a threat to microbicides or as a substitute for the male condom; and 
enable it to become seen instead as a promising permanent choice by 
the global health governance, needing special measures from the 
public sector to increase women’s choices to protect their bodies. 
3.5 Conclusion
Data available in the public domain do not suggest that adequate 
measures for marketing and demand creation, including product 
innovation, have been made for the female condom as compared to the 
male condom and microbicides. Somehow there is a problem with the 
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product of the female condom as neither the actors of the private 
commercial sector nor the ones in the public sector seem to trust that 
there is a potential market for the female condom. Although the three 
products have a lot in common, there are no signs of taken measures in 
a holistic way to change the situation. The male condom industries 
with their huge marketing expertise and potential are not ready to 
invest in female condoms, and the public sector does not invest in the 
‘hidden marketing’ of the female condom in the same way as takes 
place for microbicides. Without negotiations between the different 
sectors about these crucial issues, the high price and thus unaffordability 
of the female condom for women in sub-Saharan Africa will continue.
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THE FEMALE CONDOM:  
THE INTERNATIONAL DENIAL OF  
A STRONG POTENTIAL3
3 Published as: Peters A, Jansen W, van Driel F. 2010. “The female condom: The inter-
national denial of a strong potential.” Reproductive Health Matters, 18(35):119-128.
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Abstract 
The female condom has received surprisingly little serious attention 
since its introduction in 1984. Given the numbers of women with HIV 
globally, international support for women’s reproductive and sexual 
health and rights and the empowerment of women, and, not least, due 
to the demand expressed by users, one would have expected the female 
condom to be widely accessible 16 years after it first appeared. This 
expectation has not materialised; instead, the female condom has been 
marginalised in the international response to HIV and AIDS. This paper 
asks why and analyses the views and actions of users, providers, 
national governments and international public policymakers, using an 
analytical framework specifically designed to evaluate access to new 
health technologies in poor countries. We argue that universal access 
to female condoms is not primarily hampered by obstacles on the users’ 
side, as is often alleged, nor by unwilling governments in developing 
countries, but that acceptability of the female condom is problematic 
mainly at the international policy level. This view is based on an 
extensive review of the literature, interviews with representatives of 
UNAIDS, UNFPA and other organisations, and a series of observations 
made during the International AIDS Conference in Mexico in August 
2008.
Keywords: female condom, HIV prevention, UNAIDS, UNFPA, WHO, 
donors
501567-L-bw-Peters
99
INTERNATIONAL DENIAL OF A STRONG POTENTIAL
4.1 Introduction
Since the beginning of the AIDS epidemic, condoms have been the 
single most efficient available technology to reduce the transmission of 
HIV and other sexually transmitted infections (STIs). In 1984, Lasse 
Hessels invented the female condom, a transparent sheath with the 
same length as the male condom and a flexible ring at each end. In 
1993, the United States Food and Drug Administration (US FDA) 
approved the female condom as a safe and effective contraceptive and 
protective device impermeable to various STI organisms, including 
HIV. The American Foundation for AIDS Research stated that the female 
condom is 94-97% effective in reducing the risk of HIV infection, if used 
correctly and consistently (American Foundation for AIDS Research 
2005). The potential contribution of female condoms to STI/HIV 
prevention is well documented (Artz et al. 2000; Fontanet et al. 1998; 
French et al. 2003; Gollub 2000; Hoffman et al. 2008), and highly 
cost-effective (Dowdy et al. 2006). A review of 137 articles on the female 
condom concluded that it is effective in increasing protected sex and 
lowering STI incidence (Vijayakumar et al. 2006). A significant number 
of studies have also demonstrated that a wide range of choice of 
contraceptive methods and STI/HIV prevention devices is the primary 
factor in achieving safer sex practices (Gray et al. 2006; Hoffman et al. 
2004; Napierala et al. 2008). 
 As early as 1990, the South African women’s health researcher and 
activist Zena Stein made a plea for HIV prevention methods that women 
can initiate or control (Stein 1990). So far, the female condom is the 
only method that allows women to control protecting themselves and 
their partners. According to Mantell, Stein and Susser use of the female 
condom can empower women, give them a greater sense of self-reliance 
and autonomy, and enhance dialogue and negotiation with their sexual 
partners (Mantell et al. 2008).
 Access to protection has become increasingly urgent as the number 
and relative proportion of women infected with HIV have risen rapidly, 
especially in sub-Saharan Africa. This proportion rose from 50% of 
people living with HIV in 1998 to 59% in 2007 (UNAIDS 2008b). 
Promotion of male condom use for pregnancy prevention has been a 
success in Africa among young, single women (Cleland et al. 2006a), 
and young single women aged 15-24 are also at high risk of HIV in 
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Africa, due to sexual networking patterns. Although many couples 
could have benefited from the dual protection of the female condom, 
they have never heard of it, and even if they have heard of it, they are 
not able to obtain it (Hoffman et al. 2008). Nearly 25 years after its 
invention, the female condom is still not generally accessible. World 
production of female condoms remains a very small fraction (0.28%) of 
all condoms produced and access to this protective device is haphazard 
and inadequate (Höllensen 2007).
 During the two most recent international conferences on female 
condoms in 2005 (Shane 2006) and 2007 (Oxfam Novib 2007) an overview 
of female condoms was offered. There are currently three types of 
female condom on the international market, excluding the so-called 
panty or bikini kinds, which are designed for the sex industry and 
mainly used in Latin America. The Female Health Company exclusively 
manufactures two kinds of female condoms (FC1 and FC2). FC1 is made 
of polyurethane. FC2 is a newer version and is almost identical to FC1, 
except its raw material is synthetic latex, which enables a slightly 
cheaper production process (Höllenson 2007) and does not make noise 
when used, a side-effect which some people disliked in FC1 (Parker et 
al. 2000; Ray et al. 1995; Telles Dias et al. 2006). FC2 received US FDA 
approval in 2009 (US FDA 2009). A third type of female condom, the 
Reddy condom, is manufactured by Medtech Products in India. It has 
received a consumer safety mark for distribution in the European 
Union (EU) and was approved by the Indian Drug Controller in 2003. It 
has not been bought by the UN Population Fund (UNFPA) and other 
public donors, because of lack of approval from the World Health 
Organization (WHO) pre-qualification system. The Reddy condom is 
sold through the private sector in countries officially recognising its 
safety (Shane 2006; Oxfam 2008). In this article, we discuss the female 
condoms manufactured by the Female Health Company and distributed 
by international aid agencies such as UNFPA and other public donors. 
 This article analyses the roles played by a range of stakeholders – 
users of the method, providers, manufacturer, national governments, 
international development organisations and donors – to understand 
why the female condom is not more widely accessible and where, 
predominantly, it is being marginalised, using the linkages between 
acceptability, availability and affordability. 
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4.2 Methodology
We examined the literature published in 2005–2009 on the female 
condom through a search on Medline, Psych Info and Popline, using 
‘female condom’ and ‘HIV prevention’ as keywords. Studies, reviews, 
reports, policy documents, commentaries, editorials, written opinions 
and position papers were reviewed and categorised according to 
acceptability, availability and affordability issues covered. Three earlier 
reviews were also studied: a review of eight years (1996–2003) of female 
condom promotion in South Africa and the USA (Kaler 2004); the 
systematic review of 137 articles from 1996–2004 by HIV Research Unit, 
University of the Witwatersrand, South Africa (Vijayakumar et al. 
2006); and an in-depth study of the introduction of the female condom, 
guided by the Harvard School of Public Health (Frost et al. 2009). 
 Secondly, we analysed the Lancet edition on the ‘state of the art of 
HIV prevention’, presented at the International AIDS Conference in 
Mexico in 2008, written by key international HIV prevention experts 
(Lancet 2008). We compared the number of references to the female condom 
in the six articles with the number devoted to male circumcision for 
HIV prevention which, unlike the female condom, is currently being 
widely promoted and gaining funding (Mantell et al. 2008).  
 Thirdly, we observed the participation of global public policymakers 
during sessions at the 2008 International AIDS Conference, including 
about 50 high-level international and national officers in decision-making 
positions at multilateral institutions, such as UNAIDS, UNFPA, WHO, 
European Union and public donor agencies, and their international 
assistance to AIDS work. For the purpose of this article, this group of 
decision-makers is designated as ‘global public policymakers’.
 We used an analytical framework developed to assess access to new 
health technologies in developing countries (Frost et al. 2009) that 
takes social, economic, political, and cultural processes into account. 
The framework looks at three equally important aspects of ensuring 
accessibility: acceptability, availability and affordability. This allowed 
us to get a better grip on the variety of barriers and where they were 
occurring. 
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4.3 Findings
Acceptability 
A 1997 review by WHO of more than 40 acceptability studies of the 
female condom, conducted in 40 different countries around the world, 
found that 37% to 96% of female condom users rated the product as 
positive and acceptable (WHO 1997).4 The review acknowledged that 
acceptability may be determined as much by how the technology is 
introduced as by its physical characteristics. A prerequisite for 
acceptability appeared to be the education, training, and support that 
accompanied the introduction of the condom and whether it is 
sustained (Parker et al. 2000). In Europe and North America, where the 
female condom was simply made available in the mid-1990s, women 
were not automatically interested in using it. The different AIDS 
context and the easy access to other contraceptives made people less 
interested in adopting it (Parker et al. 2000). 
 After 1997, user acceptability studies in developing countries 
continued. Vijayakumar et al.’s review of 60 female condom studies 
from 1996 to 2004 (Vijayakumar et al. 2006) concluded that the female 
condom was an acceptable commodity, and that it should be made 
accessible quickly. The method has also elicited mixed reactions, 
especially when it is tried out for the first time, but may become 
acceptable after further use. Especially after a proper introduction, 
users appreciate the product. Training in insertion skills, as well as 
negotiation and communication skills, are important issues for users 
(Choi et al. 2008; Gollub 2000; Simons 2009): 
We both have to get used to it. But he doesn’t like the male condom, 
and we do need to protect ourselves. I think practice makes it 
perfect, so the more I use it, the more I get used to it (Simons 
2009:42).
The advantages of the female condom are that, we women, have our 
own condom, and our partner couldn’t say – no, I am not going 
to use it. If he doesn’t want to use it, I use it. What is he going to do? 
The other advantage is that the female condom gives more pleasure. 
(Telles Dias 2006:570)
4 I decided to repeat this study using the most recent studies (2003-2013) into acceptability 
of the female condom. In chapter 2 the results of this review are presented.
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The meetings were good, because many things were explained. I 
have rehearsed again how to insert it correctly in a model 
resembling the vagina. We also talked about how to introduce it to 
the partner. I found it very cool. (Choi et al. 2008:1844) 
Kaler (2004), Vijayakumar et al. (2006) and Frost and Reich (2009), 
describing the lessons learned from the introduction of the female 
condom, all concluded that acceptability and acceptance by users were 
not barriers for the introduction of the female condom. 
 Almost all studies and programmes have concluded that accurate, 
non-judgemental information from health care providers and media, 
and training and practice for women/couples help to make the female 
condom acceptable to the majority of potential users and women 
succeed in sustaining its use (Choi et al. 2008; Hoffman et al 2004; 
Parker et al 2000). People’s initial lack of interest can be reversed, 
negative rumours dispelled, fears alleviated, and awareness that one 
can have pleasurable sex while being protected can be raised (Choi et al. 
2008; Frost et al. 2009; Gollub 2000; Gray et al. 2006; Hoffman et al. 
2004; Hoffman et al. 2008; Kaler 2004; Mantell et al. 2008; Napierala et 
al. 2008; Parker et al. 2000; Ray et al. 1995; Simons 2009; Susser 2009; 
Vijayakumar et al. 2006). Yet, these findings have not been taken 
seriously by stakeholders at higher levels. The myth that women do not 
accept and like the female condom persists and continues to be 
influential (Nation Nairobi News 2007). 
 The lack of acceptability of female condoms by health care providers 
has been reported in several studies in South Africa, USA and Kenya 
(Frost et al. 2009; Kaler 2004; Mung’ala et al. 2006). Some providers 
found themselves without the capacity, support or training to offer 
female condoms. Others lacked, for example, pelvic models to 
demonstrate condom use. Others were concerned about likely 
inconsistency of supply. Health providers lacked not only knowledge 
and support, but also had their own inhibitions about sexuality, and 
were not convinced their patients would accept and want female 
condoms (Frost et al. 2009). The intricacies of women’s bodies were still 
a forbidden topic among some South African health staff (Kaler 2004). 
Social ideals about appropriate female sexual behaviour, such as 
demureness and innocence, increased providers’ expectations that 
women would not be interested in using female condoms. Moreover, 
female condom programmes have often been targeted only at sex 
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workers, in the belief that only sex workers can take protection into 
their own hands (Cleland et al. 2006b). Targeting sex workers might 
have led to stigmatisation rather than normalisation of the product 
(Hoffman et al. 2004; Mantell et al. 2008). According to a London School 
of Hygiene and Tropical Medicine and WHO study, the needs of married 
and cohabiting couples have been neglected, and the barriers to condom 
adoption by married couples may not be as severe as is often assumed 
(Cleland et al. 2006b). This is confirmed by the Harvard School of Public 
Health review, which noted that too little information has been 
directed to male partners and too little effort is made to encourage 
open communication between partners about protection (Frost et al. 
2009). 
 The media have played a very particular role in reporting on the 
acceptability of the female condom. In the USA and South Africa, some 
media have reinforced the myth that women dislike the female condom 
(Gollub 2000; Latka 2001; Kaler 2004; Susser 2001). Susser found that 
the US media dismissed the female condom on the assumption that 
uptake would fail because women have a limited say about their bodies, 
and would find the product unacceptable (Susser 2001). Media in 
general continue to portray the female condom as still ‘on trial’ 
(Mantell et al. 2008; Frost et al. 2009). At the 2008 International AIDS 
Conference, 24 years after it was first produced, many participants still 
perceived it as a novelty.
 Several political leaders in Uganda (IRIN 2009) and ministries of 
Health of African countries (Musoni 2007) have referred to cultural 
barriers to accepting the female condom (Mantell et al. 2008). In 
response, leaders of Uganda’s women’s organisations successfully urged 
their government to make the method available again, after the 
government halted distribution in 2007. Kibirige, coordinator of the 
condom unit at the Ugandan Ministry of Health said: ‘Women – both 
married and single – have asked us to bring back the female condom’ 
(Musoni 2007:1). As a result, a new female condom programme was 
begun. National women’s organisations in Namibia (Susser 2009) and 
Zimbabwe (Osewe 1999) have done the same. Other women’s groups and 
non-governmental organisations (NGOs) have been less successful, for 
example in Cameroon (Personal communication Adrienne Germain, 
Director, International Women’s Health Coalition, spring 2007) and 
Malawi (Longwe 2008). 
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 The views of international HIV experts have also influenced the 
acceptability of the female condom. In the special Lancet issue on HIV 
prevention, the female condom is mentioned in only one paragraph of 
one of the six articles (Padian et al. 2008), which references eight other 
articles. In contrast, four articles mention male circumcision and 
reference 44 other articles on male circumcision. Although the benefits 
of male circumcision for women are less clear than those of female 
condoms, circumcision programmes are nevertheless being scaled up 
(United Nations Interagency Team on Male Circumcision for AIDS 
Prevention 2009). Moreover, the one short paragraph on female 
condoms mentions the lack of large-scale epidemiological data on 
whether the female condom prevents HIV transmission. Yet, a study by 
Hoke et al in the International Journal of STD & AIDS found that adding 
female condoms to a male condom distribution system led to decreased 
STI prevalence, indirectly leading to lower HIV prevalence (Hoke et al. 
2007). Secondly, the authors did not ask why nobody ever funded 
large-scale studies, despite several recommendations to this effect 
(Höllensen 2007; Oxfam 2008; UNFPA 2006; Shane 2006). We conclude 
that the Lancet’s international HIV prevention experts seem to have 
problems accepting the female condom as an effective prevention tool. 
Lancet editor Richard Horton asked them not only to discuss state of the 
art HIV prevention, but also ‘to disrupt the usual axes of power within 
the AIDS scene’ (Lancet 2008). In our view they did not succeed. By 
barely considering the female condom, they neglected a simple and 
effective method that could help to challenge gender-based power in 
HIV prevention, and contribute to women’s empowerment in sexual 
and reproductive health and rights.
 What about UNAIDS? At the 2008 International AIDS Conference, 
Oxfam held a press conference ‘Failing women, withholding protection. 
15 lost years in making the female condom accessible’. A demonstration 
of around 200 women, mainly representing African constituencies, 
preceded this event and demanded access to female condoms. One 
commentator wrote: ‘Perhaps one of the most impressive displays of 
women’s rights activism at the conference was a rally around an issue 
that is not typically regarded as generating large, boisterous crowds: 
female condoms’ (Whipkey 2008). The day after this demonstration, 
Michael Bartos, UNAIDS Chief of Prevention Care and Support declared 
that there was hardly any user demand for the female condom (Personal 
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communication, 7 August 2008) as if the demonstration and press 
conference were insignificant or had not taken place at all. Notably, 
UNAIDS has no staff or resources dedicated to supporting female (or 
male) condom programmes and therefore has not accumulated 
expertise in this domain. In contrast, UNAIDS and WHO have numerous 
staff members and resources to work on male circumcision. George 
Brown, former Rockefeller Foundation director and Population Council 
vice-president, identified reluctance among bilateral donors to provide 
funds to scale up the promotion of female condoms (Brown 2007). 
Others, such as Oxfam in Oxford (Oxfam 2008) and the Center for 
Health and Gender Equity in Washington DC (2008) confirm similar 
attitudes among global public policymakers. Global Health Insights 
researchers Laura Reich and Beth Anne Pratt conclude that commitment, 
dedication and funding to the female condom as technology for poor 
people in poor countries has been too small (Frost et al. 2009). 
 At global level, public policymakers continue to fund mainly limited 
distribution projects, perpetuating the view that the female condom is 
not ready or acceptable for scaling-up (Frost et al. 2009). There are some 
positive developments too, however. A new female condom programme, 
Universal Access to Female Condoms (UAFC), was launched in 2008, 
which provides substantial funding for a large-scale female condom 
programme and procurement in two countries, Nigeria and Cameroon, 
supported by SIDA, Danida, Hewlett Foundation and the Netherlands 
Ministry of Development Cooperation (Oxfam 2008).
Availability 
The introduction of female condoms has been described as successful 
in three countries in sub-Sahara Africa: Ghana, Zimbabwe and South 
Africa (Warren et al. 2003). In all three countries, the success is 
attributed to the combined efforts of the Female Health Company, 
which manufactures and sells female condoms; the Female Health 
Foundation, which is hired by UNFPA to technically support the 
Ministries of Health; UNFPA, who buy and distribute them and support 
training activities; the Ministry of Health, which ensures transportation 
to the clinics and trains clinic staff; and Population Services 
International, a social marketing organisation, which distributes them 
through various private channels and advertises them in an attractive 
way. In the mid-1990s, local women and AIDS organisations, such as 
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Women and AIDS Support Network (WASN) in Zimbabwe and the 
Society for Women and AIDS in Ghana (SWAG) implemented educational 
programmes for users (Osewe 1999; Rogow 2006) and started informing 
women about the female condom. In 1996, WASN and other women’s 
organisations organised a public march to convince the Ministry of 
Health and the National AIDS Control Programme to distribute female 
condoms. The combination of research and advocacy proved to be 
successful (Osewe 1999). In 2007, however, the momentum was lost in 
all three countries. Representatives of SWAG and WASN reported in an 
international workshop that female condom availability was uncertain 
and unreliable (Oxfam Novib 2007). In South Africa, the Thohoyandou 
Victim Empowerment Programme (TVEP) organised a national workshop 
in 2008 to call for access to female condoms as a human right (2008). 
However, the existing national strategies for distribution of contra-
ceptives and male condoms in all three countries have failed to integrate 
female condoms into these programmes. Women in developing countries 
have especially felt the lack of availability as an injustice: 
 I found the female condom quite appropriate and user friendly. 
Unfortunately, it was not marketed like the male condom was, while 
many people are dying. That is a criminal offence; we need to promote 
it again and I believe it will be helpful to some of the women. I would 
rather have something that is said to be noisy or uncomfortable than 
get infected with HIV from doing nothing about it. (Muganwa, Makerere 
University, Uganda, in an interview with a local newspaper) (Ajwang 
2009:1). 
 Ida Susser did research and advocacy for female condoms in 
Namibia between 1996 and 2008 and introduced them to women’s 
organisations, who in turn tried to convince their Ministry of Health to 
make them available. However, Susser concludes that no systematic 
distribution programme is in place in Namibia to date (Susser 2009). In 
Cameroon, the female condom was introduced by the Society for 
Women and AIDS in Cameroon (SWAC) but the country faced complete 
stocks-outs in 2006 (Personal communication Adrienne Germain, 
spring 2007). Malawi, where the female condom was introduced by 
UNFPA, also faced a stock-out in 2007 (Longwe 2008). 
 Many people in the field feel frustrated by the failure to scale-up 
female condom distribution, despite the success of several pilot 
programmes (Artz et al. 2000; Cleland et al. 2006b; Frost et al. 2009). 
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Availability could increase demand considerably (Artz et al. 2000; 
Cleland et al. 2006b; Frost et al. 2009). According to Friel and other 
experts, regular stock-outs have been hugely damaging to the 
availability of this method (Friel 2005). The FC2 is not yet available on 
the private market and the Reddy condom is not yet on the public 
market. The production capacity of the Female Health Company is a 
serious perennial problem: it cannot meet even the existing worldwide 
demand, as small as it is (Personal communication, Rino Meijers, 
consultant, IDA Solutions, June 2008). Their global production is limited 
to 34.7 million female condoms per year, compared to 12 billion male 
condoms, in short only a small fraction (0.28%) of all condoms produced 
(Höllensen 2007).
 In 2005, UNPFA launched a Global Female Condom Initiative, to 
scale up female condom programming in 23 countries, mainly in Africa 
(UNFPA 2006). It successfully increased the total number of female 
condoms distributed in Africa, from 4,9 million female condoms in 
2005 to 16,5 million by 2008 (UNFPA 2008), but the annual distribution 
per country is less than 1 million female condoms. This UNFPA 
initiative has not been evaluated. According to Frost & Reich, UNFPA 
decided in 2005 after the global consultation meeting in Baltimore to 
do away with pilot projects in favour of national distribution strategies 
(Frost et al. 2009), but so far they have not been successful in guiding 
countries to set up a reliable national distribution system (Longwe 
2008; Oxfam 2008). In a meeting at UNFPA in New York in January 2008, 
several female condom experts argued that distributing a few thousand 
female condoms per country in 23 or even more countries was ineffective, 
and that countries needed to ensure scaling-up in a reliable distribution 
system, preferably integrated into other existing distribution systems 
(Oxfam 2008).
 We consider that UNFPA’s strategy is based on the perception of the 
female condom as a niche product for a few selected groups of women 
(Frost et al. 2009; Oxfam 2008; Oxfam Novib 2007). We think female 
condoms should be considered as a public good and should be made 
available to all sexually active couples who need to protect themselves. 
Affordability 
Almost everything written on the female condom refers to price 
barriers (Oxfam 2008; Osewe 1999; Stein 1990; Vijayakumar 2006). 
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From the first international meeting on female condoms in 1993 to the 
sixth in 2007, global public policymakers such as UNFPA and USAID 
have considered the price a major barrier to access (Finger 1997; Oxfam 
Novib 2007). Users in developing countries have been unable to 
purchase female condoms on the private market, because they cost 
US$2–3 each (FC1) (Frost et al. 2009). This is far too expensive, especially 
for poor women.5
  The Female Health Company, which has a monopoly on USFDA and 
WHO-approved female condoms, sells the majority of its condoms to 
UNFPA and public donors (Höllensen 2007) and sets the price. UNFPA 
and bilateral donors buy condoms in bulk. For these bulk purchases, 
UNFPA was only able to negotiate a price 29 times higher than the male 
condom, i.e. $0.58 per female condom versus $ 0.02 per male condom 
(Frost et al. 2009). Detailed data about the basis for this price are not 
publicly available. According to Svend Höllensen, the Female Health 
Company has not exploited economies of scale as a price reduction 
strategy (Höllensen 2007). As a result of low production rates, the price 
remains high, and the production volume cannot meet demand. Market 
rationality concerning the female condom is lacking, and this has led 
to a price monopoly. Why this monopoly and a lack of competition 
continue to exist deserves a separate study.
 One solution to the problem of affordability could have been re-use 
of the female condom. Already in 1993, Zimbabwean women who were 
among the first to try out the female condom suggested this idea (Ray 
et al. 1995). Sixteen years later, in spite of numerous studies, global 
consensus was not reached regarding re-use in two WHO consultation 
meetings in 2000 and 2002. WHO has therefore left the final decision 
regarding re-use to national governments (WHO 2002). By remaining 
ambivalent, WHO has contributed to the non-affordability of the 
female condom. Sunanda Ray, in a presentation at an international 
workshop on condoms in 2006, said: 
 If you re-use the female condom five times it cuts the cost of a 
female condom by five. However in the WHO consultation on re-use 
of female condoms, two thousand women asking for advice on how 
to re-use the female condoms were defeated at the international 
5 As this article was published in 2010, more recent developments influencing the 
price of the female condom are included in chapter 3. 
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level by the recommendations of microbiologists, for whom standards 
of hygiene were more important than the number of women who 
got infected with HIV in the meantime. What is needed is a “good 
enough” solution not a perfect one. This separation of realities also 
exists in the dissonance between users and health workers, policy - 
makers and programme implementers. (Ray 2006: 9) 
Moreover, global public policymakers have barely contributed to research 
and development on female condoms, although this might lead to a 
breakthrough in price and costs (Höllensen 2007; Oxfam 2008). Yet 
advocacy for research on microbicides as chemical barriers against HIV 
infection has been successful in acquiring funding for new product 
development. Research and development on the female condom – a 
proven method that already exists – has attracted hardly any funding 
(Oxfam 2008). 
 Some national governments, like South Africa and Brazil, use their 
own health budgets to purchase female condoms. Others receive support 
from donors. The Brazilian government decided for reasons of price to 
buy female condoms only for sex workers and drug users, and not for 
the public. As Freire, the Minister for Women’s Affairs of Brazil, stated 
in 2007: 
 I cannot sell this concept to my government as long as the 
purchasing price of one female condom is US $ 0.74, the negotiated 
price with the Female Health Company (Oxfam Novib 2007:17). 
Susser reported in 2009 that the Namibian government, like Brazil’s 
government, did not want to buy female condoms due to the high 
price (Susser 2009). Concerted efforts at global and national level and 
listening to the organised voice of people living with HIV and AIDS 
successfully achieved strategic cost reductions on antiretroviral treatment. 
For the female condom, however, cost reductions have not taken place 
and the voices of women activists are still not heard. As a result, the 
cost of the female condom has been caught in a vicious circle – perceived 
low demand, perceived low acceptability, unwillingness of public 
policymakers to invest in female condom production, purchase and 
programmes, stock-outs, high prices and frustrated demand (Friel 
2005; Kaler 2004; Mantell et al. 2008). The result is a stalemate. 
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4.4 Conclusion
 Stalemate: ‘The great enemy of truth is very often not the lie – 
deliberate, contrived, and dishonest – but the myth – persistent, persuasive, 
and unrealistic’ (John F Kennedy, 1962). As long as global public 
policymakers hide behind the argument of high prices or the myth that 
there is no demand and therefore no supply, no market, access to female 
condoms will remain out of reach worldwide. Breaking the myths 
surrounding the female condom has been impossible for 16 years. We 
conclude that female condom programmes have been sabotaged by 
problematising acceptability among users and by stakeholders failing 
to create access that would satisfy and increase demand. All stakeholders 
contribute in different degrees to the marginalisation of the female 
condom, except women users themselves and some women activists. 
Collective and synergistic action to increase access to the female 
condom has not yet been undertaken. On the contrary, according to 
Frost and Reich, a process of marginalisation of the female condom 
started shortly after its introduction (2007), and has persisted. This is 
incomprehensible given that: The failure of recent trials to show the 
efficacy of new microbicide candidates and the diaphragm, make the 
promotion of the female condom as a life-saving intervention more 
prominent than ever (John McConnell, Editor, Lancet Infectious Diseases, 
2008). Further exploration of the profound reasons for the ongoing 
denial of the value of female condoms at global public policy level is 
needed because leadership at that level is crucial, for example in 
ensuring that more manufacturers enter this area, produce more 
condoms, negotiate better prices and develop effective promotion and 
distribution programmes to the general public, women as well as men, 
who might prefer to use a female condom. 
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WHERE DOES PUBLIC FUNDING  
FOR HIV PREVENTION GO TO?  
THE CASE OF CONDOMS VERSUS 
MICROBICIDES AND VACCINES6
6 Published as: Peters A, Scharf M, Van Driel F, Jansen W. 2010. “Where does public funding 
for HIV prevention go to? The case of condoms versus microbicides and vaccines.” 
Globalization and Health 6: 23 http://www.globalizationandhealth.com/content/6/1/23
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Abstract
This study analyses the priorities of public donors in funding HIV 
prevention by either integrated condom programming or HIV 
preventive microbicides and vaccines in the period between 2000 and 
2008. It further compares the public funding investments of the USA 
government and European governments, including the EU, as we 
expect the two groups to invest differently in HIV prevention options, 
because their policies on sexual and reproductive health and rights are 
different. We use two existing officially UN endorsed databases to 
compare the public donor funding streams for HIV prevention of these 
two distinct contributors. In the period 2000-2008, the relative share of 
public funding for integrated condom programming dropped 
significantly, while that for research on vaccines and microbicides 
increased. The European public donors gave a larger share to condom 
programming than the United States, but exhibited a similar downward 
trend in favour of funding research on vaccines and microbicides. Both 
public donor parties invested progressively more in research on 
vaccines and microbicides rather than addressing the shortage of 
condoms and improving access to integrated condom programming in 
developing countries. 
Keywords: funding, HIV prevention, condoms, microbicides, vaccines.
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5.1 Background 
The number of people living with HIV worldwide has continued to 
grow, reaching 33.4 million in 2008. In the same year 2.7 million new 
HIV infections occurred, almost half (45%) among people younger than 
25 years (UNAIDS 2009a). Despite a more than eight-fold increase of 
total global financing for fighting AIDS, from US $ 1.6 billion in 2001 to 
US $ 13.8 billion in 2008, a small fraction has gone to HIV prevention 
(Izazola-Licea 2009). Public donor expenditures for treatment have 
grown much faster than the spending for prevention (Bertozzi et al. 
2008; Haslegrave 2004; Kumaranayake et al. 2001). The two largest 
public AIDS funds, the Global Fund for AIDS Tuberculosis and Malaria 
(GFATM initiated in 2001) and the Presidents’ Emergency Programme 
for AIDS (PEPFAR since 2003), spend about 70% and 80% of their 
respective HIV budgets on treatment and care programmes in developing 
countries (Over 2008; GFATM 2010). However, as of December 2008, mainly 
due to the high costs of treatment, 58% of those infected and requiring 
antiretroviral treatment cannot access such treatment (UNAIDS 2009a). 
Prevention, to halt the increase in new infections, therefore, remains 
as urgent as before. HIV experts currently agree that prevention is 
underfunded (Bertozzi et al. 2008). Therefore, insight into how the 
limited public funding for prevention is distributed is important. 
 At the end of 2008, for every two people starting antiretroviral 
treatment, five were newly infected (UNAIDS 2009a). Even if there were 
a cure for HIV, treatment only would by no means suffice to control the 
epidemic (Schwartländer et al. 2006). Although HIV infection is 
avoidable, HIV prevention interventions are estimated to be accessible 
to less than one in five people worldwide (Global HIV Prevention 
Working Group 2006). Similarly, less than 40% of young people in 
developing countries are estimated to have basic information about 
AIDS and HIV prevention (UNAIDS 2009). This knowledge gap might be 
due to the frequently expressed objections of political and religious 
leaders to sexual behavioural change programmes known to reduce 
HIV infection rates, such as integrated condom programming (Coates 
et al. 2008). The same leaders, however, seem to be eager to welcome 
donor support to antiretroviral treatment for their populations (Coates 
et al. 2008). The knowledge gap on prevention is reproduced on another 
level. Only a limited number of studies provide information on the 
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coverage level of HIV prevention programmes in different developing 
countries (Haslegrave 2004), while ample data are available on the 
coverage rates of treatment and care programmes (UNAIDS 2009). 
Public funders could play a crucial role in supporting developing 
countries to extend the coverage of evidence-based HIV prevention 
programmes. So might private and philanthropic donors, but due to 
lack of information on these funding streams they are excluded here 
from the analysis. 
 Within HIV prevention, different approaches can be distinguished, 
such as prevention by vaccines or microbicides, prevention by integrated 
condom programming, and some recently introduced prevention 
technologies such as male circumcision and prophylactic use of 
antiretroviral drugs. Prevention by vaccines or microbicides has been 
considered an important means to stop the AIDS epidemic since the 
beginning of the 21st century. Recently, the director of UNAIDS 
expressed his belief, that a preventive HIV vaccine holds the greatest 
opportunity for ending the epidemic and many share his view (Sidibé et 
al. 2010). Several scientists, however, among them the chief editor of the 
Lancet, seriously question the possibility of developing a successful HIV 
preventive vaccine and criticise the overly optimistic prospect portrayed 
by the vaccine research community (Horton 2004). In 2007, five 
large-scale HIV vaccines studies were stopped because they failed to 
show satisfactory results (National Institute of Allergy and Infectious 
Diseases 2008). In the same year, two microbicides trials were halted 
because they led to more HIV infections instead of less (Stephenson 
2007). In 2009, vaccine researchers reported some success in a trial in 
Thailand, but the observed vaccine efficacy was too modest to be of any 
public health significance (Kapiga et al. 2010). In 2010, microbicide 
researchers reported a first success in a trial in South Africa. Women 
who used the to-be-tested microbicide were 39 percent less likely to 
become infected with HIV than women who received a placebo gel 
(Evans 2010). However, the consequences of these recent findings for 
prevention schemes are not clear yet and currently under discussion. 
Consequently, these technologies still are being researched and have 
not yet been applied in HIV prevention programmes. This means that 
the funding directed to this category of HIV preventives totally goes to 
research rather than to application in HIV prevention programmes, 
and therefore has not yet a direct effect on prevention. 
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 Another HIV prevention technology is condoms and integrated 
condom programming. In contrast to vaccines and microbicides, male 
condoms have existed since at least 1000 BC. Female condoms, which 
are as effective as male condoms, have existed since 1984, and were 
officially approved by the United States Food and Drug Administration 
(US FDA) in 1993 (Carey et al. 1992; Population Action International 
2002). In 2009, UNAIDS, WHO and UNFPA renewed their joint position 
statement on condoms: ‘The latex condom is the single, most efficient, 
available technology to reduce the sexual transmission of HIV’ (UNAIDS 
2009b). Empirically, its cost-effectiveness in comparison to other HIV 
prevention methods has been proven (Demaria et al. 2007; HIV-2031costs 
and financing working group 2008). Female and male condoms are 
central to efforts to halt the spread of HIV. This was officially recognized 
as early as 1994 in the Programme of Action of the International 
Conference on Population and Development (UNFPA 1995); again in 
2001 in the Political Declaration of commitment on HIV/AIDS in the 
United Nations General Assembly Special Session (UNGASS) on HIV/
AIDS (UNGASS 2001); and again in 2005 as part of a plan to achieve the 
Millennium Development Goals (United Nations Development Programme 
2005). The female condom in particular is currently the only technology 
that gives women greater control over protecting themselves from HIV, 
other STIs and unintended pregnancy (Peters et al. 2010a; UNFPA 2009b; 
chapter 4).
  Integrated condom programming is essential to the realisation of 
sexual and reproductive health and rights, including the prevention of 
HIV (Albarracin et al. 2004; Bedimo et al. 2002; Creese et al. 2002). 
Integrated means that the programme is delivering two or more types 
of services previously provided separately, as a single, coordinated, and 
combined service. Examples are condom programming combined with 
counselling services on family planning, or with HIV/STI testing services 
or with sexuality education (Management Sciences for Health 1998). 
Integrated condom programming has proven to be successful, under 
the condition that a gender, relational and community perspective is 
used (Foss et al. 2007; Pinkerton et al. 1997). And that the condoms are 
affordable. Cost studies have shown that the consumer price of condoms 
has a strong effect on access and, thus, usage (Weller et al. 2007). 
Integrated programmes, which subsidise or freely distribute condoms, 
have led to increased usage, a condition for effectiveness in HIV prevention 
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(Cohen et al. 1999). In July 2010, during the last international AIDS 
conference in Vienna, UNAIDS reported on successes in HIV prevention 
by integrated condom programming in a multi country study (UNAIDS 
2010). At the same conference, a researcher from John Hopkins 
University showed convincing results of declining HIV infection rates 
in countries with generalised HIV epidemics. These declines occurred 
in a time when antiretroviral treatments were not yet available and 
when priority was on prevention through sexual behavioural change 
programmes combined with unproblematic access to condoms (Gregson 
et al. 2009). It is beyond the scope of this article to discuss the factors 
leading to successful condom programming in-depth. However, it is 
important to recognise that it is an evidence-based, cost-effective, efficient, 
and directly available way of delivering HIV prevention services to people.
 Apart from the two above mentioned prevention approaches, three 
other HIV prevention technologies were introduced in some developing 
countries such as male circumcision (WHO 2010), use of anti-retroviral 
drugs in pregnancy to prevent mother to child transmission (PMCT) 
(WHO 2010), or prophylactic use of antiretroviral drugs (PreP) (Underhill 
et al. 2010). All three technologies will only be partly efficacious for 
preventing sexual transmission of HIV. Circumcised men may still 
contract HIV (and other STIs), and can still pass it on to their next 
partner, making protection with condoms still necessary and thus, the 
need for integrated condom programming. The need for protection also 
remains when introducing PMCT or PreP. There is still much discussion 
on the assessment of the effectiveness of the various HIV prevention 
technologies. The assessment varies with the researchers’ disciplinary 
perspective. Kippax concluded in her study that the (bio-) medical 
sciences are dominant in the discussion on HIV prevention, leaving 
hardly any space for social sciences (Kippax 2010). In this article, we 
will not address the different scientific interpretations in HIV 
prevention effectiveness, since this is done recently by Heise et al (2011). 
We will focus on the funding choices being made in HIV prevention. 
Our first question is therefore: How is the public funding from USA and 
Europe for HIV prevention divided over research on HIV preventive 
vaccines and microbicides and integrated condom programming in the 
period 2000 to 2008? 
 We are particularly interested in the funding choices in HIV prevention 
taken by two different public donors, the USA government, and European 
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governments, including the EU. The European public donors have a 
long tradition of supporting gender and sexual and reproductive health 
and rights as part of Official Development Aid (Claeys et al. 2005; Henry 
J. Kaiser Family Foundation 2008).The following statement on HIV 
prevention of the Council of the European Union illustrates its position:
We re-affirm our commitment to tackle the HIV pandemic in a 
comprehensive and integrated way and in particular the HIV 
prevention gap. We are profoundly concerned about the resurgence 
of partial or incomplete messages on HIV prevention, which are not 
grounded in evidence and have limited effectiveness. We, the 
European Union, firmly believe that HIV prevention must utilise 
all approaches known to be effective, like universal access to sexual 
and reproductive health information in accordance with the 
international decisions at the International Conference on 
Population and Development agenda and reliable access to essential 
sexual and reproductive health commodities, including male and 
female condoms (European Council 2005:2). 
The European donors thus clearly recognise the importance of sexual 
and reproductive health and rights, and explicitly state the necessity to 
provide reliable access to male and female condoms. In contrast, the 
USA government failed to set up a holistic sexual and reproductive 
health and rights approach in development aid. In the period between 
2000 and 2008, especially with the Bush presidency, it has implemented 
a conservative HIV policy leading to a global anti- condom movement 
(Boonstra 2003; Evertz 2010), started earlier by the Catholic Church. 
Because of this difference in policy, we expect to find that the European 
governments and the EU give a larger share of the funding to integrated 
condom programming in the period 2000 – 2008 than the USA. Our 
second question therefore is: Is there a difference in public donor 
funding within HIV prevention between the EU and the USA?
5.2 Methods
We compare the actual amounts and relative share of public funding by the 
USA and Europe for two categories of HIV prevention. This comparison 
limits itself to public funds donated to HIV prevention by donor 
governments, i.e. public donors. Private and philanthropic donors are 
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not included in our study for several reasons. Firstly, the public donors 
have a responsibility to take measures for HIV prevention and for the 
development of HIV prevention technologies. New HIV technologies are 
mainly being developed with public sector financing and not private 
sector funding (Henry J. Kaiser Family Foundation 2008). Secondly, 
public donors are primarily accountable in relation to the effectiveness 
and efficiency in HIV prevention, especially under Official Development 
Aid (ODA). Data availability is a third reason. While data on public 
funding are relatively easily detectable, data on private funds are scattered 
and no integrated database exists containing all the foundations active 
in the field. Public donors are primary donors. These primary donors 
provide the basic information for our study. We review actual donor 
government expenditures in support of HIV prevention for two groups 
of primary donors, i.e. European governments including the European 
Commission, and the USA. The funding comes directly from these public 
funding agencies, and is directed to research bodies and international 
development assistance agencies. 
 This study is based on secondary analysis, using information from 
two available databases, of which UNAIDS endorses one and UNFPA the 
other (HIV vaccine microbicide resource tracking group 2010; UNFPA/
Netherlands Interdisciplinary Demographic Institute (NIDI) 2010). We 
did not gather new data, but categorise, compare and analyse existing 
data. 
 Tracking donor government financing for HIV vaccines and micro- 
bicides is relatively easy since these two prevention methods are still in 
the stage of research and not in delivery and, thus, are not yet part of 
daily programming. It is relatively easy to classify financial support to 
research and trials, which have a clear start and ending. Computing 
donor government funding levels for integrated condom programming 
is more complicated, because of its integration in different programmes 
and services. Condoms offer dual protection: against unintended 
pregnancy and against sexually transmitted infections. Consequently, 
integrated condom programming is an essential component of family 
planning, reproductive health, and AIDS interventions. In our study, 
we do not distinguish financial flows for integrated condom programming 
used for family planning and reproductive health purposes from those 
used for HIV prevention, as we will elaborate below.
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  The data on funding for research on HIV vaccines and microbicides 
are collected on an annual basis by the HIV Vaccine Microbicide 
Resource Tracking Group, which consists of three organisations: the 
HIV Vaccine Advocacy Coalition (AVAC), the Alliance for Microbicide 
Development (AMD), and the International HIV Vaccine Initiative (IAVI) 
supported by UNAIDS (HIV vaccine microbicide resource tracking 
group 2010). To analyse the financial resource flows for integrated 
condom programming, we used the database of the UNFPA/NIDI project 
‘Financial resource flows for population and HIV activities’ as a source 
(www.resourceflows.org). This project monitors the global financial 
flows allocated to sexual and reproductive health and rights, including 
AIDS, to assess the fulfilment of commitments made at the International 
Conference on Population and Development (ICPD) Programme of 
Action, in 1994, and at the UNGASS on HIV/AIDS in 2001, as described 
earlier. On an annual basis, UNFPA/NIDI report and present their data 
to the UN Secretary-General (UNFPA/NIDI 2010). The UNFPA/NIDI 
database, like the one from the HIV Vaccine Microbicide Resource 
Tracking Group, tracks financial resource flows of primary donors, 
among others. Their data are comparable because they both use the 
same definition and categorisation of donors. Moreover, both databases 
make use of the same research methodology, surveying donors by using 
self-administered standard questionnaires about their funding streams. 
However, calculating the exact funding for condom programming 
from the UNFPA/NIDI database was not self-evident, because condoms 
are often an integrated part of a project and thus calculation of funding 
levels for integrated condom programming requires certain estimates. 
We used the following approach to reach the best estimates. 
 In the UNFPA/NIDI questionnaire, donors categorise their funding 
in line with that of the 1994 and subsequent ICPD programmes of 
action as follows: family planning, AIDS, reproductive health, and basic 
research. Integrated condom programming can be part of any of these 
four categories. By far the majority of projects are classified as mixtures, 
meaning that they fall in two or more of the four categories, expressed 
in percentages. Thus, we considered all four categories equally to find 
the total funding for integrated condom programming. The UNFPA/
NIDI database contained 6,707 projects in 2000, which increased to 
15,098 projects in 2008 (Table 5.1 Column A). The total amount of 
funding increased from 1,887 million US$ in 2000 to 10,778 million 
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US$ in 2008 (Table 5.1 Column B). To establish the integrated condom 
projects, we counted the number of projects with the word ‘condom(s)’ 
and ‘contraceptive(s)’ in the project title and/or in the project 
description, which typically summarizes the project in about 300 
words. We assumed that if there is no mention of ‘condom(s)’ or ‘contra-
ceptive(s)’ in the title or description of a particular project, condom 
programming is not part of the project. This resulted in 294 projects in 
2000 and 68 in 2008 (Table 5.1 Column C), and total amounts of funding 
of 189 mUS$ and 42 mUS$, respectively (Table 5.1 Column D). Among 
the total number of projects, there were many without or with a very 
short project description of less than 50 characters, and thus with a 
little chance of including the words ‘condom(s)’ or ‘contraceptive(s)’. We 
therefore discarded all these projects and only took into account the 
projects with a full project description of more than 50 characters, 
which had a sufficient chance to contain the words ‘condom(s)’ or ‘con-
traceptive(s)’ and describe the integration of condoms in the project 
(Table 5.1 Column E). For each year, we calculated the proportion of 
the projects with either one of these words by dividing column C 
(number of projects with ‘condom(s)’ or ‘contraceptive(s)’ in the title or 
description) by column E (total number of projects with a project 
description of more than 50 characters) and multiplied by 100 to find 
the percentages (Table 5.1 Column F). We multiplied this percentage 
with the total amount of public donor expenditure on family planning, 
AIDS, reproductive health and basic research (Column B), assuming 
that the projects without any project description, or a very short one, 
were similar to the projects with descriptions. 
 The figures presented in Column G are currently the best available 
estimates for the total public donor expenditures for integrated condom 
programming. We use these figures to compare the funding streams of 
the EU and USA on integrated condom programming. Still, one should 
be aware of the assumptions made in calculating these figures and 
consider that we are interested in the observed trends, rather that the 
precise data for a particular year, 
 Since we estimated the volume of integrated condom programming, 
we considered it important to add sources for counterchecking these 
estimates. Additionally, we studied the global trends in donor purchases 
of condoms in the period 2000 – 2008 by using the annually produced 
UNFPA reports called ‘Donor support for contraceptives and condoms 
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for STI/HIV prevention’ (UNFPA 2009a). This report is based on a 
database, produced by the commodity management branch of UNFPA, 
which directly collects data from donors on the procurement and 
international transport of condoms. (http://rhi.rhsupplies.org). However, 
this database is not suitable to compare data between the USA and 
Europe, because it does not make a clear distinction between primary 
and secondary donors. This latter group includes for example 
international NGOs, whose funding originates from primary donors, 
making original funding from USA or European governments indistin-
guishable. We also compare our results with the estimated shortages of 
condoms in developing countries, as described in literature. 
5.3 Results 
Figure 5.1 shows the amounts and trends in donor government financing 
for our two categories of HIV prevention: ‘vaccines and microbicides’ and 
‘integrated condom programming’ by primary donors: the governments 
of Europe, including the EU, and the government of the USA.
Both Europe and USA increased funding to research into vaccines and 
microbicides between 2000 and 2008. The USA has constantly and steeply 
increased their funding to research into vaccines and microbicides, 
from USm$ 307 in 2000 to USm$ 799 in 2007, and a slight decrease in 
2008 to USm$ 774. A constant rise in funding for this sector is also 
evident for Europe: from USm$ 24 in 2000 to USm$ 139 in 2007 and a 
slight decrease in 2008 to USm$ 109. Moreover, USA funding to research 
in vaccines and microbicides is significantly higher than European 
funding. Both Europe and USA decreased funding to integrated condom 
programming in the period 2000-2008, in a similar way and figure 5.1 
does not show any difference in these two trend lines. They are rather 
overlapping. USA and Europe gave about the same amount of funds to 
integrated condom programming, although irregular. The USA decreased 
their funding between 2000 and 2008 from 79 to 40 mUS $. In 2008, 
funding was about 50% under the level of 2000. European governments 
decreased their funding to the delivery of integrated condom programming 
from 90 mUS $ in 2000 to 33 mUS $ in 2008 and, like the USA, in 2008 
ended under the level of 2000. Figure 5.1 also shows that financing 
priorities of governments in Europe have shifted from integrated condom 
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programming to research into vaccines and microbicides between 2003 
and 2004. It also shows that 2008 might be the beginning of a shift towards 
slightly increased investments in integrated condom programming.    
 For a further interpretation of the quantity of public donor 
expenditures by Europe and the USA, it is important to consider the 
size of the respective populations and economies. Between 2000 and 
2008, the countries that had the largest contributions to the total of 
sexual and reproductive health and rights including AIDS were the 
United Kingdom, the Netherlands, Norway, Denmark, Finland, and 
Sweden, each contributing between US $ 400 to $ 800 per million 
dollars of gross national income (GNI) (Population Action International 
2007). Within Europe, there are also differences. Norway contributes 
2000 2001 2002 2003 2004 2005 2006 2007 2008
Europe: condom programming 90 40 61 131 62 119 54 11 33
Europe: vaccines and microbicides 24 32 44 55 87 125 139 139 109
USA: condom programming 79 61 56 140 51 139 41 9 40
USA: vaccines and microbicides 307 375 451 542 608 676 784 799 774
Figure 5.1   Trends in donor expenditures for vaccines and micro - 
bicides vs. for integrated condom programming from 
Europe and the USA 2000 – 2008 (mUS$)
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almost four times as much as Italy, despite having an economy six 
times smaller. The Netherlands contributes more than six and half 
times as much as France, although its economy is less than a third of 
that of France (The Henry J. Kaiser Family Foundation and UNAIDS: 
2009). The American government gave about half of the average amount 
of European countries: between US $ 200 to $ 400 per million dollars of 
GNI (Population Action International 2007).
Figure 5.2 shows that Europe shows a similar decrease in the share of 
funding to implementation of integrated condom programming as the 
USA: the share of funding to integrated condom programming by 
Europe decreased from 79% to 23% between 2000 and 2008. The share 
of funding to integrated condom programming by the USA decreased, 
2000 2001 2002 2003 2004 2005 2006 2007 2008
Europe: condom programming 79 56 58 70 42 49 28 7 23
Europe: vaccines and microbicides 20 14 11 20 8 17 5 1 5
USA: condom programming 21 44 42 30 58 51 72 93 77
USA: vaccines and microbicides 80 86 89 80 92 83 95 99 95
Figure 5.2   Relative share of funding for vaccines and microbicides  
vs. for integrated condom programming by governments 
from Europe and USA 2000 – 20
Europe: condom programming Europe: vaccines and microbicides 
USA: condom programming  USA: vaccines and microbicides 
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with fluctuations, from 20% to 5%. Our results show a turning point in 
2004 in funding practices for the European governments: before 2004, 
the majority of funding goes to integrated condom programming while 
after 2004 research into vaccines and microbicides increasingly receives 
more. It is noteworthy that Europe shows a similar sharp reduction of 
their financial support of condom programming as the USA and its 
conservative condom sentiments. 
 Our countercheck, described in our methods paragraph reveals the 
global trends in total donor funding for male and female condoms in 
the period 2000 – 2008, as shown in figure 5.3.
 Donor expenditure on male condoms is relatively constant over 
these nine years, on female condoms increasing. Our observed trend in 
decreased funding for integrated condom programming is not contra -
dictory to the trend in total donor funding for only the purchase of 
male and female condoms. Most years the funding spent on integrated 
condom programming is 2 to 4 times more than the money spent on 
the purchase of condoms. This means that programming costs are 2 to 
2000 2001 2002 2003 2004 2005 2006 2007 2008
Male condoms 46 91 76 65 72 76 69 84 66
Female condoms 0 2 3 3 6 5 9 13 14
Figure 5.3   Trends in total donor expenditures for male and female 
condoms 2000 – 2008 based on UNFPA database (mUS$)
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4 times the costs of buying the commodities. Our results also match a 
same type of trend in global condom shortfalls as analysed in a few 
other studies (Shelton et al. 2001; UNFPA 2009). A global condom 
shortage existed before 2000 and persisted during the period under 
research. UNFPA calculated a shortfall of 7 billion male condoms in 
developing countries in 2000 (UNFPA 2001) increasing to 16 billion in 
2006, mainly due to increased population figures (UNFPA 2007). The 
global shortfall of condoms exists despite an increased provision of 
condoms by the private sector. Middle income countries such as Brazil, 
China, India, and South Africa do not depend on foreign public donors 
for their condom supply, unlike some low income developing countries 
(Global Industry Analysts 2010; Poly Tech Synergies 2005; Reproductive 
Health Supplies Coalition 2009). We did not observe a significant 
increase in public donor support for integrated condom programming 
in relation to this existing and increasing condom shortfall. The 
current shortfall of the female condom is much higher than of the 
male condom (Peters et al. 2010). Above data shows some increased 
funding for female condoms, but this amount remains minimal in 
relation to the rest of the amounts. 
5.4 Discussion 
Our study leads to a new insight into the trends in public funding on 
HIV prevention. There is a remarkable shift away from supporting low 
cost and effective technologies to funding the research into as of yet 
not proven high technology HIV preventives. Moreover, our expectation 
that the European donors let themselves be guided by their sexual and 
reproductive health and rights policies and their claims for universal 
access to condoms, proved incorrect. Unexpectedly, they have decreased 
their relative share of funding to condom programming during a 
period when the AIDS problem exploded further. It looks as if the 
European public donors now follow the American prevention agenda 
and move away from the 1994 programme of action of the ICPD, 
specifically from its integrated condom programming (UNAIDS 2005b; 
UNAIDS 2010). 
 Although we are not in a position to fully discuss the determining 
factors behind the found public funding trends on HIV prevention, we 
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want to consider a few. This enables the readers to place our findings in 
a broader context. One such factor might originate from the 2001 
United Nations General Assembly Special Session (UNGASS) on HIV/
AIDS. This assembly ended with a declaration of commitment on HIV/
AIDS (UNAIDS 2001). Afterwards, UNAIDS developed indicators, aimed 
to monitor global progress on this declaration of which only one is 
related to HIV prevention: ‘the level of public sector investment in 
research and development (R&D) for HIV vaccines and microbicides’ 
(UNAIDS 2005b). Reference to fund other HIV prevention strategies, 
such as integrated condom programming, is absent. We assume that 
this global indicator made American and European donors alike raise 
investments in research into vaccines and microbicides.
 The position taken by UNAIDS, the global lead agency on AIDS, 
might also contribute to diminishing investment in integrated condom 
programming by the European donors. Although UNAIDS mentions 
condom promotion in its HIV prevention policy, it does not prioritise or 
highlight integrated condom programming (UNAIDS 2005b). Even the 
most recently published UN progress report - ‘Towards universal access. 
Scaling-up priority HIVAIDS interventions in the health sector’ - totally 
ignores integrated condom programming (UNAIDS 2010). Indeed other 
researchers earlier pointed to the weak promotion of condoms by UNAIDS. 
They literally speak about the virtual disappearance of condom 
promotion in UNAIDS literature and campaigns (Haslegrave 2004).
 Another factor, mentioned in recent studies (McCoy et al. 2009), is 
the influence of philanthropic donor organisations on public donors. 
Specifically, the priorities of the biggest private AIDS donor organisation 
in the USA, the Bill and Melinda Gates Foundation (BMGF), might have 
an impact on government funding policies. Globally, USA government 
and BMGF account for 79% of the global funding for vaccines and for 
59% of the global funding for microbicides (HIV vaccine microbicide 
resource tracking group 2010). The two agencies have the same type of 
HIV prevention funding focus, namely new, biomedical technologies, 
such as vaccines and microbicides (McCoy et al. 2009).
 Our findings clearly demonstrate a global under-exploitation of 
integrated condom programming, a phenomenon heavily debated in 
the context of global health governance (Fidler 2007; Sridhar 2010). 
Some scholars link such priority shift in funding HIV prevention to 
economic and scientific interests of the donors (Beck et al. 2009; Gómez 
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2010). Recipients of funding for integrated condom programming are 
above all the governments of developing countries or NGOs (UNFPA/
NIDI 2010). Recipients of funding for vaccines and microbicides are 
primarily privately owned medical pharmaceutical companies or scientific 
research institutes based in North America and Western Europe, with 
associations in developing countries (Beck et al. 2009; Gómez 2010). 
Illustrative is also the title of the new annual report of HIV Vaccines 
and Microbicides Resource Tracking Working Group: ‘advancing the 
science in a time of fiscal constraint: funding for HIV prevention 
technologies in 2009’ (2009). The advancement of science clearly is 
different from the advancement of HIV prevention in the context of 
development assistance. In terms of official development assistance, 
concern is expected to be with women and men in developing countries 
who daily run the risk of infection and urgently need access to low cost 
and effective HIV preventive means and programming. They should not be 
left in the cold with only the promise of a forthcoming ’biomedical 
magic bullet to solve HIV’. Other scholars have noted a bias in favour of 
biomedical research rather than an investment into socio-cultural studies 
that re-examine sexuality and gender relations to better implementation 
of condom programming (Askew et al. 2003; Kippax 2010). Further 
research into the power and gender issues that are at play in decision- 
making on public funding for HIV prevention is necessary. 
5.5 Conclusion
The governments of the USA and Europe (European countries and the 
EU) both shifted their attention from funding of integrated condom 
programming to research into new prevention technologies, such as 
vaccines and microbicides. We revealed a disturbing unexpected trend 
in funding from the group of European public donors in contrast with 
their fierce fight for the ICPD programme of action of 1994. The 
tendency that American and European donors are both increasingly 
reluctant to commit sufficient funds for sexual and reproductive health 
and rights have been concluded earlier (Mayhew 2002). Our study adds 
the revealing conclusion that the European donors have cut funding on 
integrated condom programming to the same extent as the USA.
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5.6 Recommendations
We recommend that public funders aim at a clear insight into funding 
trends, and reflect on the consequences of the shifts in these trends, 
and what they actually mean for people in need of HIV prevention. 
We recommend that increasing funds for developing one type of HIV 
preventive should not be detrimental to the support for another, an 
already effective means of protection, as long as these are not yet 
generally available and accessible. Public funders should better realise 
that education and access to condoms remain a central priority issue in 
HIV prevention.  
 We recommend that public funders who like to adhere to sexual 
and reproductive health and rights policies not only monitor and 
extend funding for integrated condom programming, but also show 
the value of sociological research for the successful implementation of 
HIV prevention and integrated condom programming. 
 Further research is necessary to understand better why public 
donors make certain funding choices on HIV prevention for developing 
countries, and particularly to assess how power and gender issues are 
involved in decision making on funding for HIV prevention.
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SILENCING WOMEN’S SEXUALITY.  
GLOBAL AIDS POLICIES AND THE 
CASE OF THE FEMALE CONDOM7
7 Published as: Peters AJTP, van Driel TM, Jansen WHM. 2013. “Silencing women’s 
sexuality: global AIDS policies and the case of the female condom.” Journal of the 
International AIDS Society, 16:18452 http://www.jiasociety.org/index.php/jias/article/
view/18452
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Abstract
The female condom is the only evidence based AIDS prevention 
technology that has been designed for the female body, yet most women 
do not have access to it. This is remarkable since women constitute the 
majority of all HIV positive people living in sub-Saharan Africa and 
gender inequality is seen as a driving force of the AIDS epidemic. In 
this study we analyse how major actors in the AIDS prevention field 
frame the AIDS problem, and in particular the female condom in 
comparison to other prevention technologies, in their discourse and 
policy formulations. Our aim is to gain insight into the discursive 
power mechanisms that underlie the thinking about AIDS prevention 
and women’s sexual agency. We analyse the AIDS policies of 16 agencies 
that constitute the most influential actors in the global response to 
AIDS. Our study unravels the discursive power of these global AIDS 
policy actors, when promoting and making choices between AIDS 
prevention technologies. We conducted both a quantitative and 
qualitative analysis of how the global AIDS epidemic is being addressed 
by them, in framing the AIDS problem, labelling of different categories 
of people for targeting AIDS prevention programmes and in gender 
marking of AIDS prevention technologies. We found that global AIDS 
policy actors frame the AIDS problem predominantly in the context of 
gender and reproductive health, rather than that of sexuality and 
sexual rights. Men’s sexual agency is treated differently from women’s 
sexual agency. An example of such differentiation and of gender 
marking is shown by contrasting the framing and labelling of male 
circumcision as an intervention aimed at the prevention of HIV with 
that of the female condom. The gender stereotyped global AIDS policy 
discourse negates women’s agency in sexuality, and their sexual rights. 
This could be an important factor in limiting the scale-up of female 
condom programmes and hampering universal access to female 
condoms. 
Keywords: global policy; AIDS prevention; gender; sexual agency; 
female condom.
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6.1 Introduction 
Central in the formulation of global AIDS policies is the creation of 
access to existing evidence-based HIV prevention technologies (UNAIDS 
2005c). Condoms are proven to be effective HIV prevention technologies, 
and male condoms are widely accepted and easily accessible, although 
less so within marriage as they are mainly associated with AIDS prevention 
in extra-marital sexual relations (Chimbiri 2007). Female condoms, 
however, are far less accepted and accessible, and have remained 
expensive and highly underfunded (Peters et al. 2010a). Consequently, 
most women and girls in sub-Saharan Africa lack access to the female 
condom (Peters et al. 2010; chapter 4). This despite the fact that women 
and girls make up 61% of all HIV positive people living in sub-Saharan 
Africa (UNAIDS 2010). Gender inequality is considered one of the key 
drivers of the sub-Saharan AIDS epidemic (UNAIDS 1988). Nonetheless 
it is not clear how global AIDS policy actors include the concept of gender 
in their programming, especially when prioritising HIV prevention 
technologies. 
 Gender, which generally denotes the social and cultural constructions 
of femininity and masculinity, is multi-dimensional and works out 
differently among different cultural contexts. Feminist theories and 
women’s health research share the common intention of reflecting 
critically on biology as a stable and fixed framework. Gender produces 
diversity. Some consider gender as ‘a set of practices that bring reproductive 
distinctions between human bodies into social processes’ (Connell 
1987). It is therefore more than the cultural inscription of meaning on 
a pre-given sex and concerns the discursive means by which ‘a natural 
sex’ is produced (Butler 1997). Likewise, gender designates the very 
apparatus of production whereby the sexes themselves are established 
(Butler 1990). We have to bear in mind that ‘our beliefs about gender 
affect what kinds of knowledge scientists produce about sex in the first 
place’ (Fausto-Sterling 1978: 3). The concept of gender includes the 
power relations that produce and perpetuate gender identities (Rutter 
et al. 2012). Therefore a gender analysis concerns an analysis of power 
and is increasingly concerned with the ways in which other structures 
of inequality and power intersect with those of gender: such as sexuality 
(Rutter et al. 2012), race and ethnicity (Mohanty 1991), and religion 
(Raday 2003). 
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 Global AIDS policies, like other policies (Brock et al. 2001), result from 
a complex configuration of interests of a range of actors; the formulation 
of such policies is not a neutral process. Gender arrangements, which 
are shaped by and shape individual actions, are an intrinsic part of 
policy formulation processes. Thus, particular ways of thinking about 
gender and about AIDS gain ascendancy, and determine the frame 
through which the AIDS problem and its solutions are formulated and 
adopted. 
 Framing is a necessary, nonetheless often implicit dimension of 
policy formulation (Lewicki et al. 2001). It is defined as the way policy 
actors perceive and interpret the features of the phenomenon at hand, 
and how they attach meaning to it. The global AIDS problem can be 
framed in many ways: as a health, medical, pharmaceutical, economic, 
social, sexual, moral, political, security and/or development problem 
(Rabinow et al. 2006; Rushton 2010). Its framing by policy makers 
reveals how they choose to view the AIDS problem. This framing is a 
continuous process, influenced by a variety of stakeholders who bring 
in their particular positions, perceptions and solutions. Power positions 
come into play, and eventually certain views will prevail and become 
the dominant way of thinking, while other views will be overshadowed 
(Fee et al. 1993). We consider AIDS policies part of what Foucault would 
call ‘bio power’, a tool by which people’s sexuality can be administered, 
cultivated, and controlled. Therefore, policy papers are considered as 
one important discursive practice that shape perceptions of sexuality 
(Foucault 1979).
 In this paper we study how global AIDS policy actors frame the 
AIDS problem in relation to women’s sexuality and the female condom, 
by analysing the discourse used in policy papers. It is beyond the scope 
of the article to prove the impact of this discourse on female condom 
use. Since the female condom is a technology used during sexual 
intercourse, and as AIDS concerns a sexually transmitted disease that 
affects people’s sexual and reproductive health, we choose to analyse 
how the AIDS problem is being framed by global AIDS actors in the 
context of sexuality. Sexuality is a central aspect of humanity, 
encompassed by gender ideologies. Both gender and sexuality are 
culturally constructed and key to consider when addressing the AIDS 
problem (Connell et al. 2005; Higgins et al. 2010; Holland et al. 1992; 
Jewkes 2010). 
501567-L-bw-Peters
139
FRAMING POWER
 The World Health Organisation (WHO) defines sexual health as a 
state of physical, emotional, mental and social well-being related to 
sexuality. Sexual health requires a positive and respectful approach to 
sexuality and sexual relationships, as well as the possibility of having 
pleasurable and safe sexual experiences, free of coercion, discrimination 
and violence. For sexual health to be attained and maintained in a 
population, the sexual rights of all persons must be respected, protected 
and fulfilled (Edwards et al. 2004). This approach of sexual health 
includes the notion of sexual agency. Globally, sexual and reproductive 
health is recognised as universal concepts since the International 
Conference on Population and Development (ICPD) in 1994. While the 
initial draft Programme of Action that was formulated at the ICPD 
included sexual rights in a broad sense for both men and women, the 
text that was eventually adopted restricted women’s rights to decisions 
about human reproduction (Jong 2000). Similarly, women’s reproductive 
rights are often referred to in the policies of individual agencies, rather 
than their sexual rights (Gerntholtz et al. 2011; Glasier et al. 2006). The 
World Health Organisation’s working definition of sexual rights is the 
right of all persons, free of coercion, discrimination and violence, to 
the highest attainable standard of sexual health, including access to 
sexual and reproductive health care services; the right to information 
related to sexuality; to sexuality education; to respect for bodily 
integrity; to partner choice; to decisions about whether or not to be 
sexually active; to consensual sexual relations; to consensual marriage; 
to decisions about whether or not, and when, to have children; and to a 
satisfying, safe and pleasurable sexual life (WHO website 2013). 
Remarkable is the fact WHO states that this definition of sexual rights 
‘does not represent an official WHO position, and should not be used or 
quoted as WHO definition.’ Certain political and religious leaders, 
especially the more conservative ones, consider sexuality to solely serve 
reproductive interests and they deny men’s and women’s entitlement to 
experience and enjoy sexuality independent of reproduction. In this 
study we critically look at the way the global AIDS policy actors label 
people and deal with the notion of sexual agency when framing the 
AIDS problem. 
 Labelling people by classifying them into target groups with specific 
characteristics is common practice in development cooperation, and 
global AIDS programmes are no exception (Eyben et al. 2006). AIDS 
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policy makers construct categories of people to target their programmes 
and to allocate and manage their resources. Categorisation of target 
groups is typically based on epidemiological risk profiles. In many 
countries in sub-Saharan Africa women have an epidemiological profile 
that is based on the label ‘being married’ (UNAIDS 2007), and this high 
risk is associated with their husbands’ extramarital sexual activities 
(Anderson 2012; Parikh 2007). Categorizing according to risk profiles is 
common practice and may look efficient, but it is neither value free nor 
necessarily a one way process (Lee et al. 2006). 
 Since labelling determines access to resources and services, certain 
population groups organise themselves around a perceived common 
identity and seek to make themselves visible in society, in particular 
towards the state, service providers and aid agencies. Groups of people 
may use an established label to influence global AIDS policy actors. The 
gay movement in the western world (Merson et al. 2008), and the sex 
workers movement in Kolkata, India (Busza 2005), for example, successfully 
organised themselves in an effort to reduce HIV transmission through 
campaigns and lobbying, which were instrumental to making themselves 
visible and being heard by politicians. In this sense, labelling is positively 
related to social activism, as it helps particular interest groups to create 
solidarity and mobilise resources for a common purpose (Yoder et al. 
2011). 
 But labelling has its downsides too. Being pointed out as a high risk 
group or victim in global AIDS policies may lead to stigmatization and 
exclusion. HIV positive people often experience stigma, discrimination 
and blame (Duffy 2005; Petros et al. 2006). And among them, those that 
are poor and female in general suffer disproportionately (Campbell et 
al. 2005; Lawness et al. 1996; Mills 2004). Stigma comes in different 
forms, but it is basically an attribute that is deeply discrediting within 
a particular social setting (Goffman 1963). Moreover, Deacon et al. 
(2005) argue that negative labelling or stigmatisation often turns into 
self-stigmatisation, due to feelings of helplessness and powerlessness. 
Stigmatisation thus can influence people’s agency and their confidence 
to claim their rights, including access to social services and the use of 
(AIDS) prevention technologies (Malcolm et al. 1998).  
  AIDS policy actors are in a position to mark some technologies as 
more appropriate than others, and to leave certain solutions as unmarked. 
We are interested in the gender marking of health technologies and the 
501567-L-bw-Peters
141
FRAMING POWER
effect this may have on people’s perceptions and acts. The word 
‘condom’ for instance is an unmarked term as far as gender is concerned: 
it is a device that could be used by men or women. As with many other 
supposedly gender neutral terms, however – think of youth criminals, 
politicians, or house-keepers – most people automatically associate these 
with one of the two sexes. Yet, by not gender marking a term, this 
common sense association goes unnoticed. Other words however, are 
typically marked in gender terms; for example the female condom and 
male circumcision. Gender marking is generally applied to situations 
or technologies in which the normative and so-called non-normative 
categories are hierarchically positioned. The gender unmarked sense 
often remains politically unnoticed, such as ‘condom’, a term that is 
often used to designate the male condom. The marked sense, on the 
other hand, is more heavily articulated and observed (Brekhus 1998). 
 Our study primarily aims to unravel the discursive power of global 
AIDS policy actors in depicting women’s sexuality and sexual rights 
and in prioritising specific AIDS prevention technologies for specific 
categories of people, in particular the female condom. To assess this 
power and the way it works out in policy papers of global AIDS actors, 
we use the concepts of framing, labelling and gender marking. Basic to 
our approach is seeing policies not only as ‘data’, but also as ‘discourse’. 
‘Data’, because policies give information on the AIDS problem, population 
groups and proposed solutions; and ‘discourse’ because policy makers 
employ a specific terminology and narrative strategies when defining 
their target groups and stating their objectives, which may in turn 
affect the persons involved and their attitudes and acceptance of 
certain prevention technologies (Cameron 2001). In analysing these 
discourses, the terminology, how often certain terms are used, and 
their various underlying meanings, are important. So are the forms 
and the events during which the discourse is presented (Peters 2010a). 
Foucauldian research from a relativist epistemological perspective 
defines ‘discourse’ as a group of statements, objects or events that 
represent knowledge about, or construct a particular topic. Therefore, 
‘discourse analysis’ is an analysis of the ways in which knowledge is 
created through existing discourses; the question of which discourse 
prevails and whose interest it serves are most important (Graham 2005).
 We seek an answer to the question of what the discursive power of 
global AIDS policy actors has been in dealing with women’s sexuality 
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and sexual rights, and in particular the female condom. This central 
question is divided into three sub-questions. What AIDS prevention 
technologies do global AIDS policy actors prioritise in their policy 
papers? How do they frame the AIDS problem in the context of gender 
and sexuality? How are categories of people labelled, and what are the 
consequences for the gender marking of AIDS prevention technologies? 
After presenting our methodology, we describe the results of our 
analysis in relation to these questions, followed by a discussion and 
conclusion. 
6.2 Methodology
This article examines the policies of 16 international AIDS actors that 
are most essential to the global AIDS governance structure (Seckinelgin 
2007). As noted by Rushton, the literature is quite unanimous on the 
question of who the key actors are in the global governance of AIDS 
(Rushton 2011). Among the key actors, there are seven UN agencies, four 
bilateral agencies (three European and one American), the World Bank 
(WB), the European Union (EU), the Global Fund for AIDS Tuberculosis 
and Malaria (GFATM), the Bill and Melinda Gates Foundation (BMGF), 
and the Global HIV Prevention Working Group (GHPWG). The latter 
one is an international AIDS policy advisory panel, convened by BMGF 
and the Henry J. Kaiser Family Foundation. We analyse the way these 
institutions have formulated their AIDS policies and strategic 
documents, specifically the attention they give to the different AIDS 
prevention technologies and how they link them to various target 
groups, each with their distinct labels. The following table presents the 
data sources of our study. All are available on the websites of these 
institutions. Of each actor, we selected the most recent and substantive 
policy or strategic document that used the words HIV or AIDS in the 
title. An exception was made for the strategic document of Global Fund 
for AIDS, Tuberculosis and Malaria, which did not have HIV or AIDS in 
its title. When institutions had more than one policy or strategic 
document on HIV/AIDS on their website, we selected the one of which 
the title indicated the area of HIV prevention or the most recent one. 
 The year of appearance of the latest policy paper for each actor 
varies, but at the time of writing this article, all 16 AIDS policies are 
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valid. On average, an AIDS policy paper consists of 37 pages, ranging 
from 3 to 68 pages. The purpose of our analysis is not to highlight 
differences between the agencies, but rather to detect commonalities 
in the way they prioritise AIDS prevention technologies, how they 
frame the AIDS problem in the context of gender and sexuality, and 
consequently the way they label people to target programmes and 
gender mark their technologies. 
 Firstly, we listed all AIDS prevention technologies that the 16 actors 
refer to in their policies. We counted a total of 9 different technologies 
and grouped them, as recommended by the Interagency Coalition on 
AIDS and Development, into existing and potential technologies 
(Interagency Coalition on AIDS and Development 2010). Five existing 
HIV prevention technologies are mentioned: two types of condoms, i.e. 
male condoms and female condoms; two anti-retroviral based technologies 
(ART), i.e. prevention mother-to-child HIV transmission (PMTCT) and 
test-and-treat; and male circumcision. Three potential HIV prevention 
technologies, all still in their trial phase, are mentioned: pre-exposure 
prophylaxis (PrEP), microbicides and vaccines. For the purpose of our 
article we also included sexuality education, which is dubbed the 
‘social vaccine’ for HIV prevention (Obaid 2011). 
 Secondly, having identified the 9 technologies, we counted the 
frequency with which each of them was mentioned. The frequency 
count gives insight into the relative importance and priority accorded 
to each technology by the 16 actors. From our epistemological perspective, 
digital frequency counts are important, as they reflect an underlying 
power to define what is important and at the same time produce certain 
views and assumptions (Ryan 2006).
 As to the framing of the AIDS problem in the context of gender and 
sexuality, we covered this by using the text analysis method to obtain 
frequency counts for four key terms: ‘gender’, ‘sexuality’ (or ‘sexual 
behavio(u)r’), ‘reproductive health’ and ‘sexual rights’ (including ‘sexual 
and reproductive health and rights’ and its abbreviation ‘SRHR’). We 
used ‘gender’ as a single term, despite its variety of understandings in 
different cultural contexts. We composed a second frequency table for 
the four key terms for framing the AIDS problem, and complemented 
this with qualitative information from the texts. We then analysed the 
way people are categorized and labelled in the 16 AIDS policies. We listed 
all terms used and identified 14 different labels, as shown in table 6.2.
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The labels and the frequency with which they are used can inform 
about global AIDS actors’ assumptions about the target groups of 
their policies (Hankivsky et al. 2009). We therefore composed a third 
frequency table for the 14 labels that categorise people. The qualitative 
data are presented as quotes taken from the 16 global AIDS policy 
papers. 
 To add further substance to the discourse on the female condom, 
we analysed United Nations Population Fund (UNFPA) experiences on 
female condoms. UNFPA falls outside our 16 source documents, since it 
does not have a stand-alone AIDS policy. However, since UNFPA is the 
designated UN lead agency on sexual and reproductive health and 
rights (SRHR), we analysed their latest official document on female 
condoms as an extra source document: ‘HIV prevention gains momentum. 
Successes in female condom programming: tips for negotiating safer 
sex; helping women to overcome social taboos and marketing female 
condoms to groups at risk.’ (UNFPA 2011). An extra literature search 
was done to see whether the use of the generic term ‘condom’ included 
the female condom. 
6.3 Results
AIDS prevention technologies
Table 6.3 presents the frequency with which the nine AIDS prevention 
technologies appear in each of the 16 AIDS policy papers. The condom 
is the most frequently mentioned AIDS prevention technology (30% of 
more than a thousand times that specific AIDS prevention technologies 
are mentioned in the 16 source documents). They are mentioned by all 
Table 6.2   List of 14 labels identified, by sex
Categories Labels
Females Woman/women, mother(s)/maternal, girl(s), 
lesbian(s)/women who have sex with women/homosexual women
Males Man/men, father(s)/paternal, boy(s), 
gay(s)/men who have sex with men/homosexual men
Undefined 
sex 
Youth/young people, transgender/bisexual(s)/queer(s),
sex worker(s), drug user(s), prisoner(s), migrant(s)
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but 3 of the 16 actors: the Bill and Melinda Gates Foundation, the Global 
Fund and UNESCO. Condoms are in frequency followed by test-and-treat 
(19%) and PMTCT (11%). Both technologies are based on anti-retroviral 
treatment and together they represent 30 % of the total number of 
times a technology is mentioned. Male circumcision comes fourth: it is 
mentioned by 12 agencies with a total frequency of 12%. Sexuality 
education is mentioned by seven agencies, with a total frequency of 
11%, mainly in the policy papers of UNESCO and UNICEF. The majority 
of agencies (9 out of 16) do not mention sexuality education in their 
policies. The three technologies that are still in their trial phase are 
mentioned for a total of 12%, including microbicides (5%), vaccines (4%) 
and PrEP (3%). 
 Although the condom is mentioned by 13 actors with a total 
frequency of 30%, only nine agencies mention the female condom with 
a total frequency of 4%, most of which is accounted for by PEPFAR. 
Besides BMGF, who missed out on the condom, an additional six global 
AIDS policy actors (EU, GFATM, GWGHP, UNDP, UNESCO and SIDA) that 
mentioned the condom completely miss out on the female condom. It 
might be possible that some agencies group the female condom under 
the gender un-marked technology ‘condom’. To find out if people, and 
thus also likely global AIDS policies, refer to both male and female 
condoms when using the generic term condom, we studied 10 most 
recently published articles with condom(s) in the title in three journals: 
‘AIDS’, ‘AIDS and behaviour’, and ‘AIDS patient care and STDs’; all 
articles published before July 2012. These 10 articles actually considered 
male condoms only when mentioning condoms. When articles do 
consider female condoms, they specifically mark them. This extra 
analysis demonstrates that female condoms are indeed generally 
excluded when the gender un-marked technology of condoms is 
addressed. This means that we can safely assume that when the gender 
unmarked term condom is used, it typically involves the male condom, 
and when female condoms are involved they are explicitly mentioned. 
 The limited attention to female condoms as one of the AIDS 
prevention technologies stands in sharp contrast to the multiple 
references made to other technologies. Two technologies, microbicides 
and vaccines, are still in the development stage and therefore still not 
proven effective to be widely implemented (Baeten et al. 2013). They are 
slightly more often mentioned than the female condom, which already 
501567-L-bw-Peters
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was proven effective since 1993 (US FDA 2008). Interestingly, all 16 
global actors suggest investments in research and development for new 
technologies. For instance DFID states in its policy: ‘The UK will increase 
at least 50% of our funding for AIDS vaccines and microbicides research’ 
(DFID 2008: 58). Simultaneously, the 16 global actors suggest the 
scaling-up of existing proven technologies. The Global HIV Prevention 
Working Group for example states: ‘We could slow and even begin to 
reverse the trajectory of the global HIV epidemic by using the prevention 
tools currently at our disposal. To realize the promise of available HIV 
prevention tools, they must be brought to scale’ (Global HIV Prevention 
Working Group 2007:1). The female condom is such a proven, simple 
and cost-effective prevention tool, and it is currently at our disposal. 
However, none of the global actors explicitly offers to scale up this 
technology. There are no phrases to be found in any of the policy papers 
that suggest any intention to scaling up the use of female condoms. 
 We conclude that some technologies, of which the effectiveness is 
partial, such as male circumcision and microbicides, catch more 
attention in the number of times mentioned in the analysed text 
(respectively 12% and 5%) than the female condom (4%), which is proven 
effective. This suggests a bias in policy preference which is not 
supported by the available evidence on the efficacy of available 
technologies. The high recognition of the male condom, as an effective 
unmarked technology, compared to the low recognition of the female 
condom, as a marked technology, is noteworthy and solicits the 
question of how the problem of AIDS is framed in the context of gender 
and sexuality. 
The framing of AIDS in the context of sexuality
Table 6.4 shows the frequency distribution of four key terms used for 
framing the AIDS problem in the context of gender and sexuality. Of all 
four terms considered, the term ‘gender’ is by far most often mentioned 
(53%). All 16 AIDS policies, except the one of the Bill and Melinda Gates 
Foundation, somehow give importance to gender as illustrated by the 
following quotes. The UNDP policy paper states for example: ‘HIV/AIDS 
is not only about a virus. It is also about shame and guilt, gender 
inequality, power relations, silence and denial, stigma and discrimination’ 
(UNDP 2005:4). The PEPFAR policy declares for instance: ‘Gender inequality 
is a cross-cutting issue: all PEPFAR prevention programmes must take 
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gender dynamics into account in order to be effective’ (PEPFAR 2011:37). 
Yet another illustration taken from the UNAIDS policy paper: ‘Scaling 
up effective gender-sensitive and gender-transformative interventions 
that engage men is needed just as much as efforts to ensure that women 
have roles in decision-making from the household level to the 
parliament. These must include programmes to reduce harmful gender 
norms by actively engaging men and boys’ (UNAIDS 2010:45).
 Reproductive health (23%) is used more often than sexuality (18%). 
Global AIDS policy actors appear to favour the term gender instead of 
sexuality, when framing the AIDS problem. Sometimes they are 
Table 6.4   Frequency of gender, reproductive health, sexuality and 
sexual rights in 16 global AIDS policy papers
Agency Gender Reproductive 
Health
Sexuality Sexual 
rights
TOTAL
UNGASS 20 4 0 0 24
UNAIDS 62 17 17 5 101
UNDP 41 0 0 0 41
UNESCO 80 1 46 0 127
WHO 47 22 3 1 73
UNIFEM 16 2 1 0 19
UNICEF 17 26 19 1 63
DFID 32 20 8 18 78
Netherlands 13 45 14 22 94
SIDA 27 11 5 11 54
PEPFAR 28 6 20 0 54
GFATM 9 0 0 0 9
World Bank 34 24 4 0 62
EU 5 3 1 2 11
BMGF 0 0 0 0 0
GHPWG 4 7 7 0 18
Total 435 188 145 60 828
53% 23% 18% 7% 100%
Rank 1 2 3 4
No. of agencies 15 13 12 7 15
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connected. This is illustrated in the DFID policy paper: ‘Women and 
men face different risks and barriers in relation to the AIDS epidemic 
and in accessing services. Gender inequalities mean that women and 
girls cannot always decide if, when, how and with whom they have sex, 
or when to access basic services. Violence against women and girls 
significantly increases their risk of HIV infection. Women and girls 
report increased violence for refusing sex, requesting condom use, 
accessing HIV counselling and testing, and for testing HIV-positive. 
Women and girls also bear the greatest burden of care, including caring 
for orphans and those who are sick’ (DFID 2008:24). But the term 
sexuality, just like gender, does not feature in the BMGF policy or in 
that of UNGASS, UNDP or GFATM. 
 The term sexual rights is used even less (7%). Apart from the four 
actors who do not refer to sexuality in their policy papers, an additional 
five agencies omit the term ‘sexual rights’: UNESCO, UNIFEM, World 
Bank, PEPFAR and GHPWG. Seven agencies, predominantly the ones 
based in Europe, however, do use the term ‘sexual rights’: UNAIDS, 
WHO, UNICEF, EU, Great Britain, the Netherlands and Sweden. In this 
way, they refer to what was expressed during the International 
Conference on Population and Development, held in 1994 and 
re-enforced in 1999 during the 21st special session of the General 
Assembly of the United Nations: ‘We should assure women’s ability to 
control their own fertility. These rights rest on the recognition of the 
basic right of all couples and individuals to decide freely and responsibly 
the number, spacing and timing of their children and to have the 
information and means to do so, and the right to attain the highest 
standard of sexual and reproductive health’ (WHO 2006). These seven 
actors proficiently use the discourse of sexual and reproductive health 
and rights in their AIDS policies. Especially the Europe based agencies 
see it as essential. The DFID policy, for example, states: ‘Expanded access 
to Sexual Reproductive Health and Rights (SRHR), including family 
planning, is a key part of an effective AIDS response. Successful HIV 
prevention is about enabling individuals, couples and communities to 
make healthy choices about personal aspects of their lives – particularly 
sexual behaviour’ (DFID 2008:15). Another example is found in the EU 
policy that states: ‘Political dialogue with countries is crucial to 
addressing and defending basic principles and to raising and discussing 
sensitive issues at the highest political level. At global level, the 
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European Commission’s voice may be due to a formal mandate, e.g. in 
trade policy, or to the EC taking the initiative or being asked by EU 
Member States to take on such a role. This is sometimes also the case in 
UN processes, where it is the EU Member States that are fully represented 
and have a formal voice. Examples include preparations of UNGASS, 
follow-up to the MDGs, and UN conferences on gender equality and 
SRHR – all of which are intimately linked to the policy issues discussed 
in this Programme for Action’ (EU 2005:10). The above quotes show that 
these European actors frame AIDS not only in the context of gender, 
sexuality and reproductive rights, but also in the context of sexual 
rights. Typically we could not find any evidence of this type of framing 
of the AIDS problem in the AIDS policies of the Global Fund (GFATM) 
and the World Bank. This is remarkable, in light of the fact that these 
two agencies derive a large part of their funding from European actors 
who consider sexual rights important. 
 We conclude that global AIDS policy actors frame AIDS predominantly 
in relation to gender and/or reproductive health, rather than to 
sexuality and sexual rights. Below we will show what this implies for 
the way people are labelled in AIDS policies. 
How people are labelled 
Table 6.5 shows which categories of people are mentioned by the 16 global 
AIDS policies and the frequencies with which the terms are used. 
The 16 global AIDS policies use 14 different labels to differentiate 
people, which altogether were mentioned a total of 2469 times (=100%). 
Women (27%) are the most frequently mentioned category, much more 
often than men (7%). Girls (9%) get more attention than boys (2%), and 
mothers (5%) more than fathers (0.3%). For males, the label homosexual 
(or gay; 6%) is used almost as often as that of men (7%), while for females, 
the label homosexual (or lesbian; 0.1%) is hardly applied. It is mentioned 
by only two agencies, just once by each. 
  Of the 14 categories, the AIDS policies of 9 agencies label five 
categories of people to target AIDS prevention programmes: youth 
(25%), sex workers (7%), drug users (7%), gays/men who have sex with 
men (6%) and mothers (5%) (UNGASS, UNAIDS, WHO, UNICEF, DFID, 
MoFA, SIDA, PEPFAR, Global HIV Prevention Working Group). Two of 
these labels refer to one sex: gays, which are always men, and mothers, 
which are women by definition. The rest of these labels: youth, sex 
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workers and drug users can be both women and men: they are sex 
unmarked. We have argued earlier that unmarked categories leave a lot 
of space for ‘common sense’ assumptions that can lead to neglect of one 
gender (e.g. sex workers always being assumed females or drugs users 
as males). Another observation is that there is overlap between these 
labelled categories. 
 AIDS policies also categorise people as women (27%), girls (9%), men 
(7%), boys (2%), fathers (0.3%) and lesbians (0.1%), but these labels are not 
used for targeting purposes in AIDS prevention programmes (UNAIDS 
2010:9). Women and girls are specifically mentioned to emphasise the 
severity of the global AIDS epidemic. For example the AIDS policy paper 
of the World Bank states: ‘We are more conscious that this horrific 
scourge has disproportionately hit women and young girls’ (World 
Bank 2008:11). In addition, women and girls are extensively referred to 
in order to justify investments in new technologies. For example the 
policy of DFID proposes to ‘Increase by at least 50% funding for research 
and development of AIDS vaccines and microbicides over 2008-13, to 
reduce the impact of the disease on women and girls’ (DFID 2008:5). 
Another illustration is the statement in the policy of the Ministry of 
Foreign Affairs of the Netherlands, where categories women and girls 
are used to portray them as victims, who are coerced by males: ‘Millions 
of girls are forced into their first sexual experience, some through 
violence. Women in long term relationships run the risk of violence if 
they press their partner to use a condom’ (MoFA 2009:12).
 The discourse on men and boys differs from the one on women and 
girls. Men are described as highly sexually active, not wanting to use 
condoms and not taking responsibility for their sexual acts, such as 
stated in the PEPFAR policy paper: ‘Males are resistant to the use of 
condoms’ (PEPFAR 2011:18). Another example is in the policy of the 
World Bank: ‘The principal elements in the reduction of HIV 
transmission include a decrease in the number of partners among 
adults – particularly highly sexually active men’ (World Bank 2008:14). 
Representing men as active transmitters of HIV, resistant to HIV 
prevention technologies, is often part of describing the AIDS problem 
in sub-Saharan Africa (Poku 2001). It indicates that AIDS policy makers, 
like all people in their daily social interactions, are ‘doing gender’, 
meaning that – in words and acts, and by being held accountable for it 
- they express and construct dominant norms of masculinity and 
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femininity (West et al. 1978). Through their specific constructions of 
masculinity and femininity, policy makers not only define who receives 
which type of support, but also influence the availability of effective 
technologies by which people can protect themselves against HIV/AIDS 
Table 6.5   Frequency with which 14 labels of people are mentioned by  
16 global AIDS policy actors
Females Males Sex not specified
Women Mothers Girls Lesbians Men Fathers Boys Gays Sex  
workers
Drug  
users
Youth Prisoners Trans-gender Migrants TOTAL
UNGASS 41 8 18 0 6 0 3 7 4 5 17 2 1 1 113
UNAIDS 68 14 27 0 25 0 3 25 38 19 32 5 16 1 273
UNDP 50 0 16 0 8 0 4 0 0 0 5 1 0 5 89
UNESCO 40 2 30 0 5 0 6 9 0 2 69 2 4 1 170
WHO 30 11 7 0 3 0 2 9 10 7 14 8 7 1 109
UNIFEM 48 7 12 0 10 1 4 0 0 0 2 0 0 0 84
UNICEF 81 22 49 0 35 6 17 31 30 54 276 1 1 0 603
DFID 68 13 19 1 13 1 6 22 23 13 26 13 3 5 226
Netherlands 58 3 10 0 3 0 0 7 9 17 34 5 0 2 148
SIDA 27 0 17 1 13 0 7 7 5 7 24 1 1 1 111
PEPFAR 64 8 10 0 32 0 2 10 6 1 52 1 1 0 187
GFATM 2 8 0 0 0 0 0 0 0 0 1 1 0 1 13
World Bank 42 7 7 0 6 0 0 8 9 4 38 1 0 0 122
EU 7 2 3 0 2 0 0 1 1 4 0 2 0 1 23
BMGF 0 2 0 0 0 0 0 0 1 0 0 0 0 0 3
GHPWG 48 17 4 0 0 0 1 5 36 42 32 10 0 0 195
TOTAL 674 124 229 2 161 8 55 141 172 175 622 53 34 19 2469
27% 5% 9% 0,1% 7% 0,3% 2% 6% 7% 7% 25% 2% 1% 1% 100%
Programme 
target
x x x x x
Rank 1 8 3 14 6 13 9 7 5 4 2 10 11 12
No. of agencies 15 14 14 2 13 3 11 12 12 12 14 14 7 10
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infection (Holmberg 2005). 
 While AIDS policies do differentiate between the sexes by labelling 
women and men, the category of young people is predominantly left 
gender unmarked in AIDS prevention. For example the UNGASS 
Table 6.5   Frequency with which 14 labels of people are mentioned by  
16 global AIDS policy actors
Females Males Sex not specified
Women Mothers Girls Lesbians Men Fathers Boys Gays Sex  
workers
Drug  
users
Youth Prisoners Trans-gender Migrants TOTAL
UNGASS 41 8 18 0 6 0 3 7 4 5 17 2 1 1 113
UNAIDS 68 14 27 0 25 0 3 25 38 19 32 5 16 1 273
UNDP 50 0 16 0 8 0 4 0 0 0 5 1 0 5 89
UNESCO 40 2 30 0 5 0 6 9 0 2 69 2 4 1 170
WHO 30 11 7 0 3 0 2 9 10 7 14 8 7 1 109
UNIFEM 48 7 12 0 10 1 4 0 0 0 2 0 0 0 84
UNICEF 81 22 49 0 35 6 17 31 30 54 276 1 1 0 603
DFID 68 13 19 1 13 1 6 22 23 13 26 13 3 5 226
Netherlands 58 3 10 0 3 0 0 7 9 17 34 5 0 2 148
SIDA 27 0 17 1 13 0 7 7 5 7 24 1 1 1 111
PEPFAR 64 8 10 0 32 0 2 10 6 1 52 1 1 0 187
GFATM 2 8 0 0 0 0 0 0 0 0 1 1 0 1 13
World Bank 42 7 7 0 6 0 0 8 9 4 38 1 0 0 122
EU 7 2 3 0 2 0 0 1 1 4 0 2 0 1 23
BMGF 0 2 0 0 0 0 0 0 1 0 0 0 0 0 3
GHPWG 48 17 4 0 0 0 1 5 36 42 32 10 0 0 195
TOTAL 674 124 229 2 161 8 55 141 172 175 622 53 34 19 2469
27% 5% 9% 0,1% 7% 0,3% 2% 6% 7% 7% 25% 2% 1% 1% 100%
Programme 
target
x x x x x
Rank 1 8 3 14 6 13 9 7 5 4 2 10 11 12
No. of agencies 15 14 14 2 13 3 11 12 12 12 14 14 7 10
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document declares that ‘Young people are leading the global prevention 
revolution’ (UNGASS 2001:5), suggesting that girls and boys are alike 
and face similar challenges. Another example comes from the policy 
paper of UNAIDS: ‘It is critical that we empower and facilitate young 
people as change agents in activating their communities to redress 
harmful social norms governing sexuality, gender roles and other 
behaviour’ (UNAIDS 2010:35). In the policy of WHO, youth is described 
as a category of people who lack information: ‘Young people must have 
access to education on sex and sexuality to ensure they have 
comprehensive, correct knowledge about HIV; currently it remains 
low’ (WHO 2011:19). We highlight the fact that the label youth is largely 
left gender unmarked in AIDS policies, while the norms on young 
people’s sexual behaviour and their gender roles are known to be 
different, in all cultural settings (Austveg et al. 2011). Young people’s 
sexual behaviour is a sensitive issue in global politics (Austveg et al. 
2011). By not gender marking young people in global AIDS policies, 
global AIDS policy actors silence gender, an essential aspect of sexuality, 
especially for young people on their way towards adulthood. By choosing 
not to challenge gender differences in sexual behaviour, taboos 
surrounding young people’s sexuality are not being problematized and 
thus they persist without being addressed.
 We conclude that labelling is common practice in global AIDS 
policies in order to target specific population groups. On the one hand 
it leads to exclusion of certain categories of people from AIDS prevention 
programmes and technologies; on the other hand it focuses the 
attention on other groups, with the inherent risk of stigmatizing them. 
Moreover, the labels that are being used imply different notions of 
sexual agency for specific groups of people. Before we draw further 
conclusions, we investigate gender labelling more in-depth, by 
considering two typically gender marked AIDS prevention technologies 
more closely: the female condom and male circumcision.
Gender marked AIDS prevention technologies
Male circumcision (12%) is mentioned three times more often as a 
prevention technology in global AIDS policies than the female condom 
(4%; see table 6.3). Twelve of the 16 global AIDS agencies refer to male 
circumcision in their policies. The remaining four actors (UNDP, 
UNIFEM, EU and SIDA) had their AIDS policies approved between 
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2005-2009, when male circumcision was not yet widely promoted. Most 
agencies promote a package of interventions, with male circumcision 
as an integrated intervention. The WHO policy, for example, states: 
‘Interventions to reduce sexual transmission include behaviour change 
counselling, male and female condom programming, early initiation 
of antiretroviral therapy, safe male circumcision (in high HIV-prevalence 
settings), post-exposure prophylaxis, and quality-assured HIV testing 
and counselling of sero-discordant couples’ (WHO 2011:11). Some 
policies warn that male circumcision does not provide full protection; 
for example the paper of the Global HIV Prevention Working Group, 
which states: ‘Health experts stress the importance of accompanying 
the roll-out of adult male circumcision with strengthened HIV 
prevention efforts to avoid giving circumcised men the impression that 
the procedure obviates the need for other standard prevention 
precautions, such as condom use or limiting the number of sexual 
partners’ ( Global HIV Prevention Working Group 2007:10). 
 Others, for example BMGF, see male circumcision as a technology 
that needs to be promoted: ‘The foundation is investing in advocacy 
efforts to encourage more rapid scale-up of male circumcision for HIV 
prevention’ (Bill and Melinda Gates Foundation 2010:2). We saw this 
type of advocacy during the 2010 International AIDS Conference in 
Vienna. Bill Gates showed the promotional film documentary: 
‘Reducing HIV risk through circumcision’. It did not indicate in any way 
that circumcised men still need to use a condom to practice safer sex. 
Neither did it pay any attention to women, who may be at greater risk 
if their male partners believe they are fully protected once they are 
circumcised. Some researchers argue that male circumcision was being 
promoted in a rather absolute manner, like a ‘magic bullet’ (Boyle et al. 
2011; Shelton 2010). It appears as though some global AIDS policies 
promote male circumcision as a panacea for HIV prevention, at least in 
countries with a high HIV prevalence. However, many ethical issues are 
not resolved (Hellsten 2004), and adequate education about HIV 
infection risk and human rights before men undergo circumcision are 
still lacking (Gwandire 2011). 
 Meanwhile, female condom programmes receive much less support. 
The global AIDS policies are generally positive about the promotion of 
condoms, both male and female condoms. The WHO policy document 
states: ‘HIV programmes should promote equity between the sexes in 
501567-L-bw-Peters
158
CHAPTER 6
sexual decision-making, including negotiation of safer sex and use of 
male and female condoms’ (WHO 2011:28). And according to PEPFAR: ‘A 
growing body of evidence shows that effective female condom 
promotion to both women and men can increase the proportion of 
protected sex acts’ (PEPFAR 2011:17). UNIFEM writes: ‘The female 
condom provides women with an option where they may have greater 
control in negotiating condom use’ (UNIFEM 2005:4). The female 
condom is actually a technology that potentially gives women more 
control over their own bodies, recognizing women’s agency (Susser et 
al. 2000), although women experience limited possibilities for 
negotiating condom use, given the current problematic ideologies of 
gender (Day et al. 2010). The various texts say little about women’s own 
agency, though, in accepting or rejecting the female condom. Several 
agencies recognise that female condoms are currently not universally 
accessible; the Ministry of Foreign Affairs of the Netherlands for 
instance states: ‘But the female condom is, for example, rarely available, 
and too expensive for most women’ (MoFA 2009:26).
 According to UNFPA programming for female condoms has the 
goal ‘to develop strategies and programmes through which every 
sexually active person at risk of HIV or other sexually transmitted 
infections – regardless of age, marital status, gender, sexual orientation, 
economic status, cultural and religious beliefs or HIV status – has 
access to good quality condoms when and where he or she needs them; 
is motivated to use male or female condoms, as appropriate; and has 
the information and knowledge to use them consistently and correctly’ 
(UNFPA 2011:6). In its current on-going programmes however, UNFPA 
like several other global actors normalise the use of the female condom 
for commercial sex workers rather than for women in general, as 
illustrated by the following quote: ‘More sex workers are using the 
female condom … probably because they are in a stronger position to 
negotiate than married women or single girls’ (UNFPA 2011:16). This is 
in contrast to male circumcision programmes which target men in 
general, without a restriction to any particular subcategory. 
 To sum up, the discursive power of global AIDS policy actors in 
framing the AIDS problem is located in defining gender from the 
perspective of women and girls, rather than men, and with a focus on 
reproductive health, rather than sexual health or sexual rights. This 
implies that women and girls are mainly portrayed as victims, rather 
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than sexual agents. Women and girls are considered as homogenous 
groups, without any distinction for specific programmes or technologies. 
Policy makers target women as mothers in PMTCT (Prevention of 
 Mother-To-Child Transmission) programmes to prevent their new-borns 
from becoming HIV infected. Seldom, women are labelled as lesbians, 
and as a result they are excluded from AIDS policies. This denial of 
other sexual orientations of women illustrates the general disregard 
for women’s sexual agency. And this colours the prejudices about the 
female condom as a prevention technology. We argue that global AIDS 
policy actors contribute to re-enforcing the denial of women’s sexual 
agency. Other researchers also found that existing gender stereotypes 
about sexual behaviours have hindered AIDS prevention (Charania et 
al. 2011; Davis et al. 2010). 
6.4 Discussion
The social environment represents social and sexual (risk) relations 
between all kinds of people. Running risks is considered as an 
expression of tension and of power relations in society. This view on 
risk means that the whole community is involved and everyone 
contributes one way or the other to risk taking behaviour, not only 
high risk groups defined as such by others (Riley et al. 2010). This 
approach looks similar to the local approach towards AIDS prevention 
in Uganda, adopted at the start of the AIDS epidemic in the 1980s. 
 We found a very different approach towards AIDS prevention among 
global AIDS policy actors who labelled specific categories of people at 
high risk. They do not consider AIDS as a threat to society as a whole, 
rather to specific categories of people. At the beginning of the AIDS 
epidemic in Uganda, AIDS prevention programmes were made 
accessible to all people, who could make their own free choice to use 
prevention methods, without any stigma. When the AIDS problem 
grew into a global issue, labelling people to target programmes and 
technologies became common practice, excluding some categories, and 
stigmatizing others. Global policies may be more effective if they avoid 
labelling but address the social environment in general and create 
space for local players to make sense of the AIDS problem. By targeting 
specific groups and labelling some and not others, they unwittingly ‘do 
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gender’ and so might contribute to less variety in and space for local 
responses to the AIDS epidemic, as also concluded by Ailio (2011). 
 Normalizing female condom use for commercial sex workers 
rather than for other categories of women, who are sexually active, 
implicitly links HIV to sexually immoral behaviour, thus stigmatizing 
HIV positive women in their local communities. Once a woman is 
known to be HIV positive, she is often seen as sexually immoral, which 
in fact is a negative interpretation of her sexual agency (Mills 2004; 
Petros et al. 2006). This might link to our finding that the attribution of 
sexual agency to women is limited to sex workers in global AIDS policy 
papers, which strengthens the association between HIV in women and 
sexually immoral behaviour. Men’s sexual agency is generally not 
negated, while women’s sexual agency is (Neal et al. 2010; Quevedo- 
Gómez et al. 2012). Women’s autonomy and power in sexual relations is 
often perceived ‘unfeminine’ and threatening to men (Burman 2002; 
Holland et al. 1992; Tolman 2002). Female condoms, which may be seen 
to increase women’s power in sexual relations, can thus also be perceived 
as threatening. In general, women’s agency in accepting or resisting 
the female condom, and the effects this has on gender relations, need 
more profound study. A review of the literature on this issue (Peters et al. 
2014; chapter 2) shows however that women’s acceptance of the female 
condom and their readiness to use it in order to gain more control over 
their sexuality proves to be greater than is generally assumed. This 
contrasts with the observed limited sexual agency attributed to women 
in AIDS prevention policies and the quasi complete avoidance of 
framing the AIDS discourse in terms of sexual rights.
6.5  Conclusion 
The nature of the discursive power of global AIDS policy actors was the 
central theme of this paper, with particular reference to the female 
condom. We found that global policy actors frame the AIDS epidemic 
mainly in the context of gender and reproductive health, rather than 
that of sexuality and sexual rights. Women and girls are often referred 
to, but more as victims than as specific target groups, and not as sexual 
agents. Female target groups are mostly mothers (focusing on their 
reproductive role) and commercial sex workers (focusing on their role 
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to give men sexual pleasure), leaving out women in their own right, as 
sexual agents. Homosexual men (gays) are explicitly labelled to target 
AIDS prevention programmes, while homosexual women (lesbians) are 
not labelled at all. Among the prevention technologies, the condom is 
prioritised in the policy discourse. Although it remains gender unmarked 
it is implicitly associated with men (men only), reinforcing the gender 
notion of sexual agency of men. It is almost taken for granted that 
(male) condoms need to be accessible for all men and not only specific 
categories of men. In contrast, the female condom is normalised for sex 
workers. None of the 16 policy papers analysed makes a serious attempt 
to insist on a programme of action to make female condoms universally 
accessible, that is: to all sexually active women. There is a deliberate 
effort to portray male circumcision as the norm for all men in sub- 
Saharan African countries that have high HIV prevalence rates, but 
without proper additional sexual education this may create extra risks 
for female partners. The gender stereotyped AIDS policy discourse at 
the global level negates women’s agency in sexuality, and her sexual 
rights. This in turn might have limited the scale-up of programmes 
that would make female condoms universally accessible. 
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Appendix 6.1   List of the names of the 16 institutes and their  
websites of the AIDS policies included in this study  
(all websites were last accessed on 5-5-2012)
1  UNGASS. Uniting for universal access towards zero new HIV infections, zero-discrimi-
nation, and zero AIDS related death. New York: United Nations, 2011. Available from: 
http://www.un.org/en/ga/aidsmeeting2011 
2  UNAIDS. Joint United Nations Programme on HIV/AIDS. Getting to zero. UNAIDS 
2011-2015 strategy. Geneva: UNAIDS, 2010. Available from: http://www.unaids.org/en/
media/unaids/contentassets/documents/unaidspublication/2010/jc2034_unaids_
strategy_en.pdf 
3  UNDP. Leadership for results. UNDP’s Response to HIV/AIDS. New York: UNDP, 2005. 
Available from: http://www.undp.org/content/undp/en/home/ourwork/hiv-aids/overview.
html 
4  UNESCO. UNESCO’s strategy for HIV/AIDS. Paris: UNESCO, 2011. Available from: http://
unesdoc.unesco.org/images/0014/001499/149998e.pdf 
5  WHO. The global health sector strategy on HIV/AIDS 2011-2015. Geneva: WHO,2011. 
Available from: http://whqlibdoc.who.int/publications/2011/9789241501651_eng.pdf 
6  UNIFEM. Women: meeting the challenges of HIV/AIDS. New York: UNIFEM, 2005. 
Available from: http://www.unifem.org/gender_issues/hiv_aids/  
7  UNICEF. Opportunity in crisis. Preventing HIV from early adolescence to young 
adulthood. New York: UNICEF, 2011. Available from: http://www.unicef.org/lac/
Opportunity_in_Crisis-Report_EN_052711.pdf 
8  DFID. Achieving Universal Access. The UK’s strategy for halting and reversing the 
spread of HIV in the developing world, 2008. Available from: http://www.appghivaids.
org.uk/.../government.html 
9  Dutch Ministry of Foreign Affairs. Choices and opportunities. Policy memorandum 
HIV/AIDS and sexual and reproductive health and rights in foreign policy, 2009. 
Available from: http://www.minbuza.nl/binaries/content/assets/minbuza/en/import/
en/key_topics/development_cooperation/dutch_development_policy/millennium_
development_goals_mdgs/dutch_aim_for_mdg_5/sexual-and-reproductive-health-
and-rights-srhr-in-dutch-foreign-policy/ 
10  SIDA. Government, the right to a future: Policy for Sweden’s International HIV and 
AIDS efforts, 2009. Available from: http://www.regeringen.se/content/1/c6/13/32/42/
418c92ab.pdf 
11  PEPFAR. Guidance for the prevention of sexually transmitted HIV infections, 2011. 
Available from: http:// www.pepfar.gov/guidance/171094.htm  
12  Global Fund AIDS Tuberculosis Malaria. The global fund strategy 2012 – 2016: investing 
for impact, 2011. Available from:  http://www.theglobalfund.org/documents/core/strategies/ 
Core_GlobalFund_Strategy_en 
13  World Bank. The World Bank’s commitment to HIV/AIDS in Africa. Our agenda for 
action, 2007-2011. Washington: World Bank, 2008. Available from: http://web.
worldbank.org/wbsite/external/countries/Africaext/extafrheanutpop/extafrregtophiv/
aids
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14  EU. A European programme for Action to confront HIV/AIDS, malaria and tuberculosis 
2007-2011, 2005 available from: http://www.eurlex.europa.eu/LexUriServ/LexUriServ.
do?uri=COM:2005;0179:FIN:EN;PD
15  Bill and Melinda Gates Foundation. The Gates Foundation’s HIV strategy, 2010. 
Available from: http://www.gatesfoundation.org/hivaids/.../hiv-strategy  
16  Global HIV Prevention Working Group. Bringing HIV prevention to scale: an urgent 
global priority, 2007. Available from: http://www.globalhivprevention.org/pdfs/
PWG-HIV_prevention_report_FINAL.pdf
501567-L-bw-Peters
501567-L-bw-Peters
Chapter 7
‘PROMOTION IS NOT AN OPTION’:  
A CASE STUDY ON ATTITUDES AND 
IMPLICIT ASSOCIATIONS AMONG 
STAFF WORKING ON AIDS POLICIES 
AND THE FEMALE CONDOM8  
8 Authors: Anny Peters and Lisa van Son
501567-L-bw-Peters
166
CHAPTER 7
Abstract 
Ideas about the female condom as an effective technology for AIDS 
prevention and contraception are not only framed within formal 
policies, but are also expressed informally in the workplace through 
implicit associations, word use and narratives. In an earlier study, we 
found that global AIDS policymakers deny the potential of the female 
condom. However such a general conclusion might not apply to those 
policymakers who work in organisations that have AIDS policies which 
favour creating access to the female condom. Therefore, in this article, 
a case study of such an organisation is presented, examining implicit 
associations, word use and narratives to explore the prevailing attitudes 
which have a bearing on support for the female condom among key 
staff responsible for implementing the AIDS policies. Qualitative 
analysis of the data collected during in-depth interviews with staff was 
carried out to see whether or not there was a difference between the 
formal policies policymakers were committed to and their personal 
perspectives and attitudes about this product. We have analysed staff 
members’ underlying notions of sexuality and gender, as these too 
could have an influence on how female condoms were perceived and/or 
promoted. Staff showed ambivalent, gender and culturally stereotyped, 
and sometimes contradictory ideas. Staff largely perceives the female 
condom as having a marginalised future. We conclude that having an 
AIDS policy that is supportive of the female condom may not be 
sufficient to realise the potential of this technology. Addressing the 
‘implicit power’ of staff attitudes, which in turn may affect the personal 
and organisational mind-sets within supporting agencies, is essential. 
Keywords: organisational culture, narratives, HIV prevention, female 
condom, sexuality and gender
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7.1 Introduction 
The female condom is a public health technology which serves as a 
contraceptive and effective preventive method against sexually 
transmitted infections, including HIV, and gives women a say in 
protecting their body (Gollub 2000; Mantell et al. 2008; Susser 2001). 
UNAIDS, and other multilateral agencies which work on HIV-related 
issues such as WHO and government donors cite the female condom as 
part of the mix of solutions to be promoted in preventing HIV infection, 
yet other similar public health products receive political priority (see 
chapters 4, 5 and 6). This disposition against the female condom tends 
to be most commonly ascribed by global policymakers to the poor 
acceptability and affordability of the product. 
 The analytical literature review in chapter 2 considered acceptability 
and found that in research studies that included an intervention 
component, i.e., which did not merely ask participants whether the 
female condom was acceptable or not, but provided access to the female 
condom together with counselling on how to use it, and/or other relevant 
social support, participants reported a high degree of acceptability. It 
suggested that acceptability of the female condom was problematic less 
at user level than at policy maker level, and this might be interpreted 
as a gap between policy and practice. Such a gap is also found when 
studying the lack of affordability of the female condom as the relative 
price of the female condom (USD 0.59) is higher than the male condom 
(USD 0.03) (chapter 3).
 The measures that are commonly applied to impact price, and thus, 
affordability, such as increasing supply of the product or promoting 
demand creation, whether initiated by the public or private sector, 
were analysed in chapter 3 and found to be extremely limited in the 
case of the female condom compared to other products such as the 
male condom. Creating access to this public health good depended 
greatly on the public sector, which in turn depended on the policy 
stance of global policy makers, which appeared weighted towards 
vaccines and microbicides development rather than the female condom 
(chapter 4). The systemic and structural factors responsible for the lack 
of affordability did not receive ample attention or action from global 
AIDS policymakers. 
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 Besides existing gaps between policy and practice domains, a third 
domain is often mentioned, that of research. Jansen et al. (2010:37), 
citing Berridge (1999), Beyer et al. (1982) and Bolton et al. (2003), suggest 
that these three domains form ‘more or less independent “niches”…
characterised by specific ideologies as well as unique norms and values, 
internal orientations, communication and languages, internal codes of 
behaviour, self-corrected improvement processes, independence and a 
strong desire to protect themselves against the outside world’. Given 
that the practice of global policy makers working on HIV prevention 
does not seem to favour the female condom, in apparent contradiction 
of user demands and research findings, it appeared worthwhile to 
study and explore some of the ‘norms and values’, ‘orientations’, 
‘communications and languages’ of such policy makers who not only 
help to construct policies, but are also entrusted with the task of 
implementing them. 
 To this end, the staff members responsible for these functions in 
one representative European donor agency which supports HIV and 
AIDS prevention policies and programmes, and gives importance to the 
female condom, were interviewed to explore their understandings of 
the potential of the female condom. The aim of choosing such an 
organisation was to understand whether, in such an organisation, the 
attitudes and understanding of the staff members were congruent or 
not with the explicit policies and programmes in favour of the female 
condom, and whether they supported the policies and programmes of 
their organisation. 
 To explore the attitudes and understanding of staff about the 
relevant issue, staff was interviewed to collect their ideas, staff 
narratives (Thaden et al. 2012). Narratives are everywhere as they form 
a basic human way of making sense of the world, and they include the 
way people frame their ideas, creating heuristics or cognitive shortcuts 
to help make sense of complex information (Bamberg 2012; Miller et al. 
2010). Narratives often express underlying values and norms that are 
important to consider, and represent frames that reveal how reality is 
constructed within institutions (Fisher 1989; Kühberger 1995). Underlying 
values and norms are often implicit and play a role at a preconscious 
level (Walby 1986; Ross 2008). Similarly, so are ideas about gender and 
sexuality as they tend to be embedded in institutions to such an extent 
that they appear to be completely natural or self-evident, obvious 
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truths (Eckert et al. 2003). However, in recent decades these traditional 
essentialist conceptions of male and female as ascribed individual 
traits have been declared outdated, and attention has progressively 
focused on gendering processes: that is, on how gender is constantly 
redefined and negotiated in the everyday practices through which 
individuals interact and via which men and women ‘do gender’ (Poggio 
2006; West 1987). Therefore a critical gender lens was used when 
collecting and analysing staff narratives exploring underlying social 
norms and values, concerning sexuality and gender within the 
frameworks of the organisation’s own culture and those of the countries 
in which these policies and the programmes were implemented. The 
purpose was to gain greater insight into the constituents of the informal 
attitudes, which might differ from formally expressed attitudes, but 
which could nevertheless impact practice. Our research question was 
formulated as follows: Do the staff narratives in this case study contribute 
to an organisational context that is an enabling, neutral or disabling 
environment for facilitating the implementation of the female condom 
as stated in the organisation’s policy, and why? 
7.2  Methodology
The organisation we selected was one which has AIDS policies that are 
in favour of the female condom and is one of the largest financial 
contributors to the global response to AIDS (Kates et al. 2010). It has 
advanced policies on AIDS that are integrated with policies on sexual 
and reproductive health and rights, and it takes a special interest in the 
female condom, implementing a female condom programme through 
a public private partnership. 
 To interview staff members of this organisation, semi-structured 
interview protocols were designed to elicit their understandings of and 
attitudes towards gender and sexuality in their own context and those 
of other countries in which AIDS programmes were being funded, as 
well as towards AIDS policies, trends in treatment and prevention, and 
the relevance of different preventive methods, including the female 
condom. Interviews were conducted with five staff members associated 
with HIV related policy and implementation in the organisation. The 
interviewer was completely neutral and was not known by the AIDS 
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policy makers. This allowed the respondents to speak freely. 
 The respondents comprised three women and two men who had 
different positions, from manager to policy advisor; and different 
numbers of years of experience in the organisation. A mixture of 
purposive and snowballing techniques were used to identify participants 
in the study, first purposefully identifying and listing the staff members 
working in the department which dealt with, among other issues, AIDS 
policies, and then, using snowballing techniques to identify staff 
members working closely with the relevant issues. 
 Time constraints on the part of the staff members limited the 
number of interviews we could conduct in the organisation. However, 
after interviewing five staff members, we found that the collected data 
were rich and contained a variety of narratives, suitable for an initial 
exploratory qualitative research study. In the article, the name of the 
organisation is not disclosed and the respondents are numbered to 
guarantee anonymity and to ensure confidentiality. 
 The respondents were interviewed in their working environment, 
using open-ended questions, with probes as necessary to trigger in-depth 
information about the topics at hand, allowing them to develop their 
own story, follow-up on their own associations and use their own 
vocabulary. Each interview took about one and a half hours. 
 The interviews were fully transcribed, followed by a process of coding 
and analysis of the transcribed texts, separately executed by each of the 
two researchers. The narrative analysis explored the content, the word 
use and tone of the interview transcripts, and the internal coherence 
and diversity of the narratives at the organisational level, identifying 
themes as they emerged from the narratives but paying special 
attention to the focus of the interviews, namely, AIDS policies, sexuality 
and gender, and various aspects related to the female condom. 
 The results that are described in the following section do not 
represent the organisation’s formal public stance, but are rather based 
on personal statements which represent the understandings of these 
policies and issues related to their implementation by the people 
responsible for formulating these policies and implementing them. 
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7.3 Results
The results are presented according to the topics discussed during the 
interviews, starting with AIDS policies, ideas about the female condom, 
sexuality and gender.
7.3.1 AIDS policies
We asked the respondents about the current policies on AIDS of their 
organisation, especially policies on AIDS prevention. References to the 
financial aspects were the first thing people mentioned. As one 
respondent pointed out: 
Preventive measures are altogether simply cheaper in monetary 
terms than treatment. Treatment remains expensive, no matter 
what we do it will always remain expensive. (R1)  
When asked to elaborate further, most respondents continued to 
contextualise prevention in the light of AIDS treatment. The elaborations 
justified why treatment deserved more funding than prevention:
You should not regard the two (prevention and treatment) to be in 
competition at all, I mean to say that one is simply much more 
expensive than the other….. You can transport yourself with both a 
car and a bicycle; a car is just much more expensive than a bicycle. 
Sometimes you just have to choose and of course you need to invest 
in both of them. (R2)
On probing further about why more money should be spent on 
treatment, the ‘self-evident’ nature of the reasons was pointed out: 
The fact that more money is spent on treatment is evident ..umm 
the necessity of treatment is of course very evident because those 
people are sick, they need medicines because otherwise they are 
going to die. That is just very evident. (R3) 
Other respondents too placed people with AIDS at the center of the 
argument in favour of treatment, arguing that they were more in need of 
attention. Denying people’s access to treatment was regarded as unethical:
There is simply this ethical side about it: you have something 
[medicines] that can extend the life of people, you have resources at 
your disposal that actually avoid dying of AIDS [sic] so that is also 
an ethical decision... should we say we will spend less money on it, 
let them buy less ARVs (treatment), let the mortality-rate go up 
again? (R4) 
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Both R3 and R4 reasoned along similar lines, seeing treatment as a 
moral obligation. In other words, treatment is framed as an ethical 
matter. Prevention is framed differently and respondents listed all 
kinds of difficulties of prevention: 
It is so complicated…There are so many different ways…There are a 
lot of questions about what is good information….In many 
countries, it is difficult to talk about behaviour change, and very 
difficult to talk about sex…. Even when good information is given, 
it is very difficult to enforce safe sex.  
Most respondents thought that prevention activities are highly complex 
and that the impact of prevention is not well known, as they generally 
doubted that preventive activities could positively influence safe sexual 
behaviour. R3 concurred, identifying ‘prudishness’ as a barrier to 
effective prevention work:
Prevention raises difficult issues – drug use, sex work, sexuality, 
interventions like condom use and harm reduction. Moral 
values can be at odds with the realities of daily lives. … in southern 
Africa, for example, for one-third of the girls, the first sexual 
relations are forced and not voluntary. In such a context, a 
prevention message which includes abstinence as a method rings 
hollow. (R3) 
Above all, the lack of a linear, causal relationship between prevention 
efforts and tangible results was perceived as a major constraint. 
Funding prevention is difficult to measure: you know, what do you 
get out of it? Distributing ARVs (treatment), on the contrary, clearly 
shows how many people you reach with it, it is more concrete than 
whatever educational program in which it is difficult to demonstrate 
what exactly it is you are preventing. (R2)
Respondents, therefore, frame prevention as something that is less 
solid than treatment.  With results being difficult to measure, the 
effectiveness of prevention programs is questioned. This is based on the 
idea that people who are receiving treatment can be easily counted 
with the effect of treatment seen as self-evident. On the other hand, 
counting people who receive information or other preventive methods 
is considered a more vague result, and measuring the actual impact of 
their putting such methods into effective practice, after establishing a 
causal relationship, even more so. According to respondent 5, this is a 
more widely held notion, and some of the AIDS professionals whom 
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s/he occasionally meets at international conferences have lost their 
faith in the effectiveness of HIV prevention programs:
If you speak to people in the ‘AIDS world’ very often you find that 
people are so tired of condoms and they say it is difficult to enforce 
safe sex. You should just search for technological solutions instead 
of always coming up with this story about prevention because that 
is such a complicated story and we all wonder how effective it is. 
(R5) 
This narrative shows that it is not always the ‘target group’, or users, 
who are ‘weary of condoms’.  Rather, AIDS policy makers are, apparently, 
also susceptible to these kinds of attitudes. Repeating the same old 
story over and over is more tiring and less respected than telling and 
selling new treatment options. Further, the female condom is part of 
the preventive approach of HIV and it would be interesting to know 
whether this weariness about condoms in general also resonates in the 
views on the female condom, even though it may not have been given a 
fair chance as a preventive method, given that, for the most part, it has 
been made available to a much smaller extent than the male condom.
 The effectiveness of prevention programmes was also seen as 
suspect because of the difficulties associated with the educational 
aspect. For example abstinence messages were seen as ineffective and 
pointless: 
Young people will experiment like their parents before them .. 
Saying that sex is ‘positive, good, healthy’ is an improvement, but 
if young people cannot get the pill, it’s not there yet. That’s a 
fundamental mistake, to talk sex and not create the conditions [for 
people to access necessary products and services]. (R1)
Negative perceptions about prevention efforts are probably affecting 
(funding) practices:
It is very complicated. At present, there is not enough money for the 
whole package, absolutely, without a doubt, so choices must be 
made. (R1)
Our findings show that choices might not have been clearly made in the 
policies, but at a later stage in real practice when programmes need to 
be funded, these choices seem to be made:
The preventive side is now very underexposed... Maybe we can 
focus on technical stuff now, on treatment as prevention …It is 
being said that there is a little too much emphasis on treatment. 
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That is not entirely true because you can also treat and lower the 
viral load per patient, and therefore the transmission is also lower… 
the dynamics are complex…(R2)
Most respondents stressed that prevention was tiresome, complex and 
repetitive. Staff did not put forward any ethical reasons for providing 
people with prevention programmes as they did for providing people 
with treatment. 
7.3.2 Ideas about the female condom
Respondents explicitly agreed with the AIDS policies and the rationale 
behind the promotion of the female condom as a product which women 
could use themselves to protect their own bodies from the risks of 
sexually transmitted diseases and unintended pregnancies. However, 
the implicit attitudes revealed through the narratives showed that 
ideas about the female condom, including providing universal access 
for women, whether it was suitable for all women, were more divergent 
and inconsistent. Narrative analysis revealed ambiguities within the 
narratives of individual respondents, incongruences between the narratives 
of multiple respondents, and sometimes paternalistic mind-sets about 
particular categories of women who stood in need of the female condom. 
 Narrative analysis of the interview transcripts showed that 
respondents were often ambiguous about elements of the policy that 
they were expected to support and implement.  For instance, considering 
the different implications associated with promoting the female 
condom, one respondent said:    
The way the female condom has been promoted was based on the 
simple assertion: ‘let’s just give women the opportunity to protect 
their bodies’. It is not that I disagree with that but I just struggle 
very much with the fact that I also think that couples should talk 
about sexuality before they ...well ‘get on with it’ [sexual 
intercourse]. A product that is inserted in advance will result in 
nobody needing to talk about anything anymore. I just find that 
risky business. It is not that I cannot see the rationale of it [the 
female condom] but I just find it risky that a girl can think ‘oh well 
I do not need to tell my boyfriend anything anymore because I am 
protected against HIV anyway’. (R1)
Clearly, this respondent has strong personal opinions about the 
conditions under which the female condom should be used, viewing 
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communication in a sexual relationship as essential. At the same time, 
the respondent also had opinions about the relative responsibility of 
sexual partners who might use the product:
Women over there are much more inclusive; they are not as 
self-centred as men who only follow their sexual instincts. No, 
women take more responsibility for their community. Therefore, 
they are more receptive to messages about health. (R1)
Thus, ‘women over there’ are framed explicitly as responsible for the 
health of others, as responsible caretakers, and men as ‘uncontrollable’ 
sexual beings. The clear cultural and gender stereotyping continues: 
Men could potentially be angry with women when they find out. Or 
they will just be frightened by the sight of it (the female condom), 
you know African men and gynecology...... they do not want 
anything to do with that. (R1)
On the one hand, the respondent appears concerned that ‘African men’ 
will potentially react very negatively when their partners use the 
female condom, stating earlier that girls should communicate and not 
hide the use of a female condom. There is an ambiguity in expecting 
girls to be responsible on the one hand, while on the other, being 
concerned that they will abuse it and men will not like it.  
 Although this respondent felt that giving women the female 
condom to protect themselves rather than relying entirely on men to 
prevent the spread of HIV might be a good option, s/he was nevertheless 
one of the most vocal opponents of the female condom among the 
respondents. S/he had many objections to the female condom, including 
the poor design of the first female condom, FC1, which had ‘creaked 
and squeaked on all sides’ and was ‘obviously not a great success’. In the 
course of the interview this same respondent said that:
We’re a funding organisation so we make sure of course that we 
fund everything – there is an adequate balance. (R1) 
Though after listing her/his perceptions of the negative aspects of the 
condom, s/he went on to explicitly say that funding the female condom 
is not a choice:
Promotion [of the female condom] is not an option…funding [it] is 
not as interesting. (R1) 
Clearly this respondent had divergent and inconsistent ideas about the 
female condom and showed difficulties in dealing with the complexities 
of female condom promotion. 
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Attitudes towards universal access to female condoms 
A key finding was that, contrary to the official stance and programming 
of their organisation, staff did not frame access to female condoms in 
terms of universal access. Rather, the female condom was perceived as 
a ‘niche product’, meaning a product catering to a specific category of 
potential user, perceived to be in a position to use the female condom:
Those yuppies and well educated women, they might have a greater 
possibility to assert how they want to protect themselves. (R3)
This respondent obviously saw educated women as more independent 
and likely to be more receptive to the product. Other respondents 
mentioned marginalised women as being a good target group as these 
women in abusive situations are receptive to using the female condom 
covertly:
I have also once heard that if men are really drunk they do not 
know whether a woman has inserted a female condom or not. 
Women supposedly like to use the female condom secretly during 
these occasions because men are so drunk that they will not notice 
it. (R2) 
In such cases, the female condom is perceived as offering an optional 
solution to ‘African women’ who are suppressed and/or oppressed and 
they attributed some categories of women with sexual agency:
It [the female condom] is a very good product for sex workers. They 
will be able to protect themselves and will no longer be dependent 
on whether a man wants to use a condom or not. (R3) 
At least two respondents mentioned a story, attributed variously to 
Zimbabwe and Suriname as the source, that there was a practice by 
which female sex workers inserted a female condom into their bodies 
and then took it out several hours later, or even only the next day, after 
they had had sex with several clients. The respondents mentioned this 
story as an example of the female condom promoting irresponsibility 
in women, as the sex workers were themselves protected from HIV by 
such a practice, while exposing their clients to greater risk than 
themselves. However both respondents seemed not to realise that there 
is not such a big difference in the risk for men when they share the 
same female condom and when they share the same vagina without 
female condom. Typically respondents shared a common gendered 
view of women being the more responsible partners in sexual 
relationships ‘over there’. Overall the respondents identified three 
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categories which they viewed as potential target groups, potential 
niches for the female condom: educated women, marginalised women, 
and sex workers. Respondents suggested that women in general cannot 
actively take the initiative to use a female condom. Consequently, any 
efforts to use the female condom were perceived to be tricky: 
I really struggle with it (whether or not the female condom is a 
preferable method of contraception). I know many women in Africa 
find themselves in situations where they are suppressed, where 
they cannot protect themselves and where they are highly 
dependent on dominant men. (R1)
In the view of the respondents, these ‘other’ women  have little or no 
power to make decisions on matters of their sexual health. As one 
respondent observed: 
I think in most cases whether those men are married or not, they 
decide whether they want to use it (contraceptives) or not. (R3) 
Another respondent concurred: 
You simply have to be realistic, most women are not in the position 
to negotiate the use of the female condom, and they will be in 
trouble when they want to use a female condom when a man does 
not want to use it. (R2)
‘African men’ are framed as being dominant over ‘African women’. 
Throughout the interviews, respondents tend not to specify in which 
African country the men and women they describe in their narratives 
live.  Such perceptions of culture, gender and sexuality as they apply to 
the communities targeted by the AIDS policies and programmes could 
influence the manner in which the respondents frame the potential for 
the use of the female condom among these communities, and the 
resulting efforts at promoting the product. Such framing is based on 
the respondents’ perceptions about the prevailing sexual norms in 
these communities, and influences the language used to express them, 
for example the gendered active-passive divide where the man is 
supposed to always take initiative and control and the woman is 
supposed to be the one to passively wait for the man (Bordo 1993):
It could certainly be problematic when a girl is carrying a condom, 
the girl will be perceived to be a slut or a sex worker. I also think 
that it is difficult for a man if a girl has the control over the use of 
a condom you know, that the girl takes the initiative. (R4)   
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This particular frame seems to suggest that most ‘other’ women cannot 
actively take the initiative to use a female condom. However, this does 
not apply to all women, and some categories of women are attributed 
with sexual agency, perceiving the female condom to be an ideal 
product for a certain category of women, while being inappropriate for 
a larger sub-group of women who cannot take the risk of being 
‘perceived to be a slut or sex worker’. The gender divide of active – 
passive described earlier is not applied to female sex workers, and, for 
this sub-group, the female condom is perceived as being a tool for 
empowerment, giving them the ability to initiate and negotiate safe 
sex. Most respondents argued explicitly or implicitly that the female 
condom, as opposed to the male condom, is just not for everyone, in 
contrast with what the formal policies lay out. It is striking that  the 
category of female sex worker, in particular, hired by men for sexual 
services, seems to escape the gendered active-passive divide while 
‘other women’ are stereotyped as sexually passive and thus unable to 
initiate female condom use. Thus although the policies of the 
organisation were to make the female condom accessible to all women, 
in practice the staff had many different observations and opinions 
about it.  
Attitudes to the ‘visibility’ of the female condom 
More ambiguities were found when the respondents started talking 
about the outer ring of the female condom, which is visible outside the 
vagina. This visibility of the female condom is framed in several ways 
by the respondents as being problematic. Referring to a recent experience 
in Nigeria, one respondent shared that:
Women say that they are going to the doctor for their kids, while in 
reality they ask for a contraceptive injection. In this way, the 
partner does not have to know and women are consequently able to 
space births. This happens a lot especially because men cannot see 
it [contraceptive injection]. Unfortunately the female condom does 
not have this advantage. (R5)
The visibility of the female condom is seen as an obstacle for men, who 
are perceived as being unwilling to accept any form of contraception, 
let alone ones that they can see and feel. In this respondent’s 
understanding, these ‘other’ women’ – women ‘over there’, framed as 
‘other’ than European women – need to dupe’ their men with invisible 
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contraceptives. Consequently, the female condom, which is visible, is 
not perceived as practical for these ‘other’ women. We noted that the 
respondents did not make any comparison with the male condom, or 
see the perceptible contradictions in this approach to the female 
condom, with the perceived unproblematic nature of promoting the 
male condom in spite of the fact that it is both seen and felt.  Respondents 
were of the opinion that when men were confronted with the sight and 
the feel of the female condom, this would be undesirable:
The female condom suddenly shows up, while normally, I mean 
with the other methods, a man does not sense anything….I have 
also once heard that if men are really drunk they do not know 
whether a woman has inserted a female condom or not. Women 
supposedly like to use the female condom secretly during these 
occasions because men are so drunk that they will not notice it…. 
Other women are in situations in which they cannot negotiate 
easily…during normal circumstances a man can see the female 
condom and if he has a problem with that it will be very difficult 
for a woman who has another position than the man to negotiate 
and use the condom anyway. (R2)
In these narratives about the visibility of the female condom being an 
obstacle, these ‘other’ women are framed as being unable to negotiate 
safe sex with their partners, while ‘other’ men are framed as being 
unwilling to accept the female condom because it might be unpleasant 
to see and feel during sexual intercourse. The potential obstacles of 
visibility are intertwined with perceptions of the apparent norms 
governing gender relations, ideas about pleasurable sexuality (for men, 
as the lack of attractiveness or otherwise of the male or female condoms 
for women is clearly not considered), and differences between ‘us’ and 
‘them’. 
 Consequently, the female condom is not perceived as practical for 
these ‘other’ women. These results show how respondents reason from 
mixed cultural and gender essentialist ideas. 
Attitudes about the future of the female condom 
The data shows that respondents were conflicted about various aspects 
of how the female condom might be used and/or abused, had misgivings 
about its appearance, design and visibility, and did not think of the 
product in terms of providing universal access for women. Consequently, 
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when respondents were asked to reflect on the future of the female 
condom, this appeared to be not very bright. The question about the 
future of the female condom, often triggered respondents to refer to 
their own personal life, and the experiences of family and friends to 
illustrate their ideas about the future of the female condom: 
My wife, for example, told me: ‘I am really not going to try it. I just 
do not feel like it’. I believe this to be the case for most women. It is 
just too much of a hassle for them. (R5)
Another respondent had shown the female condom to a daughter and 
her friend. These European girls had not perceived the product as being 
a ‘sexy addition’ to their lives. The way the female condom is framed by 
the wife and daughter seeing it for the first time influenced the 
respondents’ perceptions of the acceptability and use of the female 
condom by a cross-section of women in developing countries. The 
personal ideas of staff and their family members about the female 
condom based on personal experience were shared in the workplace, 
and had some potential to reinforce the validity of these ideas within 
the formal institutional setting as well:
We have quite some resistance in our institution. Every now and 
then there are colleagues who totally do not believe in the female 
condom. … Our new director also said: ‘well I have used it with my 
wife ten years ago and it is utterly worthless. I do not believe it to 
work.’ (R5)
Most respondents explicitly expressed the view that not all the staff of 
the organisationis convinced that the female condom is a feasible 
product to be promoted in developing countries. To a certain extent, 
the utility of the female condom was framed in terms of personal 
opinions or opinions of family members or colleagues who have only 
seen or used it once, although these constituted informal data sources 
from a different context, derived from people who feel less of a need for 
such a product. In the course of the narratives, informal data sources 
were cited with greater authority than results from formal research 
studies. Personal and family opinions were offered in the context of 
providing justifications for decisions in the workplace; these were 
incongruent with official policies, and have international implications. 
In general, the female condom was perceived as highly unlikely to ever 
become a ‘mainstream’ product. Though one respondent conceded: 
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I agree that there is some interest in the female condom…however, 
I perceive the female condom to be a niche market product. It is 
expensive, and it is complicated, the male condom is just easier. (R4) 
This was asserted as an accepted fact, and consequently there was little 
reflection about whether the male condom was indeed ‘easier’; and if 
so, in terms of which parameters - for example, is it easier to use, or 
easier because in many cases, the man can take the initiative? This 
might be a consequence of, for example, the explicit promotion of 
policies over a long period which have made the male condom much 
cheaper and more easily accessible. Such reflections might assist policy 
makers and practitioners to separate ‘intrinsically difficult’ aspects of 
the female condom (say, difficulty in using) from ‘environmentally 
induced difficulties’(say, lack of ease of access). These issues might be 
addressed by policymakers and practitioners through appropriate 
strategies, for example difficulties in insertion, unattractiveness and so 
on can be related to inadequate attention to improvement of product 
design (Peters et al. 2014; chapter 3).  In the absence of such a teasing 
out of the complexities of the issue of ease/difficulty, it is not surprising 
that most respondents maintained that they believed that the female 
condom would remain a marginal product in the future, not fully 
integrated into health programs:
It is an interesting product for the method mix (of contraceptive 
supplies). The more options a person has, the greater the chance 
that someone chooses a safe option that matches the life of that 
person…..however the market of male condoms will always be 
bigger. (R5)
However there seems to be ambiguity in the thinking about the 
importance of giving people choices, aiming at offering a method mix 
of contraceptive and HIV prevention supplies. In the case of the female 
condom, some part of this choice appears to have already been made by 
policymakers, favouring the male condom, and thereby, not affording 
the female condom an equitable comparative opportunity, and perhaps, 
as a result, not exploring its full potential: 
Colleagues can, to some extent, be positive about the female 
condom. However, when you have 100 euros to spend on a mix of 
contraceptives, when you start talking about what the best mix 
would be people often say well the female condom you should not 
put too much of those in the method mix. (R5)   
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The future of the female condom was often framed as being in 
competition with and of lesser use than the male condom. This competition 
was a recurring element in the narratives. In some instances, the 
favouring of the male condom as the only reliable condom was explicit, 
with the exploration and promotion of alternatives being discredited 
as ‘dangerous’:
They are trying to come up with all sorts of techniques that are to 
serve as a bypass such as the female condom. You can get away with 
murder basically because sexual intercourse without a condom is 
risky business. The underlying idea of it all is that microbicides and 
the female condom are to be an alternative for the [male] condom 
and that is very dangerous. (R1)
When asked whether the female condom would ever become a success 
another respondent summed up:
I am moderately positive about it. However, it will never be a 
product such as the (male) condom. (R5) 
The data suggests that the values and opinions of staff members of the 
organisation on many aspects of the female condom, its potential users, 
and the comparative value of different contraceptive technologies, 
rather than hard data about the merits of the technology, influence the 
way in which the female condom is framed. These, in turn, have 
consequences for the way staff think about the future of the female 
condom. Moreover respondents did not use the same line of reasoning 
about financial aspects when discussing priorities between prevention 
and treatment (first quote R2), though they did in the comparisons 
between the male and female condoms, to the disadvantage of the 
female condom.
 Based on all the attitudinal building blocks revealed in this article 
and despite the staff’s roles in formulating and implementing policies 
and programmes for the promotion of the female condom, the 
respondents in this study were not very hopeful for the future of the 
female condom. The respondents showed little affinity with promoting 
the female condom as a gender transformative approach.
7.3.3 Sexuality
After talking about the female condom, the topic of sexuality was 
introduced with an open question, asking respondents how they would 
define sexuality in the context of their work in the organisation. Most 
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respondents had never actually given thought to the specific meaning 
of sexuality. They told the interviewer that the term they more 
commonly use is SRHR, the abbreviation which stands for sexual and 
reproductive health and rights:
I do not really know how to describe sexuality, something ranging 
from the biological, the reproductive, to the relational, to simply 
having pleasure. (R5) 
Another respondent described sexuality in the following way:
Sexuality is about social manners and morals; sexuality is not only 
about intercourse, it is about more, about mutual respect and social 
relationships. This total package, that is what sexuality is about. 
Good sexuality is all about communication. (R1) 
The metaphor of sexuality as a package represented the dominant 
frame of sexuality by the respondents, focusing on several bodily, social 
and relational ingredients. Though such an inclusive approach to 
sexuality seemed to apply primarily to European countries, as earlier 
data showed. When sexuality was discussed in the context of the 
countries in which they funded programmes, the focus primarily 
seemed to be on ‘non understanding African men’s sexual behaviours’. 
The notions of gender and gender hierarchy intersected with cultural 
generalisations about Africa and assumed differences between ‘there’ 
and ‘here’. Most respondents stressed the unique openness with which 
sexuality is discussed in their own country: 
I think that we are much more outspoken than other countries on 
a range of different topics… that has no problems with either gay 
men nor drug users, nor sex workers. We are actually one of the few 
countries that carry out a pragmatic policy. I regard our policy to 
be a reflection of our own culture. (R2)
This ‘country’s culture of sexuality’ was represented as being 
no-nonsense, emancipated and liberated. This approach to sexuality 
was often framed as a kind of good practice for AIDS prevention 
strategies at the global level. Paradoxically, the same respondent who 
claimed to be proud about the open attitude of their own country, 
walked at one point in the interview to the closet and pulled out a 
plastic demonstration model of female genitalia, which s/he called a 
‘fake pussy’, and said: 
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Some people find it difficult to talk about sex. I have started to put 
this device in the closet because some people just do not feel 
comfortable when it is just lying ….”(R2)
Most respondents showed an open, no-nonsense attitude when talking 
about the issue of sexuality, stating things rather bluntly, calling a spade a 
spade, and calling a vaginal demo a ‘fake pussy’. However, hiding the 
fake pussy in the closet to ensure that colleagues and visitors would not be 
affronted by the sight of it, shows a more ambivalent attitude than the 
expressed views about being open about sexuality, and an accommodation 
of such unease rather than an opening up of the discourse about it. 
7.3.4 Gender
Like sexuality, gender was defined broadly. The descriptions of gender 
varied: ‘all different aspects between men and women’, ‘the position of 
a man with regard to the position of a woman’, ‘something that is 
highly dependent on someone’s culture’ and ‘something that is shaped 
by the way you are raised’. When talking about gender it was remarkable 
that staff gave examples of other cultures, rather than mentioning 
examples from their own culture: 
I think gender is shaped by the society, especially in countries with 
very male dominated societies. In some African countries for 
example, the way this (gender) is shaped is not something that is in 
your genes; instead, it is learned behaviour. So perhaps you can also 
change it. (R4)
Gender was perceived to be primarily linked with sexuality. Respondents 
often linked the ideas about ‘other’ cultures to the high rates of HIV/
AIDS prevalence: 
In the Southern parts of Africa men often go out to cafes and bars 
to drink, there is a lot of alcohol involved you know. You could 
definitely say there is some sort of macho culture there…The high 
prevalence of HIV is a consequence of those specific gender 
relations, that is just very evident. Nobody has the magic bullet to 
change that. It (gender relations) contributes to the fact that people 
(development actors) are currently trying to find a medical solution 
for the problem of HIV …it is just really difficult to convince those 
men to have safe sex. In southern Africa, the fact that those men 
are all looking for young females and want multiple partners, that 
is all culturally determined….(R5) 
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As in the above quote, ‘African men’ tended to be regularly framed as 
sexually promiscuous men. This is known as a classic but deeply 
problematic frame, that is often used (Stoler 1995; Vaughan 1991). The 
framing of the sexual behavior of men from ‘other’ cultures as being 
fixed, might lead actors in this sector to prefer biomedical solutions 
rather than social or behavioral solutions. However, the behavioural 
aspect was also seen as important:
We can complain all the time and say that African men only have 
unsafe sex and have sex with several partners and so on and so 
forth. But I think you should keep on addressing this behaviour of 
African men because, apart from the fact that this (promiscuous 
behaviour of ‘African men’) causes HIV, it humiliates both women 
and girls and therefore we need to keep on trying to change this. 
(R5)
Again, it appears that the notion of women having the capacity to be 
sexual agents themselves was largely ignored in the narratives. Women 
and girls were framed as being victims of the sexual behavior of men. 
Such framing could potentially influence the way the female condom is 
provided with adequate support or not, as the device requires recognition 
of the sexual agency of women. 
 
7.3.5 Three dominant frames
The staff narratives contained three dominant frames. Firstly, activities 
and practices related to prevention were framed as being less solid than 
those related to treatment. The impact of prevention programs is 
regarded as something that is difficult to measure and consequently, 
the effectiveness of prevention programs is questioned. Working from 
such a frame might operate adversely on the promotion of a comparatively 
newer prevention technology such as the female condom, which suffers 
from added associations such as ‘unattractive’ and ‘difficult’. 
 A second important frame that emerged saw the underlying norms 
and values of the respondents’ own ‘culture of sexuality’ as superior, 
with this supposed superiority being largely created by essentialising 
the ‘other’. Thereby, terms such as ‘our approach of AIDS prevention’ 
and ‘our openness in addressing sexuality’ were used and framed as 
being a good example for ‘others’ – developing countries, particularly 
African countries, to emulate. 
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 Thirdly, the underlying norms and values of the sexuality of the 
‘others’ affected by the implementation of the institution’s AIDS 
policies are framed in culturally- and gender-stereotyped ways.  ‘Other’ 
men are perceived to be sexually assertive or even aggressive. and 
‘other’ women as sexually passive and docile, with female sex workers 
being the exception. ‘African men’ are predominantly framed as 
irresponsible about taking the initiative for protecting themselves and 
their partners, and as reacting badly to their partners when  confronted 
with the proposal to use a female condom. ‘African women’, on the 
other hand, are framed as not being able to negotiate the use of the 
female condom, and as being dependent on their partners for the 
protection of their sexual health, unless they are sex workers. This 
conceptually undermines the idea of the sexual agency of women. 
Recognition of this agency is crucial for the success of any policy that 
includes the promotion of the female condom as an element in the 
overall assemblage of prevention options offered. 
7.4 Discussion 
Our case study found that staff working at a donor organisation on 
AIDS policies and practices, partly acted upon implicit associations, 
sometimes called implicit bias. ‘Implicit bias refers to the attitudes or 
stereotypes that affect people’s understanding, actions, and decisions 
in an unconscious manner’(Staats 2014:16). Everyone is found to be 
susceptible to such implicit associations or implicit bias, which are 
normal parts of human everyday life (Nosek et al. 2007). ‘Implicit biases’ 
differ from ‘known biases’ that individuals may choose to conceal for 
the purposes of social and/or political correctness. Implicit associations 
or biases thus operate largely under the radar of human consciousness, 
though they influence the way that people see and treat others, even 
when they are determined to be fair and objective (Banaji et al. 2013). 
 Many different kinds of associations or biases were suggested 
within the narratives: cultural bias (e.g., interpreting and judging the 
acceptability of the female condom to women in Africa in terms of its 
acceptability to privileged women in Europe); sexism (e.g., worrying 
about the attractiveness of the female condom to men, without 
worrying about the attractiveness of the female or male condoms to 
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women); sensationalism (favouring the exceptional - female condoms 
for sex workers or yuppies, over the ordinary - female condoms for the 
general, sexually active, female population), etc. 
 Usually, the staff’s opinions were justified within the narrative in 
terms of the perceived exigencies of the cultural contexts in which the 
AIDS programmes were implemented, and the gender relations, and 
practices associated with sexuality, prevailing in these cultural 
contexts. Such gender relations and assumptions about sexuality 
tended to be expressed in very broad terms, often buying into 
stereotypes. Jung’s concepts of unconscious and conscious attitudes 
(McQuire 2011) were also found in the internal contradictions within 
the narratives, for instance, with respondents speaking of the female 
condom as an important part of the method mix and even identifying 
the female condom as the best solution in a particular context, but 
then focusing on the drawbacks until saying that female condom 
promotion was not an option that appeared ‘natural’ and justified. 
 The data suggest that even though formal policies and programmes 
may promote one approach (such as universal access to the female 
condom), it is possible for attitudes to exert a sufficiently strong 
influence on practice so that it is at variance with the policy (such as 
promoting female condoms among sex workers rather than among the 
broader demographic of sexually active women). This might seem 
‘irrational’ to an outside observer, but follows quite reasonably from 
the beliefs held by the actor. The results of this exploratory study 
suggest that there is enough preliminary data to carry out a larger 
study to examine the impact of staff attitudes and implicit associations 
or biases on how public health practice may be at variance with formal 
policy in the case of the promotion of the female condom.
7.5 Conclusion
Our study found discrepancies between the formal AIDS policy that is 
in favour of creating access to the female condom, and the opinions 
and attitudes of the staff responsible for implementing it. Even though 
the assumptions underlying the staff members’ narratives related to 
the female condom were often incongruent, these narratives 
predominantly ended with the idea that the possibility that the female 
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condom could become a mainstream product in the future was bleak. 
The narratives reveal how the overall opinion on the female condom is 
constructed, becoming part of a larger narrative stream within the 
organisation, which exerts significant influence that we term implicit 
power. This implicit power can potentially hinder alternative, more 
enabling narratives which are in line with study results and gender 
equity policy goals. It is therefore recommended to start with 
programmes that make staff aware of the existence, pervasiveness, and 
implicitness of this type of power when implementing formal policies. 
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The AIDS epidemic is hitting women disproportionately. Biologically, 
women are more prone to HIV infection and are twice as likely to 
acquire HIV from an infected partner during unprotected sexual 
intercourse as men. Socially, the predominantly patriarchal norms and 
values in societies that are particularly strong with regard to sexuality, 
restrict women’s opportunities to prevent HIV and compound women’s 
vulnerability to HIV and unintended pregnancies. In the introduction 
of this thesis (chapter 1) it was shown that as the AIDS pandemic 
steadily unfolded, the proportion of women among people infected 
with HIV increased over the years in all continents, and today women 
account for more than half of all people (52%) globally living with HIV. 
But women are hardest hit in sub-Saharan Africa, where they represent 
57% of those living with HIV. Moreover, as described in the first chapter, 
women in sub-Saharan Africa - one-quarter of married women and 
between 25-45 % of young women between 15-24 years of age - do not 
have access to contraception even though they are interested in using 
modern contraceptives. In this context the female condom could be a 
device in the global response to AIDS. 
 The female condom is a transparent sheath with the same length 
as the male condom and a flexible ring on the outside that came on the 
international market in 1993 as a safe and effective contraceptive and 
protective device impermeable to various STI organisms, including 
HIV. Today in some countries more than one type of female condom is 
on the market, though overall this preventive product is largely 
unavailable, unaffordable and inaccessible.  
 Preventing people from acquiring an infection is a precondition to 
halting epidemics of infectious diseases, thus also the AIDS epidemic. 
HIV prevention among young people is especially important as 
currently about half of the new infections, annually 1.6 million new 
infections, in sub-Saharan Africa concern those between 15 and 24 
years, of which the large majority is young women. The female condom 
could be one of their choices to protect them from life-long infection, 
from needing life-long ARV treatment and from unintended pregnancy. 
Moreover, using the female condom can give women a greater sense of 
self-reliance and autonomy, and enhance dialogue and negotiation 
with their sexual partners. 
 Logically, therefore, one would expect some extra attention to the 
situation of women in the global answer to AIDS, and to the female 
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condom as the only effective HIV prevention method applicable to the 
woman’s body. Globally AIDS policymakers such as WHO, UNFPA and 
UNAIDS have acknowledged that the efficacy of the female condom to 
provide dual protection against pregnancy as well as sexually transmitted 
infections, including HIV infection, matches that of the male condom. 
In spite of this, the female condom has been greatly underutilised in 
the mix of methods being used to address the AIDS epidemic, or as a 
contraceptive.
 This starting point made me select the central question of my 
thesis looking into political prioritisation in global health, more 
specifically in the global response to AIDS. I framed the central question 
of this thesis as follows: Why has the female condom remained a low priority 
product on the global health agenda in the response to AIDS?
 Studies have already shown that not always the largest health 
problem, nor the most effective solutions are politically prioritised, as 
priority setting is not a neutral process, but involves politics. The 
interests of different stakeholders and how complex power dynamics 
play a role in prioritising global health issues is not yet fully understood. 
My research represents a special case of such political global decision 
making and is different from other studies in global health priorities 
studies as it concerns the neglect of a certain prevention method for an 
epidemic that generally was prioritised as a global health issue during 
the period of my research. 
 Thus my starting point was not the insufficient political prioritization 
of a global health problem, but what led to one of the prevention methods 
being overlooked within the various processes involved in this prioritization. 
Studying neglect rather than prioritisation was recommended by 
Charli Carpenter as discussed in chapter 1, who posited that studying 
neglect might create the deepest insights into the complex question of 
issue ascendance. 
 Of the different theoretical frameworks about political prioritisation, 
the most valuable for my thesis was provided by Shiffman and Smith as 
it considered the concept of ‘actor power’. I drew significantly on this 
theoretical framework to understand the ways to study political 
prioritisation in global health, to shape the research design and 
interpret the findings presented in this thesis. The framework posits 
that four categories of factors matter in political prioritisation in global 
health: besides the power of the actors involved in the initiative, the 
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power of the ideas used to frame the issue, the nature of the political 
contexts in which they operate, and characteristics of the issue itself. 
Besides this framework, as a feminist researcher I drew on the concepts 
of gender, sexuality and power, knowing that gender and sexuality are 
influential forces driving the AIDS epidemic and intrinsically related 
to power (chapter 1).
8.1   Insights into why the female condom  
has remained a low priority in the global 
response to AIDS
In this section I will present the three main insights that I gained in 
this research. In the first part of my thesis, I researched three ‘female 
condom issue characteristics’ as Shiffman and Smith would call them: 
‘unacceptability’, ‘unaffordability’ (chapter 3), and therefore ‘denial of 
potential’ (chapter 4). This led to the first insight:
1.  Characteristics of the female condom undergo a process of 
fixation because global AIDS policy makers tend to frame them as 
unacceptable and unaffordable and as a result the female condom 
remained marginalised at global level. 
It was not the characteristics of the female condom per se that effected 
global political prioritisation, but the way global AIDS policy makers 
viewed, perceived and talked about these characteristics, when interacting 
with other stakeholders. Lack of acceptability and affordability were 
perceived as almost given characteristics of the female condom by 
these global AIDS policy makers,  and this static explanation effected 
its low priority in the global response to AIDS. 
 In chapter 2 when reviewing the most recently carried out 
acceptability studies done in sub-Saharan Africa, the analysis ended 
with the conclusion that lack of acceptability is a mutable characteristic, 
highly dependent on the definition of the concept, and whether it was 
about use and real practice or about perceptions. When women were 
asked about their perceptions without having a choice to use the female 
condom, these perceptions were often negative. However, when women 
had been given training, education and information about the product, 
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and been given an opportunity to actually use them, acceptability rates 
were found to be high, with satisfaction rates between 50 and 98%. 
These findings showed that with the support of providers during the 
process whereby women are getting used to the product, acceptability 
of the female condom is mutable and can be positively influenced 
(chapter 2). 
 Nevertheless, global AIDS policy makers repeatedly were observed 
saying that female condoms are ‘unacceptable to users’, and that ‘there 
is no demand’. Such assumptions ensured the marginalisation of the 
female condom. The global public sector showed limited interest in those 
women asking for access as for example expressed by an UNAIDS policy 
maker during an international AIDS conference who denied the demand 
among women, while at the same time women were demonstrating and 
asking for access during the same conference (chapter 4). 
 A similar reasoning applied to the other characteristic, the un-
affordability of the female condom. In the context of affordability, price is 
important and this was researched in chapter 3. The size and type of 
measures, whether by the public or private sector that are usually 
needed in the case of new public health products were analysed.  The 
idea that the high price of the female condom was only linked to the 
high manufacturing costs had grown commonplace among the global 
public sector and their influence on the marginalisation of the female 
condom stood out (chapter 4). By comparing the female condom with 
similar products, I found that the usual ways to change lack of 
affordability, i.e. negotiations by global AIDS policy makers with the 
private sector, were not in place to promote and create access to the 
female condom. 
 Although global AIDS policy makers themselves were in a position 
to positively influence the problematic high price of the product, for 
example through negotiations, subsidisations and thus demand creation, 
they rather perceived the price as a given characteristic, not showing 
any efforts to negotiate prices with the private sector or to subsidise on 
a big scale. The global public sector as the largest clients of the Female 
Health Company that produces the type of female condom which is 
approved by international agencies, failed or was not motivated to 
negotiate with the company in matters of price reductions, marketing, 
demand creation and product improvement. Synergistic actions with 
private sector stakeholders to improve the product, increase access or 
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reduce the price were found to be lacking, for example female condom 
public private partnerships were found to be limited to one. Efforts such 
as product promotion, product innovations and demand creation by 
both sectors, all crucial in creating affordability, were minimal as was 
shown by the comparison with such actions for other products used 
for a similar purpose, for example microbicides and the male condom 
(chapter 3).
 Stakeholders including academics had played a role too by 
collaborating with the public sector to develop other products than the 
female condom as they generally showed little interest in studying and 
improving the design of the female condom. In stark contrast they 
highly prioritised the development of microbicides, attracting, and 
attracted by, the funding of the global public sector (chapter 5). In the 
case of microbicides, negotiations and resonance between stakeholders 
(public sector, private sector and academia) led to increased actions, but 
in the case of the female condom such synergetic actions and 
negotiations between stakeholders were absent. Thus the global public 
sector by perceiving the characteristics of the female condom, unac-
ceptability and unaffordability, as inherent and not as variables or 
changeable characteristics, was not active in creating access to the 
female condom, as in future they seem willing to do for microbicides. 
 The ‘issue characteristics’ as Shiffman and Smith would call them 
of ‘unacceptability’ and ‘unaffordability’ were often seen as determining 
the third characteristic, ‘denial of potential’. In chapter 4, I showed that 
they were not the decisive factors for the global AIDS policy actors as 
they are indeed changeable and therefore could rather be considered 
symptoms or indicators of low potential for this product. More complex 
dynamics had to underlie ‘the fumbling’ with the female condom and 
its sustained low status in the global response to AIDS. The ‘actor 
power’ as Shiffman and Smith called it, concerning global AIDS policy 
makers seemed crucial.  This was therefore studied in the second part 
of my thesis. 
 I studied three types of ‘actor power’ in their political contexts, 
which I called funding power (chapter 5), framing power (chapter 6) 
and implicit power (chapter 7) and this led to the following insight on 
the marginalisation of the female condom at global level. 
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2.  Implicit associations, related to the meanings of gender and 
sexuality motivated AIDS policy makers to give low priority to the 
female condom in the global response to AIDS, by choosing words 
and narratives that silenced  women’s sexuality.
Global AIDS policy makers outlined the AIDS epidemic and its solutions 
within typical cultural, gendered sexuality frames. For example women 
from developing countries and more specifically from sub-Saharan 
Africa were assumed to be unable to negotiate the use of the female 
condom with their partners, and to have insufficient agency to act on 
their own behalf with respect to their health and relationships (chapter 
7). They were largely framed as being victims and not as agents in their 
sexual lives. Official AIDS policies gave them attention as being mothers 
- focusing on their reproductive role, protecting children - or as being 
commercial sex workers - focusing on their pleasuring role, protecting 
men - leaving out the possibility that women make choices in their own 
right, as sexual agents (chapter 6). Homosexual men (gays) were 
explicitly targeted for AIDS prevention programmes, while homosexual 
women (lesbians) were almost completely left out of these policies 
(chapter 6). Clearly there were many perceptions in the AIDS policies 
about how women and men viewed sexuality differently or behave 
differently, though in a typical gender stereotyped way. 
 In all 16 researched global AIDS policies the condom was prioritised 
among the preventive products, although only the male condom, 
framed as gender unmarked and implicitly associated with men (men 
only), reinforcing the gendered notion of the sexual agency of men. In 
9 of the 16 global AIDS policies the female condom was mentioned too. 
However, it was almost taken for granted that ‘male’ condoms needed 
to be accessible to all men and not only specific categories of men and 
in contrast, the female condom was not promoted in such a way that it 
needed to be accessible for all women, but was mostly targeted to sex 
workers. By targeting female condoms to commercial sex workers 
rather than to other categories of sexually active women, the problem 
of AIDS and the use of the female condom was implicitly associated 
with ‘sexually immoral behaviour’. This implicit ‘female condom-sex 
worker association’ found among AIDS policy  makers (chapter 7) 
negatively impacts on the popularity of the female condom. 
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 In the 16 researched global AIDS policies (chapter 6), AIDS policy 
makers implicitly held a  ‘sexual rights-men association’ and men’s 
sexual agency was found not to be negated, while women’s sexual 
agency, except that of commercial sex workers, was. Although formally 
recognising that men and women have equal sexual rights, policy 
makers automatically and unconsciously associated sexual rights with 
only men. The AIDS policies were based on a number of these 
preconceived or learned assumptions on gender and sexuality and 
these undoubtedly had an effect on priority setting, neglecting the 
female condom, though in a  hidden, not openly explained manner.
 Some global AIDS policy makers, when narrating about the female 
condom, mentioned that men want ‘to feel nothing’ when having 
sexual intercourse, and that therefore the female condom’s visibility 
would be problematic. The assumption was that men are supposed to 
enjoy ‘pure’ sexual intercourse. Some policy makers narrated about 
those ‘irresponsible’ sex workers, who tended to use the same female 
condom with more clients. The unpronounced assumption here is that 
men have higher risks of infection when sharing the same female 
condom than when sharing the same vagina. These two typical 
examples on implicit gendered associations on sexuality show how 
AIDS policy makers take the dominant perspective of sexual interests 
of men. This might for example have led to the high level of public 
funding for microbicides, perceiving that this product would not 
disturb men’s pleasure as it is being promoted by researchers as a 
product than can be covertly used by a woman.
 Typically, the AIDS policies did not explain the reasons certain 
frames were applied and selected, and therefore the underlying 
assumptions remained unaddressed, hidden. For example by not 
explicating the reasons for lack of recognition of sexual rights for 
women in the global AIDS policies and silencing female sexuality, 
global policy makers unconsciously exercised power (chapter 6); not 
explaining these assumptions, gender and sexuality prejudices are 
silenced and become impossible to address or problematise. 
I conceptualised such implicit associations as ‘implicit actor power’ 
which largely influenced the way global AIDS policy makers viewed the 
potential future of the female condom, embedded in widely diverging, 
sometimes ambiguous attitudes on culture, sexuality and gender 
(chapter 7).
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 By finding these different layers in ‘actor power’, the third insight 
applies to the theoretical framework of Shiffman and Smith too.
3.   The most persistent actor power that influenced the low status  
of the female condom is largely hidden, yet influencing the 
amount of funding and the way some ideas are prioritised and 
others not. Implicit power of actors should therefore be added to 
the theoretical framework to be used in studies in political 
prioritization in global health.
Jeremy Shiffman and Stephanie Smith defined global political priority 
as ‘the degree to which international and national political leaders 
actively give attention to an issue, and back up that attention with the 
provision of financial, technical, and human resources that are 
commensurate with the severity of the issue.’ From this definition and 
from their concept of ‘power of ideas’, I derived in my thesis two types 
of ‘actor power’ that I studied: funding and framing power.  While 
researching these two powers I identified a third layer of actor power, 
which I called implicit power as earlier explained. Table 8.1 presents a 
summary of these three types of actor power and three different 
parameters that I found and that typified these three types of power: 
level of visibility, level of difficulty in research, level of persistence of 
the power. In the course of this section I will clarify this table, using 
the findings of my thesis.
 Funding power might be visualised as ‘the tip of the iceberg’, as 
money is visibly and transparently allocated to policy priorities. 
Underneath the funding power there is a more subtle form of actor 
power, the power of framing - how ideas are described in global AIDS 
policies, which issues gets highlighted and which are left out, and this 
type of power was slightly visible, but more difficult to track. By 
systematically using a gender lens as a feminist researcher, I studied 
how the AIDS epidemic, the problem and the solutions, were framed in 
written global AIDS policies. By analysing the frequency of certain 
words used, patterns of dominant framings were laid bare. But still 
there remained a discrepancy between the official policy papers and 
the day-to-day conversations on the work floor. 
 When researching how these official global AIDS policies were 
applied and discussed on the daily work floor of global AIDS policy 
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makers, I found that a more implicit type of actor power mattered in 
political prioritisation. This type of power is invisible, based on 
associations, word use and narratives. To explain this in more depth, 
I first highlight what I found in my research about funding and framing 
power of the global AIDS policy makers. 
  Concerning funding power, I found in my research that the global 
public sector provided different amounts of money to global programmes 
on HIV prevention. For example in the period between 2000 and 2008, 
funding for integrated condom programming dropped significantly, 
whilst funding for research programmes on HIV preventive microbicides 
and vaccines increased (chapter 5). Both the governments of the USA 
and Europe (European countries and the EU) were found not to be 
improving access to integrated condom programming in developing 
countries, nor to be addressing the shortage of male and female 
condoms. They used their funding power in such a way that they 
invested more into researching new technologies than in implementing 
condom programmes (chapter 5). 
 Though their policy discourses were found to be different, relatively 
their funding allocations were found to be the same for the USA and 
EU, even though the USA did not use the discourse of sexual rights, but 
Table 8.1   Parameters of actor power in political prioritization in 
global health
 
Actor power  
by the global 
public sector
Funding power 
(chapter 5)
Framing power 
(chapter 6)
Implicit power 
(chapter 7)
Level of visibility or 
transparency
Visible: clear 
to insiders and 
outsiders
Not visible: clear 
for insiders, 
unclear for 
outsiders
Not visible: 
unclear to 
insiders, unclear 
to outsiders
Level of difficulty to 
research
Easy, 
straightforward
Moderately easy Difficult and 
needs time
Level of persistence 
of the power
Low persistence 
and can be 
stopped
Moderate 
persistence as it 
concerns framing 
by the actors
Very persistent 
as it involves tact 
and prejudiced 
assumptions 
embedded in 
everyday talk and 
practise.  .
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the EU and European countries did. This difference in policies clearly 
did not result in a difference in funding strategies (chapter 6). 
  This discrepancy between policy and funding was not the only 
discrepancy found, as there was also a discrepancy between what is 
policy and what the policy makers actually think. Global AIDS policy 
makers limited or reinforced each others’ ideas by politically selecting 
the way to present the AIDS problem and its possible solutions, thereby 
also subtly influencing the political context as well, having consequences 
for the case of the political prioritisation of the female condom. The 
denial of the potential of the female condom was found to be grounded 
in social norms and values. Global AIDS policy makers working in an 
organisation with a female condom endorsing policy were found to be 
sharing personal opinions, ideas and values, when explaining the 
priorities of their AIDS policies on the work floor. They expressed their 
personal opinions and their own conceptual mind maps rather than 
explaining official stances laid down in formal policies or using official 
research results and this influenced the way the female condom was 
perceived. Interestingly global AIDS policy makers seemed to be 
motivated and rewarded on the work floor for framing issues as 
rationally, value neutral as possible. For example, they reasoned that 
development results only count when these could be quantitatively 
measured. As a consequence, they severely doubted results of HIV 
prevention as they were complex to measure. In such a political context 
quantifiable, treatment solutions tend to be prioritised above time 
consuming information and social change campaigns that are complex 
and often unquantifiable (chapter 7). 
 Overall, the research found among global AIDS policy makers a 
dominant discourse that the female condom is not wanted or has no 
future potential. In table 8.1, framing power is characterised as being 
hard to discontinue without awareness creation and efforts on the part 
of insiders, as it is built on the foundations of implicit power, of the 
personal values and opinions of actors, global AIDS policy makers in 
this case. The way this type of actor power is exercised is not only 
hidden for outsiders, but also for insiders, the AIDS policy makers and 
implementers of female condom programmes themselves. They seemed 
not to be aware and did not notice that their personal opinions were so 
different from the official policies they had helped to design and were 
supposed to implement. 
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 Implicit power was conceptualised as being the most hidden form 
of power, almost completely blurred for insiders. This type of power, 
based on implicit assumptions in specific institutional cultures, is very 
difficult to tease out and very difficult to change. This power is complex 
to research though I managed this by having a research fellow whose 
agenda was completely neutral and who was not known by the AIDS 
policy makers. This allowed the respondents to speak freely and use 
their own wording. The personal, often ambiguous ideas and social 
values behind these responses were found to be persistent, a general 
underlying unconscious dynamic. 
 The social values and norms of the decision-makers at global level, 
especially the ones related to gender and sexuality remain largely 
unstudied and thus unquestioned, though they play a crucial role in 
political prioritisation in global health. My thesis clearly revealed that 
political prioritisation in global health refers not only to how problems 
are prioritised, but also to how alternative solutions and how different 
target groups are prioritised, leading to the marginalisation of certain 
solutions and certain target groups, and the valorisation of others. In 
the case of the AIDS epidemic, prevention methods other than the 
female condom, and target groups other than ‘all women with sexual 
rights’ were prioritised, a hidden, gendered and value-laden political 
prioritisation. In the following paragraph I will give three recommen-
dations according to the three insights I gained. 
8.2 Recommendations
All three recommendations are directed towards global AIDS policy 
makers, the global public health sector and researchers studying 
political prioritization in global health.
1.  Focus on the similarities between the female condom and 
microbicides as the discrepancies are rather small.
When female condom programmes are accompanied by sympathetic 
support to women by skilled providers over a period during which 
women become accustomed to the device, acceptability rates are high. 
This might be true for other new contraceptives or HIV preventives, 
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such as microbicides too. These results suggested that the female 
condom, like other health products needs active promotion and 
constant improvements. 
 Research into microbicides, a vaginal cream that needs insertion 
into the vagina just like the female condom, might better be researched 
in combination with research into a new ‘plastic’ or ‘semi-fluid’ layer, 
an improved female condom to protect the vagina wall. These two 
products – the female condom and microbicides - should not be 
considered as very different, and in competition as is presently the 
case, but in this potential combination.  That said, implementing what 
is already successful and giving choices to people on how best to prevent 
unintended infections and pregnancies needs prioritisation in the 
arena of development aid. As the core-business of the private sector is to 
create economic profits, it depends on the political priority of the public 
sector whether and how they start the negotiations with other 
stakeholders. 
 Nevertheless, limited access to the female condom for women in 
sub-Saharan Africa will not be solved simply by attributing more 
funding to it. Although AIDS policy makers do have obvious power to 
grant funding, my data show that the power of framing -  rooted in 
implicit associations to do with culture, gender and sexuality – was 
influential in maintaining the low status of the female condom. 
Therefore:
2.  Accept that implicit power exists, make it visible and come  
up with an institutional strategy to address implicit associations 
concerning the gendered culture on women and sexuality. 
Silencing issues or making them invisible is not a sign that they do not 
exist, but a sign that there is dissonance, and diversity in perspectives 
from a variety of stakeholders with different ‘actor power’. It would be 
unfortunate if only people espousing a dominant discourse or whose 
ideas fit this dominant discourse are facilitated for success, whilst 
others who don’t speak the dominant discourse or whose ideas do not 
fit the dominant discourse don’t get global political priority. Staff of 
AIDS policy institutes are recommended to participate in innovative 
programmes how ‘implicit associations’ work as these programmes 
exist for other professionals too such as judges, health care workers, 
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police and teachers, to enable them to deal with unconscious prejudices. 
Moreover, these programmes can make policy makers aware of the 
competing social values and the way they shape policy prioritisation, 
implementation of policies and research. Therefore I recommend:
3.  Use a critical gender lens when responding to global problems 
in the field of sexuality and human reproduction. 
A gender lens might contribute to better understanding of global 
health political prioritization in general and not only for the female 
condom. My research suggests that issues which frame women as 
‘innocent victims’ get global prominence, while issues related to 
‘women’s sexual rights’ or ‘women’s sexual agency’ are absent at global 
advocacy level. 
 My research results are in agreement with arguments of some 
feminists (Girard 2009, Brems 2013) that existing social norms and 
values are the major barrier to women’s rights. Also among global 
health policy makers, the norms and values related to gender and 
sexuality seem to be the major barrier that influences the low political 
priority for the female condom. Many discussions about women’s sexual 
and reproductive rights - for example, concerning safe abortion - are 
avoided and silenced at global level. Also in case of the study of global 
political neglect of maternal mortality by Shiffman and Smit that 
resulted in the theoretical framework used in this thesis, could have 
been deepened by using a gender lens.  My thesis showed how implicit 
associations of global health policy makers, concerning sexuality and 
gender play a role at global political level. Theories on political 
prioritization in global health need to acknowledge competing social 
values among decision-makers using a critical gender lens, when 
studying sexuality and different perspectives of women. Use a gender 
lens to unravel the hidden power in the global response to AIDS.
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NEDERLANDSE SAMENVATTING (SUMMARY IN DUTCH)
Nederlandse samenvatting
‘Klungelen met het vrouwencondoom’ is de titel van dit proefschrift, 
met als subtitel: ‘Verborgen invloed in  de wereldwijde reacties op de 
AIDS epidemie’. De aanleiding van dit proefschrift ligt rond 1990, aan 
het begin van de periode dat ik woonde en werkte in Zimbabwe, toen de 
regering aldaar de omvang van de AIDS epidemie niet langer kon 
ontkennen. Het aantal HIV infecties groeide exponentieel en bereikte 
een piek in 1997, met een besmettingsniveau van rond de 27% van de 
volwassen bevolking. De angst voor besmetting en vroege dood was 
voelbaar in de hele samenleving en de gevolgen waren dramatisch. 
Beroepsmatig was ik bezig met het opzetten en begeleiden van AIDS 
preventie programma’s en ik was blij verrast met de introductie van het 
vrouwencondoom in een aantal proefprojecten, die werden uitgevoerd 
door de Universiteit van Zimbabwe. Ondanks positieve testresultaten 
en een aanzienlijke groep vrouwen die het gebruik van het vrouwen-
condoom omarmde als product ter preventie van ongewenste zwangerschap 
en HIV besmetting, realiseerde ik mij langzamerhand dat er geen 
serieuze pogingen werden ondernomen om het product op grote schaal 
beschikbaar te stellen en dat besef groeide in de daarop volgende jaren. 
 Onderzoek heeft uitgewezen dat het vrouwencondoom net zo 
effectief is (94-97%) als het mannencondoom in de bescherming tegen 
ongewenste zwangerschappen en seksueel overdraagbare aandoeningen, 
waaronder HIV. In Afrika ten zuiden van de Sahara raken meer vrouwen 
besmet met HIV dan mannen, met name jonge vrouwen; jaarlijks nog 
ongeveer 870.000 vrouwen. Bovendien raken wereldwijd  elk jaar nog 
85 miljoen vrouwen onbedoeld zwanger, een teken dat er  veel behoefte 
is aan bescherming. Ik vroeg me af waarom deze problematiek geen 
aanleiding gaf aan internationale donoren om prioriteit te geven aan 
het ruimer beschikbaar stellen van het vrouwencondoom, dat een 
relatief eenvoudig product is zonder bijwerkingen. Waarom gebeurde 
dit niet en wat ligt daaraan ten grondslag? 
 De hoofdvraag van dit proefschrift luidt daarom: Waarom heeft 
het vrouwencondoom zo’n lage prioriteit op de internationale gezond-
heidsagenda?  Het theoretisch kader van Shiffman en Smith (2007) dat 
betrekking heeft op het prioriteren van wereldwijde initiatieven op het 
gebied van gezondheidsvraagstukken was bruikbaar voor het aanbrengen 
van structuur in het onderzoek. Deze auteurs definiëren politieke 
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prioritering als de mate waarin leiders van internationale organisaties 
actief aandacht besteden aan een bepaald onderwerp door beslissingen 
en instructies te geven binnen hun eigen organisaties om financiële, 
technische en personele middelen in te zetten om het onderwerp in 
kwestie aan te pakken. Het door hen ontworpen theoretisch kader 
omvat vier categorieën van factoren die  politieke prioritering bepalen: 
-  de invloed van belanghebbende partijen
-  de invloed van ideeën
-  de politieke context
-  de karakteristieken van het betreffende onderwerp zelf. 
Hoofdstuk 1 zet de keuze uiteen voor het theoretisch kader en benoemt 
een aantal concepten die voor dit proefschrift van belang zijn: macht en 
invloed, seksuele en reproductieve gezondheid, seksuele en reproductieve 
rechten, seksualiteit, gender9 en feminisme. Daarnaast beschrijft dit 
eerste hoofdstuk ook het vrouwencondoom, dat in het Engels ten onrechte 
‘vrouwelijk condoom’ wordt genoemd, terwijl er niets vrouwelijks, noch 
mannelijks aan een condoom te ontdekken valt. In 1984 ontwierp een 
Deense arts het eerste vrouwencondoom: een dunne, zachte beschermlaag 
van polyurethaan plastic. Het kokervormig ontwerp heeft twee flexibele 
ringen aan beide uiteinden. De binnenring is ingesloten in de plastic 
koker en bedoeld om het condoom met de vingers in de vagina aan te 
brengen, tegen de mond van de baarmoederhals. De buitenring plaatst 
zich rondom de buitenste vaginale lippen. 
 Geïnspireerd door het theoretisch kader van Shiffman and Smith, 
wordt verder in dit hoofdstuk de centrale onderzoeksvraag uitgewerkt 
in zes deelvragen. De eerste drie deelvragen gaan over typische kenmerken 
die aan het vrouwencondoom worden toegekend: 
-   de vermeende slechte acceptatie van het vrouwencondoom door vrouwen 
in Afrika
-  de hoge prijs van het product
-   de politieke context op mondiaal niveau, met name de achterstelling 
van het product door internationale organisaties. 
De resterende drie deelvragen gaan over de wijze waarop internationale 
organisaties en donoren hun invloed uitoefenen via financierings-
9 De Nederlandse taal kent geen woord voor gender. Gender verwijst naar de culturele, 
sociale en psychologische invullingen van mannelijkheid en vrouwelijkheid, de positie 
die mannen en vrouwen in onze en andere samenlevingen innemen. 
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beslissingen, het expliciet benadrukken van bepaalde ideeën en 
tegelijkertijd achterstellen van andere ideeën op een meer impliciete 
manier.  
 Hoofdstuk 2 geeft een overzicht van het onderzoek naar de mate 
waarin vrouwen in Afrika ten zuiden van de Sahara het vrouwencondoom 
acceptabel achten om te gebruiken als preventiemiddel. Daartoe is een 
overzicht gemaakt van de resultaten van alle empirische studies over 
dit onderwerp die plaats hebben gevonden tussen 2003 en 2013, in 
totaal 15 studies. Helaas was het niet mogelijk uitspraken te doen over 
de mate van acceptatie door diverse categorieën vrouwen die bij deze 
studies werden betrokken: seksueel actieve vrouwen in het algemeen, 
prostituees, HIV positieve vrouwen, getrouwde vrouwen, vrouwen die 
een abortus hadden ondergaan. Dit kwam doordat iedere categorie 
ofwel niet nader was omschreven was ofwel een te klein aantal bevatte 
om verschillen te kunnen omschrijven tussen categorieën. Het fenomeen 
“acceptatie” bleek op verschillende manieren te worden gedefinieerd, 
afhankelijk van het type studie, interventie of non-interventie. In de non- 
interventie studies (in totaal 6 studies: 2 kwalitatieve en 4 kwantitatieve), 
werd acceptatie geoperationaliseerd in termen van een positieve 
mening van vrouwen over het vrouwencondoom, echter niet gebaseerd 
op gebruikservaring door de vrouwen aangezien ze ook niet in de 
gelegenheid gesteld werden om het vrouwencondoom te gebruiken 
vóórdat ze een mening gaven. In de interventie studies (in totaal 9), 
vond 50% tot 98% van de vrouwen het vrouwencondoom acceptabel, hoewel 
sommigen wel aangaven dat het product verbeterd kon worden. In de 
non-interventie studies, vond slechts 2% tot 11% van de ondervraagde 
vrouwen het vrouwencondoom acceptabel. De mate van acceptatie was 
sterk afhankelijk van de opzet van de studie, van het beschikbaar 
stellen van het vrouwencondoom, de informatie rondom het product 
en de steun die potentiële gebruikers kunnen vragen bij het leren 
gebruiken van het vrouwencondoom. Van de vrouwen die toegang 
kregen tot het product en die in het gebruik van het vrouwencondoom 
ondersteund werden, gaf het merendeel aan tevreden te zijn met het 
product. 
 Het derde hoofdstuk bevat een vergelijkende analyse van bestaande 
maatregelen, vaak een mengsel van interventies door zowel de publieke 
als de private sector die vraag en aanbod beïnvloeden en invloed hebben 
op de betaalbaarheid. Een typische taak van de publieke sector is het 
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gebruik van HIV preventiemiddelen te stimuleren uit het oogpunt van 
de volksgezondheid. Dergelijke maatregelen zijn geanalyseerd voor 
drie vergelijkbare HIV preventiemiddelen, vrouwencondoom, mannen - 
condoom en microbicides, een vaginale zalf met antivirale werking die 
echter nog niet op de markt is gebracht omdat het product zich in de 
testfase bevindt. In 2012 bedroeg de wereldwijde condoommarkt 22.8 
biljard mannencondooms, met een gemiddelde groothandelprijs van 
0.03 US $, en 61.5 miljoen vrouwencondooms met gemiddelde prijs 
van 0.57 US $, dus bijna 20 keer zo duur. De drie producten worden 
vergeleken op vraag en aanbod en de maatregelen die hier invloed op 
hebben, zoals marketing, subsidieverstrekking en onderzoek naar 
innovaties. Omdat het verzamelen van primaire data bij de private 
sector, met name bij condoomfabrikanten onmogelijk bleek, zijn 
secundaire data gebruikt, met name bedrijfsjaarrapporten, aangevuld 
met analyses van markt artikelen over deze wereldwijde bedrijfstak. 
Een opvallend verschil is dat drie kwart van de vrouwencondooms 
wordt aangekocht door de publieke sector, met name UNFPA en USAID, 
die ze vervolgens gratis of tegen een gesubsidieerde prijs ter beschikking 
stellen aan het ministerie van gezondheid of een andere distributeur in 
ontwikkelingslanden. Daarentegen neemt de publieke sector slechts 
2% van de wereldwijde aankoop van mannencondooms voor haar 
rekening, behalve in Afrika ten zuiden van de Sahara, waar de 
commerciële sector nauwelijks aanwezig is. Qua aard bleken de 
wereldwijde maatregelen aardig overeen te stemmen, echter niet qua 
hoeveelheid. De maatregelen die worden genomen om het gebruik van 
het vrouwencondoom te bevorderen  door de publieke dan wel door de 
private sector, zijn van minimale omvang in vergelijking met de 
maatregelen voor de andere twee producten. Dit is van invloed op de 
toegankelijkheid van het vrouwencondoom en verklaart de tekortkoming 
in het voldoen aan de huidig bestaande vraag. De conclusie is dat het 
essentieel is de politieke context van het product nader te onderzoeken. 
 Hoofdstuk 4 beschrijft de plaats die het vrouwencondoom inneemt 
in de mondiale reactie op de AIDS epidemie. Volgens een speciaal voor 
deze problematiek ontworpen model ten aanzien van het toegankelijk 
maken van nieuwe technologieën voor arme landen zijn de gegevens 
verzameld. Dit model is gebaseerd op drie concepten die tezamen de 
toegankelijkheid van een technologie bepalen: acceptatie, beschikbaar-
heid en betaalbaarheid. Naast een uitgebreide en gefocuste literatuur-
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studie op deze drie concepten, bevat dit hoofdstuk ook een analyse van 
artikelen in de speciale editie van de Lancet in 2008 ‘de kunst van HIV 
preventie’, aangevuld met interviews gehouden met beleidsmakers die 
aanwezig waren op de internationale AIDS conferentie in 2008 in 
Mexico. Eén dag na de persconferentie van Oxfam en een demonstratie 
van ongeveer 200 vrouwen die pleitten voor een betere toegang tot 
het vrouwencondoom, verklaarde een UNAIDS beleidsmaker dat er 
nauwelijks een vraag bestaat, daarmee ook de activiteiten van de dag 
ervoor terzijde schuivend. Vooral internationale beleidsmakers blijken 
terughoudend te zijn om het vrouwencondoom te benoemen als een 
volwaardig HIV preventiemiddel. Zij verschuilen zich achter de mythe 
dat er geen vraag zou zijn, en nemen de hoge prijs als vaststaand 
gegeven en verklaren hierbij dat het niet nodig is om het aanbod te 
verzekeren. Beleidsmakers zetten hun invloed niet in, maar blijven de 
potentiële waarde van het vrouwencondoom in de mondiale reactie op 
de AIDS epidemie bagatelliseren, of zelfs ontkennen. 
 Hoofdstuk 5 beschrijft de financieringsstromen van internationale 
actoren en de prioriteiten van de publieke donoren bij het financieren 
van HIV preventieve activiteiten. De hoeveelheid geld die wordt gegeven 
aan geïntegreerde condoomprogramma’s in ontwikkelingslanden wordt 
vergeleken met het geld dat aan onderzoek naar microbiciden en 
vaccins wordt besteed. De analyse maakt onderscheid tussen de 
publieke investeringen vanuit de Verenigde Staten en vanuit de landen 
van de Europese unie, inclusief van de EU zelf. Het internationale AIDS 
beleid van deze twee continenten verschilt met name ten aanzien van 
seksuele en reproductieve gezondheid en rechten. Het is een trendanalyse 
over de periode tussen 2000 en 2008 gebaseerd op gegevens uit bestaande 
door de Verenigde Naties opgezette databases.  De relatieve bijdrage aan 
geïntegreerde condoomprogramma’s daalde gestaag tussen 2000 en 
2008, terwijl dat aan onderzoek naar microbiciden en vaccins gestaag 
steeg. De overheden van beide continenten veranderden hun financiering’s 
prioriteit van condoomprogramma’s naar onderzoek, met als gevolg 
dat het mondiale tekort aan geïntegreerde condoomprogramma’s en 
condooms bleef bestaan. Het Europese AIDS beleid gebaseerd op 
reproductieve en seksuele gezondheid en rechten heeft er niet toe 
geleid dat condoomprogramma’s duurzaam gefinancierd werden. 
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 Verder onderzoek naar ‘de invloed van ideeën’ in beleid van 
internationale organisaties en donoren is beschreven in hoofdstuk 6. 
Het betreft de analyse over de wijze waarop belangrijke internationale 
actoren het AIDS probleem ‘framen’10, in het bijzonder het vrouwen-
condoom. Het doel is om inzicht te geven in de bewoordingen en de 
ideeën die ze kiezen in hun beleidsformulering. Dit wordt ‘discursieve 
invloed’ genoemd omdat het de basis vormt van keuzes in HIV preventie en 
haar doelgroepen. De analyse betreft het AIDS beleid van 16 organisaties 
die behoren tot de meest invloedrijke actoren in de mondiale reactie op 
AIDS, zowel private als publieke actoren. Een gemengde onderzoeks-
methode, met gebruikmaking van zowel kwantitatieve als kwalitatieve 
technieken is toegepast om te onderzoeken hoe het AIDS probleem 
besproken wordt, welke ‘framings’ gebruikt zijn en hoe verschillende 
categorieën van mensen als doelgroepen voor AIDS preventie aangewezen 
zijn. AIDS werd vooral benoemd als een probleem waar vrouwen en 
kinderen passief het slachtoffer van zijn. Vrouwen werden niet gezien 
als actoren met seksuele en reproductieve rechten en zelfbeschikkings-
recht in seksuele relaties. Mannen, homoseksuelen, moeders en kinderen 
waren de meest genoemde doelgroepen voor HIV preventie en gender 
stereotyperingen beïnvloedde nadrukkelijk het denken over seksualiteit 
en seksuele rechten. Het merendeel van de 16 AIDS beleids stukken gaf 
geen aandacht aan seksuele rechten van vrouwen, bijvoorbeeld het 
recht op gelijkwaardige invloed in seksuele relaties. Ondanks dat het 
condoom het meest genoemd werd van de preventietechnologieën, 
wees het typisch ongeslachtelijke neutrale gebruik van de term 
condoom op de impliciete associatie met mannen, hetgeen het idee van 
seksuele ‘agency’ van mannen op een gender stereotype manier 
benadrukt. Automatisch werd er vanuit gegaan dat het mannen- 
condoom beschikbaar gesteld moet worden voor alle mannen, terwijl 
het vrouwencondoom werd benoemd als product voor slechts bepaalde 
groepen vrouwen, met name prostituees die daarmee ook seksuele 
10 Framen is in het Nederlands te vertalen met inlijsten of inkaderen. In het Engels 
verwijst het ook naar een in ons brein georganiseerd netwerk van impressies en 
 ervaringen, met bijbehorende associaties en waardeoordelen. Een frame helpt om de 
complexe realiteit te versimpelen en deze een betekenis te geven. 
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‘agency’11 toegedicht kregen. Omdat vrouwen geen actieve rol toebedeeld 
werd in seksuele relaties, is er ook geen aandacht  voor bijvoorbeeld 
lesbiennes en worden alleen prostituees gezien als potentiele gebruikers 
van het vrouwencondoom. Dit is een logisch gevolg van het niet 
benoemen van seksuele ‘agency’ voor vrouwen in het algemeen. Deze 
typische ‘framing’ verklaart waarom de beleidsstukken geen motivatie 
zijn om het vrouwencondoom universeel te promoten. 
 Hoofdstuk 7 is een beschrijving van een onderzoek door middel 
van diepte-interviews bij één donor organisatie met een duidelijk 
positief beleid ten aanzien van het vrouwencondoom. Het doel is om te 
achterhalen of stafleden achter het officiële beleid staan en hoe ze 
spreken over het vrouwencondoom op de werkvloer. De 5 geïnterviewde 
stafleden hadden ambivalente denkbeelden die vaak bestonden uit 
 genderstereotype of cultureel bepaalde ideeën. Hun mening over het 
vrouwencondoom is nogal uitgesproken en lijkt deel te zijn gaan 
uitmaken van hoe over het vrouwencondoom gedacht wordt binnen de 
organisatie. Deze impliciete vorm van invloed valt gebrekkig samen 
met het officiële beleid op gendergelijkheid en de aandacht voor het 
vrouwencondoom. De geïnterviewde stafleden beoordeelden dat de 
toekomst van het vrouwencondoom in het algemeen zeer marginaal 
zou zijn. Het hebben van een institutioneel AIDS beleid dat positief is 
ten aanzien van het vrouwencondoom is onvoldoende. De impliciet 
invloed bestaat uit de houding van de stafleden en is bepalend voor 
zowel de persoonlijke als de institutionele denkwijze. Een succesvolle 
uitwerking van het beleid is derhalve onwaarschijnlijk, tenzij stafleden 
bewust raken van het bestaande, alles doordringende en geïmpliceerde 
karakter van dit type van invloed en daarmee om leren gaan als 
instituut.
 Dit proefschrift onderscheidt zich van andere studies naar politieke 
prioritering in het internationale domein, aangezien het probleem 
AIDS een hoge politieke prioriteit had in de periode van mijn onderzoek, 
terwijl een mogelijke bijdrage aan de oplossing van het probleem het 
vrouwencondoom, een lage prioriteit had. Het bestuderen van een 
dergelijk fenomeen zou optimaal kunnen bijdragen aan het begrijpen 
11 Agency is een sociologische term die verwijst naar persoonlijke capaciteit om actie te 
ondernemen van iemand die ook het recht, de vaardigheid of de macht heeft om dat 
werkelijk te doen. 
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van politieke prioritering volgens de wetenschapster Charli Carpenter. 
Het heeft geleid tot drie nieuwe inzichten. Allereerst raakten vermeende 
kenmerken van het vrouwencondoom gefixeerd als vaststaande 
kenmerken door een proces dat aangejaagd werd door internationale 
AIDS beleidsmakers die het vrouwencondoom zelf als onacceptabel 
beoordeelden en de hoge prijs gebruikten als reden voor lage prioritering, 
terwijl deze twee kenmerken typisch veranderbare variabelen zijn. 
Ten tweede, lagen de impliciete associaties met betrekking tot gender 
en seksualiteit verscholen in de bewoordingen en verhalen van 
beleidsmakers op de dagelijkse werkvloer. Officiële AIDS beleidsstukken 
leggen de redenen en de onderliggende aannames voor het kiezen van 
bepaalde perspectieven of bewoordingen niet uit. Ten derde is gebleken 
dat de meest persistente vorm van invloed van beleidsactoren groten - 
deels impliciet is. Daarom pleit ik ervoor dat deze vorm van invloed 
toegevoegd wordt aan het theoretisch kader over de analyse van 
politieke prioritering in internationale gezondheidszorg. Die impliciete 
invloed kan alleen bloot gelegd worden met behulp van een gender 
analyse. Erkenning van het belang van dergelijke analyse zou wellicht 
‘het klungelen met het vrouwencondoom’ doen verdwijnen.
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